roche annual report create value patientskey figure roche group index sale mchf free cash flow mchf research development mchf total dividend mchf operating profit mchf number employee income taxis mchf total employee remuneration mchf net income mchf patient clinical trial core earning share chf ecoefficiency rate price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebase key figure index figure annual report core result index global reporting initiative gri propose board director indicator report development phase wwwrochecomreportingandindice calculation ecoefficiency rate wwwrochecomenvironmenthighlight january january february commission approve fda approve actemra roche annual general meeting vote herceptin treatment treatment moderately severely increase shareholder dividend positive advanced stomach cancer active rheumatoid arthritis april june july roche acquire medingo expand fda expand lucentis approval athena clinical trial demonstrate position grow insulin delivery include treatment macular edema high medical value cobas system market follow retinal vein occlusion hpv test detect highrisk genotype screen cervical cancer woman september september october fda clearance cobas roche name healthcare super encourage new clinical datum modular analyser series high sector leader dow jones sustain avastin ovarian metmab lung volume lab testing ability index second year run tdm breast cancer present esmo conference october november rdge efirsmtincblasse grri schizophrenia create value patient mean report promise phase result launch operational excel tpheh acosuer aiig ttuod gyo wwihtehr inresetdsi narec glaresast braf inhibitor lence initiative maintain longterm cthoemrs phaovue nfadile rdg show new target medicine innovation capability improvement negative symptom advance melanoma oe pbaf oeii tslena wic tib feift viil ecv nea aah yst cmge uar tia etcp itee sfs ifh soeooscfdi ttt eiv inse tiy oop prs thhe strabele phnasesi gepfn efo wec viseae icld hteog ntfri ifne semsacttt son fue aao cttp ovtie sayllmy pctoonmtrsolle positive symptom affect nearly million people worldwide schizo glycine reuptake inhibitor gri develop phrenia severe mental disorder distort roche drug treat negative way person think act express emotion symptom schizophrenia represent entirely ceive reality relate lifelong novel approach normalise glutamate neu disease cure average shorten rotransmission increase synaptic level glycine life expectancy year high risk target important pathway psychiatric suicide cardiovascular pulmo disorder potential firstinclass nary event negative symptom compound type treatment schizophre usually great impact quality life nia addition combination current patient unable live independently hold job treatment potential treat suboptimally con establish personal relationship manage troll positive symptom little increase day social situation drug develop treat effect novel mode action negative symptom fail clinical trial valu able therapeutic application psychiatric available treatment offer modest benefit disorder rochearengdiagnosticsindd pharmaceuticals pipeline target area high unmet medical need phase phase phase iii registration project projectproduct indication project projectproduct indication project projectproduct indication project projectproduct indication oncology oncology oncology oncology dulanermin cancer pertuzumab early mabtherarituxan nhl fast infusion mabtherarituxan indolent nhl stline maint braf kinase inh metastatic melanoma pertuzumab mbc ndline mabtherarituxan nhl formulation avastin ovarian cancer stline mdm antag solid hematologic tumour adc trastuzumabdm early avastin adj breast cancer avastinxeloda meet breast cancer stline antiegfr humab solid tumour hedgehog pathway inh advanced basal cell carcinoma avastinherceptin mbc stline tarceva nsclc egfr mutation cifmek dual inh solid tumour hedgehog pathway inh operable basal cell carcinoma avastin adj nsclc positive stline raf mek dual inh solid tumour antimet mab metastatic nsclc avastin adj breast cancer herneg kinase inh solid tumour anticd mab nhl cll avastin adj triple negative inflammation autoimmune disorder antiplgf mab solid tumour braf inh meet melanoma ndrdline avastin relapse ovarian cancer mabtherarituxan ancaassociate vasculitis antiegfl mab solid tumour navitoclax abt solid hematologic tumour avastin highrisk carcinoid actemraroactemra jia systemic onset mek inh solid tumour chu topoisomerase inh gastric cancer avastin gbm stline mek inh solid tumour avastin meet colorectal cancer treat kinase inh solid hematologic tumour inflammation autoimmune disorder ment multiple line chu epogin epoch chemotherinduce anemia akt inh solid tumour lebrikizumab asthma avastin meet breast cancer ndline antifgfr mab multiple myeloma oxl mab asthma herceptin formulation iap antag solid tumour lymphoma rontalizumab systemic lupus erythematosus herceptin adj treatment adc anticd hematologic malignancy antilt mab rheumatoid arthritis pertuzumab mbc stline nme antiangiogenic solid tumour xolair chronic idiopathic urticaria tarceva adj nsclc antiher mab metastatic epithelial tumour antim prime mab asthma tarceva nsclc egfr mutation antiglypican mab liver cancer positive stline chu alk inh nsclc virology adc trastuzumabdm mbc stline chu solid tumour hpv immunotherapy cervical neoplasia adc trastuzumabdm advanced mbc nucleoside polymerase hepatitis anticd mab chronic lymphocytic leukemia inflammation autoimmune disorder inh prodrug anticd mab indolent nhl antiil mab rheumatoid arthritis danoprevir hepatitis braf inh metastatic melanoma stline crth antag asthma anti rhumab ulcerative colitis cardiovascular metabolic disease inflammation autoimmune disorder select abbreviation antip selectin mab cardiovascular disease actemraroactemra ankylose spondylitis adj adjuvant treatment hpv human papillomavirus virology sglt inh type diabetes actemraroactemra formulation adc antibodydrug conjugate inh inhibitor nucleoside polymerase hepatitis actemraroactemra early rheumatoid arthritis amd agerelate macular jia juvenile idiopathic arthritis inh central nervous system actemraroactemra dmard inadequate antag aneg tae nra ist tion maa trt eib tmdy ent chu serine palmitoyltran hepatitis gantenerumab alzheimer disease responder headtohead breast cancer meet metastatic cancer ferase inh ocrelizumab relapsingremitte cll chronic lymphocytic multiple sclerosis leukemia nhl nonhodgkin lymphoma nicotinic receptor alzheimer disease cardiovascular metabolic disease dmard diseasemodifye nme new molecular entity cardiovascular metabolic disease agonist aleglitazar cardiovascular risk reduction antirheumatic drug nsclc nonsmall cell lung cancer hsd inh metabolic disease mglur antag treatmentresistant depression type diabete erm eio pst itia emultiforme sca uta eid srthritis cat antag cardiovascular risk chronic evo nmda receptor antag treatmentresistant depression dalcetrapib atherosclerosis cardiovascular herneg hernegative kidney disease risk reduction abca inducer dyslipidemia antioxldl mab secondary prevention central nervous system cardiovascular event ocrezulimab primary progressive gipglp dual agonist type diabete glycine reuptake inh schizophrenia negative symptom legend central nervous system glycine reuptake inh schizophrenia suboptimally therapeutic protein biologic mglur antag depression control small molecule gabaa inverse cognitive disorder blue type indication agonist ophthalmology black type additional indication triple reuptake inh depression lucentis diabetic macular edema antiamyloid peptide alzheimer disease lucentis amd high dose rgno roche andor genentech manage mab chu chugai manage evo evotec ophthalmology antifactor mab geographic atrophy phase initial study healthy volunteer possibly patient phase efficacy tolerability dosefinde study patient phase iii largescale study patient statistical confirmation safety efficacy registra marketing application file andor japan tion file file usa current january business innovation answer medical challenge research create stateoftheart diagnostic pioneer medicine help million people world focus personalise healthcare roche aim develop novel medicine diagnostic help patient live long well life constantly strive scientific excellence continue develop effective thera peutic option previously world large biopharmaceutical company number supplier vitro diagnostic roche bring highly effective drug market include industry lead portfolio cancer medicine company recognise potential personalised medicine today expertise molecular biology enable develop target medicine specific patient group contribute well safe costeffective healthcare rochearengtable contentsindd content key figure inside cover pharmaceutical pipeline inside cover highlight letter shareholder letter chairman letter ceo roche group group results outlook group strategy pharmaceutical result sale review development highlight research development diagnostic result business area highlight research development corporate governance remuneration report corporate governance remuneration report corporate responsibility stakeholder engagement patient people society responsible practice safety security health environmental protection independent assurance report gri statement rochearengtable contentsindd roche business report letter shareholder franz humer dear shareholder wasachallengingyearforthepharmaceuticalindustrymarketconditionsas anticipatedforquitesometimebecameeventougherinthewakeofthefinancial crisishighgovernmentbudgetdeficitsaddedtopricingpressuresintheglobalhealth caresectorineuropemanygovernmentscutdrugpricessignificantlywhilehealthcare reformintheusresultedinhigherrebatesonprescriptiondrugsontheregulatory frontthehurdlesforgainingapprovalofnewmedicineswereraisedevenhigherdra maticallyincreasingthecostofdrugdevelopmentanddelayingaccesstoinnovative treatment amidthesechallengesrochepostedgoodfullyearresultshoweverwealsofeltthe effectsofthemarketchangesivejustdescribedinjulytheusfoodanddrugadmin istrationfdarejectedourapplicationforacceleratedapprovaloftdmeven thoughthisnovelcompoundisexpectedtosignificantlyimprovethetreatmentofbreast cancerthiswillincreasetheclinicaldevelopmentcostsfortdmanddelaythis rochearengletter shareholdersindd letter shareholder roche business report promisingdrugsapprovallateintheyearthefdaannounceditsintentiontowithdraw approvalofavastinincombinationwithchemotherapyforfirstlinetreatmentofmeta statichernegativebreastcancerwhileawithdrawalwillnotaffectuspatient accesstoavastininitsotherapprovedcancerindicationsitwouldadverselyimpact patientswiththisveryseriousdiseasethedaythefdamadeitsannouncement theeuropeanmedicinesagencyemaconfirmedavastinsvalueinthefightagainst breastcancerineuropewomenwithadvancedbreastcancerwillthuscontinueto haveaccesstothistreatmentoption wearecloselymonitoringdevelopmentsinhealthcarepolicyaroundtheworldprecisely becausewebelieveourhighlyinnovativeproductscontributeinimportantwaysto moreeffectivecostefficienthealthcaredeliveryweconsideritvitalforthefuturethat policymakersandhealthofficialslooknotonlyatthecostsofnewmedicinesbutalso attheinnovationtheyembodyandthebenefitstheyofferpatientsgiventhemanydis easesthatstillcannotbetreatedsatisfactorilyoratallmedicalprogressshouldbe viewedmoreasapublicgoodthatdeservesvigorouspoliticalsupport whenwediscussinnovationwemustbearinmindthatitisinherentlyriskypioneering researchanddevelopmenteffortssometimesproducebreakthroughsbuttheyalsocan sometimesnotachievethedesiredendpointstaspoglutideisacaseinpointwesus pendedalatestagedevelopmentprogrammeonthisnewtreatmentfortypediabete ataverylatestageofdevelopmentaftercarefulassessmentoftheavailablesafetyand efficacydata ourintenseresearchanddevelopmentactivitiesalsoyieldedsomeverystrongand promisingresultslastyearwecurrentlyhavetwelvenewmolecularentitiesinlatestage developmenthalfofwhicharedesignedfortargeteduseinspecificpatientpopulation withthehelpofcompaniondiagnostictestswehavemadeenormousprogressin personalisedhealthcarehelpedbythecloseinterplaybetweenourpharmaceutical anddiagnosticsdivisionsthesedevelopmentsrepresentmajorstridesandmakeus confidentthatwewillremainanindustryleader rocheconvincinglymetitssalesandearningstargetsforexcludingsalesofour influenzamedicinetamifluwhichasexpectedweredownsharplyfortheyeargroup salesroseinlocalcurrenciesnetincomeattributabletorocheshareholder showedastrongincreaseadvancingtobillionswissfrancsdespitethecost associatedwiththeoperationalexcellenceprogrammeamountingtoaconsiderable billionswissfrancscoreearningspershareakeyindicatorofunderlyingbusiness performanceincreasedinlocalcurrenciesinswissfranc inviewofthecompanyshealthycashflowandpositiveoutlooktheboardofdirector willproposeadividendincreaseforoftoswissfrancspershareand rochearengletter shareholdersindd roche business report letter shareholder nonvotingequitysecurityupfromswissfrancsforsubjecttoyour approvalattheannualgeneralmeetingagmthiswillberochesthconsecutive annualdividendincrease lookingaheadtotheannualgeneralmeetingonmarchiwouldliketomention theupcomingchangesontheboardofdirectorswalterfreyandwolfgangrutten torferhavedecidednottostandforreelectiononbehalfoftheentireboardiwould liketothankthembothfortheirdedicatedservicetorocheduringhislongtenureon theboardmrfreywhorunsahighlysuccessfulfamilycompanyhasmadesignificant contributionstothegroupsgrowthandsuccessamongthestrengthsmrruttenstorfer broughttotheboardhisexpertiseonthegrowthmarketsineasterneuropeandthe middleeasthasbeenparticularlyvaluable weintendtousethisopportunitytostrengthentheboardfurtherbynominatingaddi tionalindependentdirectorsasannouncedindecemberpaulbulckeceonestlsa christophfranzchairmanandceodeutschelufthansaagandpeterrvoser ceoroyaldutchshellplcwillbestandingforelectionasnewmembersoftheboard attheannualgeneralmeetingwewillalsoproposethatthetermofboardmember bereducedfromthreetotwoyearsthiswillenableshareholderstoinfluencethecom positionoftheboardatshorterintervalsinfuture aftertenyearsofexceptionalserviceonthecorporateexecutivecommitteeerich hunzikerhasdecidedtoretirefromrocheattheendofmarcherichhunzikerwas appointedchieffinancialofficerinbecomingdeputyheadofthecorporate executivecommitteeinduringhislongcareeratrocheerichhunzikerwasone ofthekeyarchitectsofthegroupssuccessfuldevelopmentiwouldliketotakethis opportunitytothankerichhunzikersincerelyforhisoutstandingcontributiontothe groupsoverallsuccess theboardofdirectorshasappointedalanhippetosucceederichhunzikeraschief financialofficeralanhippewilljoinrocheasamemberofthecorporateexecutive committeeasofaprilalanhippeservedasamemberoftheexecutiveboardof continentalagfromtosinceaprilhehasbeencfoandamember oftheexecutiveboardofthyssenkruppag ourcompanywashonouredlastyearforoutstandingachievementsinanumberof areasiamparticularlypleasedthatthedowjonessustainabilityindexesnamedusthe supersectorleaderinhealthcareforthesecondyearinarowrankingrocheasthe worldsmostsustainablehealthcarecompanywefirmlybelievethatsustainablecorpo ratepoliciesandpracticesultimatelycreatelongtermvalueandpromoteinnovation rochearengletter shareholdersindd letter shareholder roche business report oursuccessasacompanyisbuiltonscientificexcellencethatbenefitspatientsthe successfulintegrationofgenentechhasfurtherstrengthenedourinnovativecapa bilitiesastheworldslargestbiotechcompanyandtheleadingsupplierofcancermedi cinesweleadinpersonalisedhealthcarearetheworldsnumberonesupplierof vitrodiagnosticsandhaveoutstandingproductportfoliosinboththepharmaceutical andthediagnosticsdivision ourabilitytocreatevalueforallstakeholdersiscrucialtoourfuturesuccessandwe willcontinuetovigorouslypursuethisstrategy franzbhumer chairmanoftheboard rochearengletter shareholdersindd roche business report letter shareholder severin schwan dear shareholder sandrobhadbeenrecentlydiagnosedwithmalignantmelanomashortlyafterhisth birthdaymalignantmelanomaisoneofthedeadliestmostaggressiveformsofskincancer withovernewcasesreportedworldwideeachyearitishighlylikelytometastasise ataveryearlystageandoncepatientshavedevelopedmetastasestherearealmostno treatmentoptionsavailabletothemlifeexpectancyfollowingdiagnosisistypicallyamatter ofmonthshisdoctorsgavehimfourmonthstolive sandrobmettheinclusioncriteriaforaphaseiiclinicaltrialinwhichwearetestingour novelinvestigationaldrugrginpatientswithadvancedmalignantmelanomawhose cancercellscarryaspecificgeneticmutationadiagnostictestconfirmedthathehadthis mutation beforereflectinginmoredetailsonourclinicaltrialsiwouldliketobrieflyreviewthe groupsbusinessperformanceindespitestrongpressureonpricesintheusandin europethepharmaceuticalsanddiagnosticsdivisionsbothpostedgoodresultsexclude tamiflusaleswhichweredownbillionswissfrancsfortheyearsalesinthepharma ceuticalsdivisionadvancedabovetheoverallmarketgrowthincludingtamifludivisional salesdeclinedinlocalcurrenciestobillionswissfrancsgrowthwasdrivenbykey rochearengletter shareholdersindd letter shareholder roche business report productsforoncologyophthalmologyinflammatoryandautoimmunediseaseandanemia thankstocontinuedstrongdemandforouranticancermedicinesweexpandedourleadin thisimportantmarketsegmentinthediagnosticsdivisionsalesadvancedinlocal currenciesagainsignificantlyoutpacingthemarketandsolidifyingrochespositionasthe leadingsupplierofin vitrodiagnosticsprofessionaldiagnosticsanddiabetescarewere thedivisionsprimarygrowthdriver thegroupscoreoperatingprofitgrewfasterthansalesrisingbyarobusttobillion swissfrancsinlocalcurrenciesprofitabilityimprovedfurtherwiththecoreoperatingmar ginsinthepharmaceuticalsanddiagnosticsdivisionsadvancingpercentagepointsto andpercentagepointstorespectivelyonceagaintheearningspower ofouroperatingbusinesseswasalsoreflectedinthegroupsoperatingfreecashflowwhich lastyearreachedastrongbillionswissfrancsthankstoourstrongcashflowby yearsendwehadalreadyrepaidathirdofthedebtincurredinconnectionwiththegenen techtransactionearlierthanoriginallyplanne succeedinginourindustryistougherthaneverpricingpressuresarerisingsharplyandthe requirementsforapprovalandreimbursementofnewmedicinesarebecomingincreasingly stringentatrocheweadditionallyexperiencedsetbackswithsomeofourlatestagedevel opmentprojectslastyearincludingthediabetesdrugtaspoglutide inresponsetothesechallengesmycolleaguesontheexecutivecommitteeandidecide totakeappropriateactionnowtoensurerocheslongtermsuccessinnovemberwe launchedthecomprehensivegroupwideoperationalexcellenceprogrammewhichis designedtostrengthenthegroupsproductivityandinnovativecapacityintheyearsahead wehaveidentifiedawiderangeofopportunitiestoimproveprocessesandraiseproductivity andefficiency implementationoftheoperationalexcellenceprogrammeisalreadyunderwayandwillcon tinuethroughasaresultofthisinitiativetheworkforceofroughlyatjune willbereducedbypositionsalmostoftheglobalworkforcethegreat changeswillbeinthepharmaceuticalsdivisionwherewewillbeadjustingourglobalsale organisationandtakingstepstoimproveefficiencyandproductivityinproductdevelopment andoptimiseourmanufacturingnetworkinthediagnosticsdivisionthecolocationof relatedbusinessrdandoperationalfunctionsatselectedsiteswillenablethedivisionto streamlineitssitenetwork wearetakingthesemeasuresproactivelyfromapositionofstrengthrocheistheworlds biggestbiotechcompanywithproductsandproductlinesthatgenerateannualsale ofoveronebillionswissfrancseachanddespitelastyearssetbacksourresearchand developmentpipelineremainsoneofthestrongestintheindustrywithourcombine strengthsinpharmaceuticalsanddiagnosticsandprovenexpertiseinmolecularbiologywe rochearengletter shareholdersindd roche business report letter shareholder areuniquelypositionedtorealisethepromiseofpersonalisedhealthcaretomaketreatment saferandmoreeffectivetherevolutionaryadvanceswearestartingtoseeinmolecular biologygiveusastrategiccompetitiveedgeacrossanumberofareasincludingourability toraiseresearchproductivity personalisedhealthcareparadigmsincreasinglyshapeourresearchanddevelopmentpro grammeswecurrentlyhavetwelvenewmolecularentitiesinlatestagedevelopmenthalf ofwhicharetailoredtospecificpatientpopulationsourbrafinhibitorformalignant melanomametmabforlungcancertdmandpertuzumabforbreastcancerandother projectsinvirologyandinflammationallrepresentpotentialmajoradvancesforpatient similarlyourdiagnosticsdivisionisdevelopinganumberofbiomarkerstosupportthera peuticdecisionmakingtargetedtherapiesanddiagnosticteststhatcontributetobetter medicaldecisionsnotonlyimprovepatientcarebutalsohavehealtheconomicbenefitsthat makethemattractivetoregulatorsandpayer oneofthemostimpressiveexamplesofpersonalisedhealthcareisrgthedruguse totreatmalignantmelanomawhichimentionedearlierthankstoinsightsintospecific geneticchangesintumourcellshugestridesarebeingachievednowinclinicaltrialsina diseaseonceconsideredvirtuallyuntreatable tumoursgenerallydevelopfromjustonecelleverycellcontinuouslyundergoeschange knownasmutationsthataffectcertainsignallingpathwayswithinthecellmostmutation arecorrectedspontaneouslybutsomemanagetoevadethebodysrepairmechanism causingcellstodivideuncontrollablyandthusformtumoursscientistshavediscoveredthat inoverhalfofallmelanomapatientsthediseaseistriggeredbyahighlyspecificmutation ofthegenecodingforthebrafproteinwhichisinvolvedincellgrowthabrafve mutationtriggersuncontrolledcellgrowthandthesecancerpatientssandrobfor examplehavevirtuallynoprospectofbeingcure rganoralcancerdrugcodevelopedwithourpartnercompanyplexxikonactsvia ahighlyinnovativemechanismtoinhibitthebrafproteinimplicatedinthediseasethenew drugspecificallydestroysthosecellscarryingthevemutationanddoesnotattack healthycellswithoutthemutation wehavedevelopedadiagnosticassayforusewiththedrugwhichiscapableofdetecte thevemutationintumoursandwillthushelpidentifypatientswhoareverylikelyto respondtothenewdrugthismeansthenewdrugwillbeusedonlyinpatientslikelyto benefitfromthenewtreatment theinterimresultsofaphaseiiitrialwhichwepublishedinjanuaryarevery encouragingforthefirsttimeapersonalisedinvestigationalmedicinerghasshown asignificantsurvivalbenefitinmetastaticmelanomathisisanimportantadvance letter shareholder roche business report forpeoplewiththebrafvmutationpositiveformofthediseasewhohavehad extremelylimitedtreatmentoptionsfulldatawillbepresentedatamedicalmeetinglater thisyearrocheisworkingcloselywithglobalhealthauthoritiessothatpatientsworld widecanalreadybetreatedwiththenewdrug thepursuitoftreatmentsofferingrealbenefitstopatientsisthecoreofourcorporate strategyconsistentwiththatstrategywewillcontinuetodriveprogressonourpromise developmentportfolioweexpectresultsfromatotalofphaseiiandphaseiiitrial inandbasedonourcurrentlatestageportfolioweexpecttosubmituptoeight regulatoryfilingsforapprovalofnewmolecularentitiesbytheendofmoreover wearecurrentlyworkingonmorethanadditionalindicationsforexistingproduct goingforwardinnovationsthatbenefitpatientswillcontinuetodriveoursuccessthrough excellenceinsciencewestrivetodeveloppioneeringtreatmentsanddiagnosticteststhat prolongpatientslivesandtangiblyimprovetheirqualityoflife rocheowesitssuccesstoitsemployeesthankstotheirtremendousdedicationandhard workweonceagainachievedourgoalslastyeardespiteanincreasinglychallengingmarket environmentonbehalfoftheentireexecutivecommitteeiwouldliketothankallour employeesfortheirimportantcontribution makingsurethatrocheremainsanemployerofchoiceisanimportantpriorityformeso iamespeciallypleasedtoreportthatinourcompanywasagainvotedatopemployer inpollsinanumberofcountriesbeingatopemployerisnotjustaboutgivingasmany employeesaspossibleopportunitiestodevelopprofessionallyandmakethingshappenin thecompanyinnovationdependsonadiversityofviewsandapproachesoneoftheway werepromotingdiversityatrocheisbyfillingmoremanagerialpositionswithwomenatthe startofwesetourselvesthegoalofincreasingtheproportionofwomeninthetop leadershippositionsbyhalftooverthenextfiveyearsiamhappytoreportthat wemadeprogressonthisfrontaswelllastyear whathappenedtotheyoungmanwithmelanomalikemanyoftheothertrialparticipant sandrobhasrespondedwelltoournewdrugforskincancerheisstillaliveanddoingwell thisisexactlywhatwehaveinmindwhenwetalkabouthelpingpatientsthroughexcel lenceinscience severinschwan chiefexecutiveofficer rochearengletter shareholdersindd roche group group post solid overall result challenge market core operating profit grow fast sale core earning share increase doubledigit rate steadily make progress personalise healthcare new molecular entity latestage pipeline half target specific patient population rochearenggroupindd roche group roche business report group result inthediagnosticsdivisionwasinlocalcurren ciesmainlyresultingfromsalesgrowthdueto outlook newproductlaunchesandtheongoingoperational efficiencyprogrammesthegroupscoreoperate profitmarginincreasedbypercentagepointsto overall result withthepharmaceuticalsdivisionimprove therochegrouppostedsolidoverallresultsin percentagepointstoandthediagnos groupsaleswerestableinlocalcurrencie ticsdivisionbypercentagepointsto atbillionswissfrancsinswissfranc inusdollarsthegoodunderlyinggrowthof inthegroupsnetincomeincreasedbyto bothdivisionscompensatedfortheexpecte billionswissfrancscomparedtonet declineintamiflusalesandtheimpactsofhealth incomeattributabletorocheshareholdersrose carereformsandausteritymeasuresexclude tobillionswissfranc tamiflusalesincreasedbyinlocalcurrencie thepharmaceuticalsdivisionrepresente thegroupsoperatingfreecashflowremainedstrong ofgroupsalesandthediagnosticsdivisioncon atbillionswissfrancsafreecashflowof tribute billionswissfrancswasachievedindespite higherinteresttaxanddividendpayment salesinthepharmaceuticalsdivisiondeclinedby inlocalcurrenciestobillionswissfrancs excludingtamiflulocalgrowthwasabovemar board directors ketgrowthdemandfortheoncologydrugsavastin mabtherarituxanherceptinxelodaandtarceva propose increase continuedtogrowstronglyadditionalmajorgrowth driverswereactemraroactemrainrheumatoid dividend arthritismircerainanemiaandlucentisinophthal mologyactemrawhichisnowlaunchedinsome swiss franc share countriesincludingtheunitedstatestheeuand japanreachedsalesofmillionswissfrancsin nonvoting equity security thesepositivefactorscompensatedformostof theexpectedstrongdeclineintamiflusalesthe approval annual general reductionincellceptsalesduetouspatentexpiry inmayandtheimpactsoftheushealthcare meeting reformseuropeanausteritymeasuresandpricecut injapan thediagnosticsdivisionincreasedsalestobil ofthedebtraisedinearlyhadalready lionswissfrancsingrowinginlocal beenrepaidbydecemberinadditionthe currenciesinswissfrancsinusdollar groupexerciseditsoptiontocallforredemption therebystrengtheningitsleadingmarketposition aportionoftheusdollarnotesduemarch majordriverswereprofessionaldiagnosticswith ofthetotalprincipalamountofbillionusdol salesgrowthanddiabetescarewithsale larsbillionusdollarswillberedeemedinmarch growth thenetdebtpositionofthegroupis bil lionswissfrancsadecreaseofbillionswiss thegroupscoreoperatingprofitincreasedbyin francsfromdecember localcurrenciesinswissfrancsthepharma ceuticalsdivisionincreaseditscoreoperatingprofit theboardofdirectorsisproposinganincreaseof byinlocalcurrenciesdrivenprimarilybycost inthedividendfortoswissfrancs synergiesfromthegenentechintegrationandprod pershareandnonvotingequitysecurityforapproval uctivityimprovementscoreoperatingprofitgrowth attheannualgeneralmeete rochearenggroupindd roche business report roche group thiswouldbethethconsecutiveincreaseofthe outlook dividendandcorrespondstoanincreaseinpayout ingroupandpharmaceuticalssalesexclude ratiofromintofor tamifluareexpectedtogrowatlowsingledigit ratesinlocalcurrenciesreflectingtheimpactofus financial implication operational excellence healthcarereformandeuropeanausteritymeasures onnovemberthegroupannouncedimple pharmaceuticalssalesarethereforeexpectedto mentationplansforitsoperationalexcellencepro growinlinewiththemarket grammewhichisaimedatadaptingcoststructure toanincreasinglychallengingmarketenvironment indiagnosticssalesareagainexpectedto andachievingsignificantefficiencyandproductivity growsignificantlyaheadofthemarketdrivenbyfur gainstheinitiativeisexpectedtogeneratesaving therrolloutofnewproductsinallbusinessarea ofbillionswissfrancsinwithprojecte savingsofbillionswissfrancsfromonward inspiteofamorechallengingenvironmentandthe implementationisscheduledtobesubstantially introductionofanexcisetaxintheunitedstate completedbytheendofduringtheperiod rocheaimsforcoreearningspersharetogrowata fromthroughrocheexpectstoincur highsingledigitrateinatconstantexchange restructuringcoststotallingbillionswissfrancs rate asaconsequenceofimplementingtherespective rocheaimstoincreasethedividendinlinewith restructuringmeasuressignificantcostswere coreearningspersharegrowth alreadyincurredinthecostsinofbil lionswissfrancsmainlyrelatetoseverancepayment basedonthestrongoperatingfreecashflowroche andimpairmentsofintangibleassetsthepharma expectstoreducedebtprogressivelyandtoreturnto ceuticalsdivisionaccountsforbillionswissfranc anetcashpositionby ofthesecostsandbillionswissfrancsrelate tothediagnosticsdivisionroughlyofthe chargesarenoncashbeingmainlyimpairmentsof propertyplantandequipmentandintangibleasset group expand presentation core result previously core ep show income statement group operating result divi sion show ifrs core basis allow transparent assessment actual result underlie performance business core result concept fully describe page finance report reconciliation ifrs core result give roche group roche business report key achievement businessfinance pharmaceutical sale exclude tamiflu increase market growth achievement diagnostic sale growth significantly ahead market core operating profit margin significantly division doubledigit rise core earning share constant exchange rate dividend increase propose reporting year product pipeline key drug approval include approve new indication actemra herceptin lucentis mabtherarituxan new molecular entity latestage development personalise healthcare approach new molecular entity move latestage clinical development lebrikizumab asthma metmab lung cancer hepatitis ocrelizumab multiple sclerosis diagnostic test instrument launch key market patient access define new pricing arrangement increase patient access medicine healthcare emerge market expand commitment file enforce patent low income coutrie lic define world bank launch educare progamme africa international atomic energy agency iaea establish online university provide oncology training doctor people genentech vote science magazine employer eighth time roche rise place increase percentage woman key position publish scientific article nearly highimpact journal nature science cell society employee generate million swiss franc annual children walk support aid orphans malawi refurbish primary health coach phelophepa health train south africa responsible practice year roche speakup line report violation code conduct demonstrate responsible use employee launch global marketing sale compliance questionnaire promote good business conduct roll supplier code coduct supplier receive commitment introduce online procurement training complete employee roche name healthcare supersector leader dow jones sustainability index second year run safety security health reduce ecobalance measure total environmental impact environmental year ahead target protection keep greenhouse gas emission stable despite significant growth company learn roche achievement area corporate responsibility page rochearenggroupindd roche business report roche group group strategy change healthcare sector dynamic healthcare market impact tension steadily rise demand limited financial resource grow pressure healthcare budget mean increasingly new fund available real innovation product offer patient significant add value compare conventional treatment despite current challenge pharmaceutical industry excellent prospect long term key driver success include rise life expectancy increase prosperity develop country numerous disease effective therapy rapid scientific technological advance theworldspopulationcontinuestoexpandand ashiftinthegrowthdynamicfromwesterntofar peoplearelivinglongeronaveragegreaterlife easternandlatinamericanmarketshasbeenappar expectancymeansariseinagerelateddisease entforsometimethistrendwillbecomeeven suchascancerdiabetesrheumatoidarthritis strongerinfuturebytheemergingmarketswill parkinsonsandalzheimersthisistruenotonly accountforsomeofthegrowthintheglobal oftheindustrialisedworldbutincreasinglyof pharmaceuticalmarketandtheirshareoftheworld developingcountriesandemergingmarketstoo marketwillincreasetoaroundtheasianphar moreovertherearestillnoeffectivetherapie maceuticalmarketforexamplehasgrowntwice forsome diseasesandpatientresponseto asfastastheoverallglobalmarketinrecentyear existingdrugsisoftenunsatisfactorythereis chinawhererocheagainexpandeditspres consequentlysubstantialunmetmedicalneedand encesignificantlyinhasbecomethethird increasingdemandformoretargeteddiagnostic largestpharmaceuticalmarketaftertheunite andmoreeffectiveandbettertoleratedtherapie statesandjapanin demographicchangesandgrowingdemandson medicalcareareplacinganevergreaterburdenon healthcaresystemstherecentfinancialandeco nomiccrisisandtheresultinggovernmentdeficitsin europeandtheunitedstateshavefurtherexacer batedthesituationpoliticalpressuretocurbhealth carecostshasthereforegrownineuropeseveral countriesimposedsignificantpricereductionson pharmaceuticalproductsinhealthcarereform intheunitedstateshasledtoanincreaseindrug rebatesundergovernmenthealthinsuranceplansand anewconsumptiontaxonpharmaceuticalsalesis plannedforinadditionusandeuropeanregu latoryauthoritieshavesignificantlyraisedthebar forapprovalofnewproductsandaretakingamuch morecriticallookatthetherapeuticbenefitsand safetyofnewdrugsdecisionsaboutwhichmedi cinestoadministerarebeingmadeincreasingly bypublicagenciesandhealthinsurersratherthan byphysicians rochearengstrategyindd roche group roche business report transform practice medicine tap vast potential personalised healthcare modern science tailor treatment patient inordertoremaincompetitiveinthefuturedespitea patientswiththesameclinicaldiagnosismayre tougherglobalenvironmentinthehealthcareindustry spondverydifferentlytothesamemedicineswhile rocheispursuingaclearinnovationstrategybase treatmentmaybeeffectiveandsuccessfulinsome onoutstandingscientificachievementswehavecon patientsothersmayexperienceundesirableside fidenceinmodernsciencesvastpotentialfordevel effectsorthedesiredclinicalbenefitdoesnotoccur opingtherapiesanddiagnosticteststhatwillreduce thisphenomenonisdueinmanycasestogenetic sufferingandhelppeopletolivelongerhealthier andothermoleculardifferencesbetweenindividual livesinparticularweseesignificantopportunitiesin patient thefastgrowingbodyofknowledgeaboutthemolec ularbasisofdiseasesadeeperunderstandingof treatmentstailoredtodifferentpatientpopulation diseasemechanismsandthegrowingrangeofestab havemedicalandeconomicadvantagesandarecon lishedandnewtherapeuticapproachesisenable sequentlynotonlyimportantforpatientsandphy ustodevelopmorespecifictargetedproduct siciansbutarealsowelcomedbyregulatoryagencie andhealthinsurersinadditionearlyselectionof throughourmedicallydifferentiatedtherapieswe patientswhoarehighlylikelytorespondtoanew wanttoofferpatientsanddoctorssignificantmedical compoundincreasesthesuccessrateindrugdevel benefitintermsofeffectivenessqualityandsafety opmentwhilealsoloweringdevelopmentcost toprovidelaboratorieswithefficiencygainsandto givepayershealtheconomicbenefitswealsostrive combiningstrengthsinpharmaceuticalsanddiag toensurepatientsaccesstotreatment nosticswithprovenexpertiseinmolecularbiology rocheisuniquelypositionedtomakeitspersonal targetedcosteffectivetherapiescanplayakeyrole isedhealthcarestrategyarealitythankstotheclose inovercomingcurrentchallengesinthehealthcare cooperationbetweenthepharmaceuticalsand sectorstateoftheartdiagnosticswillalsobecome diagnosticsdivisionsunderasingleroofonevery increasinglysignificantinarationalhealthcaresys thingfromresearchtosalesrocheiscommitte temdiagnosticscurrentlyaccountforonlyaround tothesystematicpursuitofpersonalisedhealthcare ofhealthcarespendingyetaroundofallme thisconceptisbecomingarealityformoreand icaldecisionsdependonaccuratefastdiagnosis moreofourdevelopmentproject heretoothereisvastpotential rochearengstrategyindd roche business report roche group pair target therapy companion diagnostic roche number product custommade specific patient population establish standard treatment include therapy herpositive breast stomach cancer infection cause hepatitis hepatitis viruse latestage pipeline contain new molecular entity tailor specific patient group companion diagnostic test include new drug skin lung breast cancer viral infectious disease feature encourage result battle thesereceptorscanbeidentifiedusingmoleculartis malignant melanoma sueteststhemonoclonalantibodymetmabbind rochesdevelopmentaldrugrgbrafinhib specificallytometreceptorsandpreventsactivation itoriscurrentlybeingtestedinpatientswith ofacancerpromotinggrowthfactorrocheisalso advancedmalignantmelanomainafinalphaseiii developingadiagnostictestfordetectingepidermal clinicaltrialdiagnosedworldwideinabout growthfactorreceptoregfrmutationsforpa peopleeachyearmalignantmelanomaisthemost tientswithnsclcpatientswithegfrmutationsre aggressiveformofskincancerthankstoinsightsinto spondespeciallywelltotheanticancerdrugtarceva specificgeneticchangesintumourcellshugestrides sodeterminingegfrmutationstatuswouldhelp arebeingachievednowinadiseaseonceconsid oncologiststopersonaliseandoptimisecancertreat eredvirtuallyuntreatabledevelopedonthebasisof mentseealsopersonalisedhealthcareforlung biomolecularfindingsrgisanoraldrugthat canceronand specificallyinhibitsthedeadlychainofeventsasso ciatedwiththedevelopmentofmelanoma progress fight stomach cancer stomachgastriccanceristhesecondleading inroughlyhalfofallmelanomapatientsthedisease causeofcancerrelateddeathsintheworldwith istriggeredbyadangerousmutationofthebraf overnewcasesdiagnosedeachyear genearocheassaydevelopedtodetectthismuta ineuropeanusandsouthkoreanregulator tionwillhelpidentifypatientsverylikelytorespond approvedherceptinforuseinherpositivemeta torginitialphaseiitrialdataareencourage staticstomachcancer diseaseprogressionwassignificantlydelayedtu moursshrankmarkedlyinoverofpatientsand alreadyanestablishedtherapeuticoptioninbreast therewasanoticeableimprovementinpatient cancerherceptinisoneofthemostsuccessful qualityoflife examplesofpersonalisedhealthcaretodatethe herbiomarkerisdetectedinaboutof extend life lung cancer patient gastrictumoursafastreliabletestforherstatus nonsmallcelllungcancernsclcisthemost providescriticalguidanceinbothapprovedher frequenttumourrelatedcauseofdeathintheworld ceptinindicationshelpingdoctorstoidentifythe accordingtopreliminarydatafromaphaseiitrial patientsmostlikelytorespondtothedrugher combiningthenovelmonoclonalantibodymetmab ceptinpluschemotherapyhasbeenshowntoprolong withtarcevaerlotinibnearlydoublesprogres thelivesofpatientswithstomachcancerbyupto sionfreesurvivalincertainpatientswithnonsmall celllungcancerthesepatientstumourcell carryanabnormallyhighconcentrationofacell surfaceproteinknownasthemetreceptor rochearengstrategyindd roche group roche business report mapk signal diagnostic therapeutic moleculartestpcr activeingredientbraf identifiespatientscarrye inhibitor rgtarget amutatedbrafgene melanomacancercell inpatientswithmutate brafgene meet signal diagnostic therapeutic tissuetestidentifie antibodymetmab tumourswithhighexpression rgdocksonmet ofthemetreceptor receptorandinhibit cancertriggeringgrowth factor signal diagnostic therapeutic tissuetestdetermine antibodydrugconjugate herreceptorsorher bindstoherreceptor geneexpression herceptinandlinke chemotherapyagentpene tratescancercelltdm test develop roche diagnostic precision twopronged attack breast cancer theantibodytrastuzumabbindstoherpositive preliminaryresultsfromaphaseiistudyoftrastuzu cancercellsandblocksasignallingpathwaythat mabdmtdminherpositivemetastatic makestumoursgrowwhilethechemotherapyagent breastcancershowthatthedrugshranktumoursin dmpenetratesanddestroysthecancercell onethirdofthewomenwhohadfailedpriorther anotherpotentialnewweaponagainstbreastcancer apiesknownasanantibodydrugconjugatetdm ispertuzumabrgthefirstofanovelclass linkstrastuzumabtheactiveingredientofhercep oftargetedtherapeuticsknownasherdimerisation tinwiththepotentchemotherapeuticagentdm inhibitorsrgblocksherfrompairingwith thisrepresentsanewtargetedtwoinone otherherproteinsthuspreventingtheabnormalac approachtotreatingcancer tivationofsignalcascadesthatoccursincancercell rochearengstrategyindd roche business report roche group combine force hepatitis hope asthma sufferers hepatitiscvirushcvcausesacuteandchronic asthmastillrepresentsamajorunmetmedicalneed liverdiseasesthatcanleadtoliverfailurecirrhosis moreovertheunderlyingdiseasemechanismsare andcancertherearecurrentlyovermillion notthesameinallcasesourscientistshavediscov peopleinfectedwithhcvworldwidediagnostictest eredthatinaparticularsetofpatientscertain basedonpcrtechnologycannowmeasureviral genesareactivatedinthewrongplaceandatthe loadinthebloodofpatientswithchronichepatitisc wrongtimebythechemicalmessengerinterleukin infectionanddeterminewhichofthefourdifferent ilakeymediatorinasthmareactionsreduc hcvsubgroupsgenotypesispresent ingillevelscouldthusbeawayofrelieve asthmasymptomsinthispatientsubpopulation thediseasecanthenbetreatedbypegylatedinter thisapproachiscurrentlybeingtestedinaphaseii feronstailoredtotherespectivegenotypeandviral trialwithlebrikizumabrginvolvingthe loadlevelsuchastherocheproductpegasysthe measurementofakeybiomarkercalledperiostin viralloadtestisalsousedafterafewweekstocheck itmaymakeitpossibletoidentifythepatientsmost treatmentresponseinmanypatientstheviruscan likelytorespondtoanantiilantibodylike becompletelyeliminatedforchronichepatitisc rgrochediagnosticsiscurrentlydeveloping patientswhodofailtobenefitfrominterferonbase anappropriateassay therapyseveralsmallantiviralmoleculesareinclinical developmentatroche oncejustavisionpersonalisedhealthcareis increasinglybecomingarealityhelpedbypioneere thefocushereisonhepatitiscsubtypeinfection effortsatrocheforyearswehavebeenworke whichisverydifficulttotreatinitialresultsshowthat toadvancemorepersonalisedtreatmentoption inpatientswhohavenotrespondedtointerferon acrossallourtherapeuticareasofinterestgoingfor thenewcombinedtreatmentcanachievea wardweareideallyequippedtoremainatthefore reductioninbloodviralloadwithinjusttwoweek frontofthisgroundbreakingnewapproachtohealth careandtocontinuerealisingitstremendous potentialforallourstakeholder rochearengstrategyindd roche group roche business report signal diagnostic therapeutic tissuetestdetermine antibodypertuzumab herreceptorsorher rginhibitspairingof geneexpression herherandher receptorsandthusprevent fatalsignallingincancer cell hepatitis virus diagnostic therapeutic moleculartestpcrto hcvnucleosidepolymerase determinelevelsofcirculate inhibitorrgprevent hepatitiscvirus reproductionofhepatitisc viruse lebrikizumab diagnostic therapeutic immunoassaymeasure antibodylebrikizumab theserumleveloftheprotein rginhibitschemical periostinanilgene messengerinterleukin productandthusdetect thattriggersinflammationin lunginflammationdriven asthmaticreaction byil molecule test develop roche diagnostic rochearengstrategyindd roche business report roche group precise diagnosis personalise therapy nonsmall cell lung cancer nsclc world number cause cancer relate death common form adenocarcinoma illustration diagnostic test provide patient suffer nsclc physician information tumour molecular profile likelihood response drug therapy appropriate therapeutic option roche develop immunohisto chemistry situ diagnosis lung hybridisation test cancer complex determine exact imaging technology type tumour present initial examination initial diagnosis prognosis tissuesamplesfromthepatientarefirstexamine thepathologistthencharacterisesthetumouron inthepathologylaboratorytoseewhethercancer thebasisofcelldifferentiationandothercriteria cellsarepresentifirregularitiesincellularshapeor rocheiscurrentlydevelopinganumberofmolecular structurearefoundmoreextensivetestsare biomarkersthatwillenablephysicianstopredict require thecourseofcancersasaccuratelyaspossible specific cancer diagnosis rochehasdevelopedseveralimmunohistochemistry andin situhybridisationtestsforuseonthebench markfamilyofinstrumentsthatreliablydeterminethe typeandsubtypeoflungtumourpresent rochearengstrategyindd roche group roche business report pathologist grade roche test tumour look market individual cell development help determine extent physicians cell differentiation stand mecha nism drive cancer growth select treatment likely benefit roche avastin specific patient tarceva pillar treat ment lung cancer roche continue develop new com pound target cancer therapy test therapy anumberofgeneshavebeenidentifiedasgrowth rochesanticancermedicinesavastinbevacizumab driversinnonsmallcelllungcancernsclcthese andtarcevaerlotinibplayacrucialroleinthe includetheegfrgenethemetreceptorsandthe treatmentoflungcancerandthecompanyiscurrently plkinase developinganumberofnewinnovativedrugsto addresscancerspecificpathwaysandofferpatient testsfromrochehelpdoctorsunderstandthemech targetedtherapiesinadditionrochediagnostic anismsdrivingtumourgrowthandthustoselect offersabloodtestenablingphysicianstomonitor drugsmostlikelytoworkbestforaparticularpatient responsestocancertreatment rochehasseveraltestsonthemarketorindevel opmentwhichusethreekeytechnologiesimmuno histochemistryihcin situhybridisationish andthepolymerasechainreactionpcr rochearengstrategyindd pharmaceutical solid local currency growth sale strategic product core operating profit despite low tamiflu revenue tough market environment additional approval key medicine progress promise project latestage development pipeline successful year pharmaceutical division focus translate excellence science effective medicine patient combine cut edge research roche genentech chugai japan partner worldwide global scale reach clinical development manufacture commercial operation rochearengpharmaceuticalsindd pharmaceutical roche business report pharmaceutical division brief sale million chf core operating profit million chf number employee key figure change change millions chf chf local currency sale sale united states western europe japan international asiapacific cemai latin america canada core operating profit operate free cash flow research development core basis cemai central eastern europe middle east africa central asia indian subcontinent pharmaceutical management team december pascal soriot chief operating officer pharmaceutical head pharma medicine hal barron global product development chief medical officer ian clark commercial operation north america ceo genentech tuygan gker commercial operation cemai meeta gulyani global portfolio management peter hug commercial operation western europe michael knierim human resources david loew global product strategy luke miel commercial operation asiapacific patrick mongrolle finance jrg rupp commercial operations latin america patrick yang global technical operation jeanjacque garaud pharma research early development pre osamu nagayama president ceo chugai richard scheller genentech research early development gred dan zabrowski roche partnering member corporate executive committee corporate governance member pharma medicine leadership team rochearengpharmaceuticalsindd roche business report pharmaceutical pharmaceutical division sale region solidlocalcurrencygrowthinsalesofstrategic productsandcoreoperatingprofitadditionalmar united states ketingapprovalsforstrategicproductsandprogress asiapacific witharangeofpromisingprojectsinourlatestage latin america rdpipelinemadeasuccessfulyearoverall region forthepharmaceuticalsdivisiongrowthwasdriven cemai primarilybystrongdemandforkeymedicinesfrom thegroupsoncologyandinflammatorydiseaseport foliosfollowingtheendoftheinfluenzaahn western europe pandemicandcompletionofgovernmentstockpile japan orderssalesoftamifludeclinedstrongly italic growth rate local currency cemai central eastern europe middle east africa weachievedimportantproductdevelopmentsuc central asia indian subcontinent cessesinincludingexpandedmarkete approvalsforactemraroactemraforrheumatoid arthritisintheusandtheeuherceptinforstomach bursementpricesorhigherrebatesonmedicine cancereuandusmabtherarituxanforchronic understatutoryhealthinsuranceorgovernment lymphocyticleukemiausandmaintenancetreat fundedprogrammesthesedevelopmentsalready mentoffollicularlymphomaeuandlucentisfor hadanoticeableimpactonsalesinand macularedemafollowingretinalveinocclusionus weexpectthistocontinueintoandbeyond keyregulatoryfilingsincludedmarketingapplica inadditionweexperiencedseveralproductdevel tionsforactemraroactemraforjuvenileidiopathic opmentsetbacksinthemostseriousof arthritisintheeuandusherceptinforstomach thesewerethedecisiontosuspendphaseiiitesting cancerinjapanandavastinforadvancedovarian oftaspoglutidefortypediabetesandregulatory cancerintheeu developmentsintheusandeuconcerningavastin asatreatmentforadvancedbreastcancer duringtheyearwemadedecisionstomoveseveral projectsintolatestagedevelopmentincluding indecembertheeuropeanandushealthauthoritie ocrelizumabformultiplesclerosisrgforhep announceddecisionsthatarepivotalindetermine atitisclebrikizumabforasthmaandrg whetheravastinremainsavailableasatreatment metmabforlungcancerpositiveresultsfromclin formetastaticbreastcancerwebelievestronglythat icaltrialswithotherlatestagecompoundssuch patientsshouldhavethisoptionandareplease asrgbrafinhibitorformelanomarg thattheeuropeanauthoritiescontinuetosupportthe gafornonhodgkinslymphomaandchronic useofavastininthisindicationitisdisappointe lymphocyticleukemiaandtdmandpertuzumab thattheusfoodanddrugadministrationfdahas forherpositivebreastcancerwerepublishedor cometoadifferentconclusionafterreviewingthe presentedatmajormedicalconferencesdure samesetofdatawebelievethatwomenwithher thesetargetedcompoundsaredesignedtomove negativemetastaticbreastcancerlivingintheus thestandardofcareforthesediseasesandimprove shouldalsohaveavastinasatreatmentoptionand patientsurvivalrochespharmaceuticalpipeline wehaverequestedahearingwiththefdaaccord currentlyincludesnewmolecularentitiesinlate inglyseep stagedevelopment respondingtothetougheroperatingenvironment atthesametimewasayearofsignificant andsetbacksoutlinedabovewecontinuedto challengespressureonhealthcarebudgetsinmany strengthenourpharmaceuticalsorganisationto countriesandhealthcarereformsintheunite statestheworldslargestmarketforpharmaceuti calstranslatedintomandatoryreductionsinreim state growth rate local currency rochearengpharmaceuticalsindd pharmaceutical roche business report increaseefficiencyandmaintainitsfocusoninno vationwebelievethatthemeasuresnowbeing exclude tamiflu pharma implementedthroughthegroupsoperationalexcel lenceprogrammewillenhancerochesabilityto ceutical division sale grow deliverbreakthroughmedicinesforpatientsallowe ustoexpandfurtherinhighgrowthemergingecon global market omieswhilestrengtheningourpresenceinestab lishedmarket healthcarereformsintheunitedstatesandausterity result main measuresineuropehadanegativeimpactontotal salesofapproximatelymillionswissfrancsor business developments percentagepointsexcludingtamiflusalesinthe usandwesterneuropeincreasedand salesbythepharmaceuticalsdivisionin respectivelycomparedwithmarketgrowthof declinedinlocalcurrenciesinswissfranc andadeclineinsalesofinjapanreflect inusdollarscomparedwithto bil bothsignificantlylowerdemandfortamifluand lionswissfrancsexcludingtamifluthedivision theimpactofrevisednationalhealthinsurancereim localcurrencysalesgrewabovetheglobal bursementpricesthatcameintoeffectinapril marketinadditiontothegroupsfivemaincancer excludingtamiflujapanesesalesgrewinavir medicinestheprimarysalesdriverswerelucentis tuallyflatmarket actemraroactemraandmirceragrowthfromthese andotherpharmaceuticalslargelycompensate coreoperatingprofitgrewinlocalcurrencie forlowersalesoftamiflucellceptandneorecor andwasstableinswissfrancsatbillionswiss monepogintogetherthetopsixsalesdriver francsthecorrespondingmarginincrease avastinmabtherarituxanherceptinlucentis percentagepointstodrivenbysynergiesfrom actemraroactemraandxelodacontributedover themergerwithgenentechandproductivityimprove billionswissfrancsinadditionalsalesin mentsthiswasachieveddespitetheexpectedsharp duetothepassingoftheinfluenzaahnpan declineintamiflusalesandtheimpactofhealth demicarelativelymildinfluenzaseasonandthe carereformsandausteritymeasuresareductionof completionofmostgovernmentstockpilingorder inmarketingexpenseswasachievedthrough salesoftamifludeclinedstronglyto million tightcostmanagementwhichmorethancovered swissfranc billionfrancslowerthanin anincreaseinallowancesforbaddebtsinsouthern europeresearchanddevelopmentexpense salesexpandedfastestintheinternationalregion declinedversusthankstoresourcepriori orexcludingtamifludrivenbydemandfor tisationwhilesecuringlongtermgrowththrough mabtheraherceptinavastinandotherkeymedi therichrdpipelineinadditiontoinvestmentsin cinesinemergingmarketsparticularlystronggrowth phaseiiiinitiationsthemetabolismfranchiseand wasrecordedinlatinamericaledbybrazil theearlierstageneurologyportfolioresearchand andvenezuelasolidgrowthintheasiapacific developmentexpensesincludedcostsassociate regionwasledbychinaandtaiwanaslight withthediscontinuationoftheocrelizumabrheuma decreaseintheunitedstatesreflectssig toidarthritisprogrammeseepbelowand nificantlylowersalesoftamifluandcellceptaswell projectterminationcostsassociatedwiththeopera ashealthcarereformimpactsaffectingallmajor tionalexcellenceprogramme productsadeclineinsalesinwesterneurope wasdueprimarilytomarkedlylowersalesoftamiflu andneorecormonandtheeffectsofgovernment austeritymeasuresintroducedinanumberofcoun pharmaceutical market growth accord ims end september triesincludinggreeceandspaininthesecond state result core basis quarterandgermanyinthethirdquartertogether finance report rochearengpharmaceuticalsindd roche business report pharmaceutical germanyandswitzerlandinadditionexpansion ofthekentuckydistributioncenterwascomplete core operating profit inthefacilitynowservesastheprimary distributioncentreforallproductsmarketedinthe margin increase percentage unitedstate point inallglobaltechnicaloperationsfacilitiespasse morethanhealthauthorityinspectionsin ourbiotechproductionfacilityinsingaporereceive thedivisionsfullyearoperatingfreecashflow itsfirstapprovalsbytheusfoodanddrugadmin remainedstrongatbillionswissfrancsthe istrationfdatomanufacturelucentisandavastin decreaseofcomparedwithprimarily biologicbulkdrugsubstanceforcommercialuse reflectsthepaymentinofcertainlarge intheusapprovalbytheeuauthoritiesistargete yearendaccrualsincludingemployeeretention forourkaiseraugstswitzerlandfacility andseverancepaymentsandhighroyaltypayment successfullylaunchedactemraproductforcommer relatingtostrongtamiflusalesinthesecondhalf cialisationintheunitedstatesdaysafterfda ofthepharmaceuticalsdivisionisontrackto approvalourbulkdrugmanufacturingfacilitiesin achieveitsgoalofpretaxannualsynergiesfrom southsanfranciscovacavilleandoceanside thegenentechmergerofapproximatelybillion californiausareceivedclassacertificationan swissfrancsbysynergiesofovermillion internationalbusinessawardrecognisingsystem swissfrancswereachievedinformore aticprocessimprovement informationonthedivisionsoperatingresult seethefinancereportpartofthisannual aspartofthecontinuousevaluationofourglobal report manufacturingnetworkwearealwaysreviewingand analysingourstructuresorganisationsprocesse intheyearunderreviewthepharmaceutical andoperationsinwesoldfacilitieslocatedin divisionincurredsignificantnoncorecostsassoci isandosouthafricaandkarachipakistanin atedwithrestructuringmeasuresimplemente additionplantsinmontevideouruguayandnutley undertheoperationalexcellenceprogrammemost newjerseyusawereclosedandwecontinue ofthesecostsrelatetoseverancepaymentsfol toplanfortheclosureofcertainoperationsinmann lowingreductionsinpositionsinsalesandmarket heimgermanyandbaselswitzerland ingglobalmanufacturingglobaldevelopment andresearchandearlydevelopmentaswellas followingadetailedanalysisoforganisational impairmentsofintangibleasset structuresandprocessesaspartofthegroupwide operationalexcellenceprogrammeglobaltechnical operationswillfurtherrefineitsorganisational manufacturing infrastructure structuretoimproveoperationalefficienciesopti misemanufacturingassetsandconsolidatethe integrationoftherocheandgenentechmanufactur technicaldevelopmentandclinicalsupplynetwork ingandsupplynetworkscontinuedinas someactivitieswillbereorganisedincalifornia initiativeswereimplementedtoensurethatglobal mannheimandothersitesbytheendofresult demandforcommercialandclinicalsuppliesof inginareductionofapproximatelyposition ourmedicinescanbemetandthatnecessaryadap inadditionrocheintendstoseekbuyersforitsus tationstoourgrowingpipelinearemadeintime sitesinflorencesouthcarolinaandboulder coloradopotentiallyaffectinganadditionaljob anumberofimportantmilestoneswereachieved togetherwithactivitiesinitiatedinthelasttwo ininaprilhillsborooperationsoregonusa yearsthesechangeswillreducethenumberof wasofficiallyinauguratedbyhillsborowill manufacturinglocationsfromtobythe betheuscommercialfillingandpackagingfacility endof forourmedicinessupplementingfacilitiesin rochearengpharmaceuticalsindd pharmaceutical roche business report sale therapeutic area oncology inflammatory autoimmune disease transplantation central nervous system respiratory metabolic disease bone disease infectious disease cardiovascular disease virology renal anemia ophthalmology italic growth rate local currency partner activity networkeinprojectwhichisdesignedtocreate anddeepenrelationswithleadingacademicinsti collaborationwithexternalpartnershaslongbeen tutionsworldwideunderaneweinpartnershipwith acornerstoneofrochesrdstrategyaccess harvarduniversityrocheprovidesstrategicque toexternalinnovationthroughlicensingandtargete tionsandknowhowtoharvardwithharvardprovid acquisitionsisasignificantmeansofstrengthene inginnovativesolution therdportfolioandexpandingthegroupstech nologycapabilitiesinrochepartneringsigne genentechpartneringcompletedfourproducttrans atotalofnewagreementsincludingoneprod actionsandresearchandtechnologycollabo ucttransactionandresearchandtechnologycol rationsinsupportingthecuttingedgework laborationsinadditiontenproductoutlicense ofgenentechresearchandearlydevelopment agreementsweresigne amongtheseisanexpansionoftheantibodydrug conjugatecollaborationwithseattlegeneticsin amongrochepartneringsmaintransactionsin oncologynewcollaborationsinimmunology wereanagreementwithbelgiancompanyremynd includedanexclusivelicensingagreementwith todevelopnoveltherapeuticsthatcouldslowdown swissbasedantibodyspecialistnovimmunecover neurodegenerationinparkinsonsandalzheimer inganantiilantibodythathasthepotential patientsanewcollaborationwasagreedwithaileron tobenefitpatientsacrossarangeofautoimmunedis therapeuticstodiscoverdevelopandcommercial easesanovelresearchprogrammewasagreed iseanovelclassofdrugscalledstapledpeptidether withuscompanyadimabwhichwilluseitspropri apeuticsapotentiallytransformativetechnology etarydiscoveryplatformtoidentifyfullyhumananti tocreatedrugsforimportantdiseasetargetsthatare bodiesagainsttwotargetsselectedbygenentech intractabletocurrentlyavailablemodalitiesin undertheagreementgenentechhasrightsto decemberrocheacquiredmarcadiabiotechapri commercialiseantibodiesgeneratedfromthecollab vatelyowneduscompanyfocusingonthedevel oration opmentofinnovativetherapeuticsformetabolic diseasesmarcadiasresearchanddevelopmentpro grammesonnewpeptidetherapiesforthetreatment sale review oftypediabetesandobesitywillbeintegrate select key product intorochesrdportfoliotheseincludenextgener ationpeptidessuchasmarcurrentlyinphasei developmentfortypediabetesseveralpartner thepharmaceuticalsdivisionsbroadbasedportfolio wereaddedtorochesexpandingtheinnovation ofmarketedproductsincludestenmedicinesfrom rochearengpharmaceuticalsindd roche business report pharmaceutical topselling pharmaceutical roche group millions chf avastin mabtherarituxan herceptin pegasys lucentis active substance active substance active substance active substance active substance bevacizumab rituximab trastuzumab peginterferon alfaa ranibizumab indication indication indication indication indication colorectal cancer nonhodgkin lymphoma herpositive breast hepatitis wet agerelate macular breast cancer nonsmall chronic lymphocytic cer advanced herposi degeneration macular cell lung cancer kidney leukemia rheumatoid tive stomach cancer edema follow retinal cancer glioblastoma arthritis vein occlusion rochearengpharmaceuticalsindd pharmaceutical roche business report thank pharmaceutical division broadbase portfolio roche world lead provider clinically differentiate medicine cancer viral inflammatory disease metabolic disorder xeloda tarceva cellcept neorecormon epogin bonvivaboniva active substance active substance active substance active substance active substance capecitabine erlotinib mycophenolate mofetil epoetin beta ibandronate indication indication indication indication indication colorectal cancer breast advanced nonsmall cell transplantation anemia osteoporosis cancer stomach cancer lung cancer advance pancreatic cancer image molecular diagram represent active substance medicine therapeutic protein small molecule yearonyear sale growth local currency sale lucentis market outside united states novartis rochearengpharmaceuticalsindd roche business report pharmaceutical sixtherapeuticareasthatgeneratedsalesofover latinamericainthethirdquarteravastin billionswissfrancseachinofthesethetop waslaunchedinchinainitsfirstindicationfirstline threerecordedsalesofwelloverbillionswiss treatmentofmetastaticcolorectalcancerinitial francseachcombinedsalesofthegroupstop uptakehasbeenveryencouraging pharmaceuticalsamountedtobillionswiss francsorofdivisionalsale fullyearsalesoncologyandautoimmunedisease ofmabtherarituxanrituximabfornonhodgkin salesofthedivisionsoncologyportfolioroseto lymphomanhlchroniclymphocyticleukemia billionswissfrancsinledbykeyproduct cllandrheumatoidarthritisratotalle bil avastinmabtherarituxanherceptinxelodaand lionswissfrancsinanincreaseofversus tarcevatogetherthesefivemedicinesaccountedfor sustainedgrowthintheoncologysegmentwas overhalfoftotalpharmaceuticalsalessalesof drivenbyuptakeincllandcontinuedstronguse antiviralmedicinesdeclinedforafullyeartotal innhlinwesterneuropeandtheussoliddouble ofbillionswissfrancsduemainlytothesharp digitgrowthintheinternationalregioninclude declineinsalesoftamifluoverallsalesoftherenal stronggainsinkeyemergingmarketsreflectsuptake anemiaportfoliodeclinedbytobillionfranc ofthemedicineinitsnhlindicationstheeuropean withstrongdemandformirceraoutweighedby rolloutofmabtherainanewindicationfirstline decreasingsalesofneorecormonepoginsalesin maintenancetreatmentofpatientswithfollicularlym thecombinedinflammationautoimmunetransplan phomacommencedinthefourthquarterestimate tationportfoliorosetobillionfrancsgrowe salesofmabtherarituxanintherasegment demandformabtherarituxanforrheumatoid reachedthebillionswissfrancmarkin arthritisandstronguptakeofactemraroactemra oftheproductstotalsaleshigherthanin offsetcontinuedgenericerosionofcellceptinthe growthisbeingdrivenbyincreasedusein unitedstate patientswithaninadequateresponsetooneormore tumournecrosisfactorinhibitorsandbygrowe oncology acceptanceofsixmonthrepeattreatmentinterval globalsalesofavastinbevacizumabforadvance colorectalbreastlungandkidneycancerandfor globalsalesofherceptintrastuzumabforher relapsedglioblastomaatypeofbraintumourrose positivebreastcancerandherpositivemetastatic tobillionswissfrancsreflectingcontinue stomachcancerrosetobillionswissfranc positiveuptakeoftheproductoverallsalesgrowth onsustainedsolidsingledigitgrowthintheunite inwesterneuropewasdrivenprimarilyby statesandwesterneuropeanddoubledigitgain continueduptakeforbreastcancerandimprove intheinternationalregionherceptinmaintained uptakeforcolorectalandlungcancerausterity itshighmarketpenetrationinbreastcancerwith measuresintroducedduringtheyearingreece salesalsobenefittingfrominitialuptakeforstomach spaingermanyandothermarketsresultedinapro cancerineucountriesandothermarketsinaddi gressiveflatteningofgrowthintheregionasa tionimprovementsinthequalityofherteste wholethatwasparticularlynoticeableinthefourth areexpandingthepopulationofpatientseligiblefor quartersalesintheuswereflatfortheyearreflect treatmentwithherceptininjapanwhereherceptin ingreserveadjustmentsduetothehealthcare hasamarketshareofapproximatelyinit reformsenactedinandregulatoryandreim breastcancerindicationsastablesalesvolumeand bursementuncertaintyregardingthemetastatic revisedreimbursementpricesfromaprilresulte breastcancerindicationseeptogetherthese inasignificantdeclineinsalesrevenuecompare factorsledtoadeclineinsalesinthesecond halfyearespeciallythefourthquarteravastinmain taineditshighusmarketshareinitsmetastatic xelodacapecitabineforcolorectalstomach colorectalandlungcancerindicationsverystrong andbreastcancergeneratedtotalsalesofbillion salesgrowthinjapanwasdrivenbycontinue swissfrancsanincreaseofcomparedwith gooduptakeincolorectalandnonsmallcelllung growthwasdrivenprimarilybystronggainsin cancerverystronggrowthwasalsorecordedin theunitedstatesjapanandchinatheproduct pharmaceutical roche business report threelargestmarketsglobalsalesofxelodaare swissfrancsinbillionfrancslow benefittingfromanumberofnewindication thaninwithgovernmentstockpilingorder includingstomachcancerinchinaanexpande largelycompletedbyearlyandtheinfluenzaa metastaticcolorectalcancerindicationinjapan hnpandemicpassingitspeaksalesfellsharply andadjuvantcoloncancerineuropeaswellas inthelastthreequarterssaleswerealsoaffecte increasedpatientshareinmetastaticbreast byrelativelymildinfluenzaseasonsinbothhemi cancerintheusandeu spheresduringrocheremainsreadytoaddress potentialthreatsposedbyinfluenzaandismain salesoftarcevaerlotinibforadvancedlung tainingproductioncapacityincooperationwith andpancreaticcancerincreasedtobillion externalmanufacturingpartnerstoenablearapid swissfrancsdrivenmainlybyincreasedusein responsetofuturesignificantoutbreaksorgovern thesecondlinenonsmallcelllungcancersetting mentstockpilingorder themaincontributionstogrowthcamefromthe internationalregionjapanandtheusmidsingle ophthalmology digitgrowthintheusreflectssteadydemandin ussalesoflucentisranibizumabforwetage thelungandpancreaticcancerindicationsandthe relatedmaculardegenerationandmacularedema impactofgovernmenthealthcarereformsagainst followingretinalveinocclusionroseto abackgroundofstabledemandsalesinwestern billionswissfrancsstronggrowththroughout europedeclinedslightlymainlyasaresultofgovern wasdrivenprimarilybyincreasesinthe mentmandatedpricereductionsandrebatesin totalnumberofpatientsreceivinglucentisandthe severalmajormarketssustainedstrongsalesgrowth timepatientsareontreatmenttheuslaunchof injapanreflectscontinuedmarketpene lucentisforthetreatmentofmacularedemaswell trationandoncologistsincreasingconfidenceinthe ingintheretinafollowingretinalveinocclusion benefitsoftreatmentwithtarceva beganinlatejuneandinitialuptakeisencourage lucentiswasdiscoveredbygenentechwhich virology retainscommercialrightsintheunitedstate worldwidesalesofpegasyspeginterferonalfaa novartishasexclusivecommercialrightsforthe forhepatitisbandcincreasedtobillion restoftheworld swissfrancsinflatsalesintheunitedstate andsalesdecreasesinwesterneuropejapan inflammation autoimmune disorder andcertainothermaturemarketswereoffsetby astheglobalrolloutofthenovelrheumatoid growthintheinternationalregionespecially arthritismedicineactemratocilizumabknownas asiapacificandcemaicountriestheproduct roactemraintheeucontinuedsalesin marketsharecontinuedtoexpandinthemain total millionswissfrancsariseofover europeanmarketstheusandjapanglobalsale uptakeofactemraroactemraintheeu continuedtobenefitfromclinicaldatareinforce theunitedstatesandotherlaunchmarketsremain thesuperiorityofpegasysoverothertreatment veryencouragingaroundofusrheumatol optionsandincreaseduseinhepatitisbthehepatitis ogistshavealreadyprescribedthemedicinecontin cmarketispoisedformajorexpansionwiththe uedstrongsalesgrowthinjapanreflectsincreas introductionofanewgenerationofdirectacte inguseofactemraasafirstlinebiologicchugai antiviralagentsexpectedfromonward announcedinaugustthatthejapanesehealth becausepegasystheleadingpegylatedinterferon authoritieshadremovedtheapprovalconditionsfor isusedinmosthepatitistreatmentdevelopment actemrafortherheumatoidarthritisandpolyartic programmestodayitisexpectedtobecomethe ularcoursejuvenileidiopathicarthritisindication backboneoffuturecombinationtherapieswiththe newantiviralsseealsopbelow followingexceptionaldemandinduetothe adjuvant treatment give surgical removal tumour low risk relapse influenzaahnpandemicsalesoftamifluosel cemai central eastern europe middle east africa tamivirforinfluenzaaandbtotalledmillion central asia indian subcontinent rochearengpharmaceuticalsindd clinical development long process continue market launch create value patient mean invest skill resource long uncertain journey molecule investment molecule volunteer patient preclinical development phase year year preclinical testing evaluate drug safety profile pharma phase trial test safety cological effect laboratory promise new compound dose new drug dur pass rigourous preclinical testing study ing phase trial researcher human new drug usually undergo vitro test tubes cell look drug absorb culture isolate organ vivo animal testing computer distribute change metabo model play increasingly important role preclinical devel lise body eliminate opment datum preclinical test essential determine long process drug safe administer people clinical unwanted trial effect trial involve small number people usually healthy volunteer case people disease advanced cancer example participate rochearengpharmaceuticalsindd patient patient patient molecule molecule molecule phase phase iii phase year year market entry phase trial test new drug new drug move phase iii phase trial conduct people disease clinical trial phase drug approve regu design treat number phase trial result suggest latory agency launch patient phase trial limit benefit patient signfi market know postmar usually large phase way phase iii trial compare kete trial design study addition safety new drug current treatment gather broad realworld experience testing trial identify appropri trial placebo new drug routine medical ate dose ranges test phase iii trial long time practice phase trial generate addi drug demonstrate clinical effi typically year tional data safety efficacy cacy proof concept new involve thousand patient large number patient par drug fail phase testing country ticular patient subgroup provide information phase iii trial include large drug work comparison number patient investiga combination treatment tor evaluate difference type treatment regula large phase iii trial iden tory agency normally require result tify potential effect phase iii trial approve area phase trial pro new drug vide essential additional information roche maintain system risk assessment programme identify evaluate effect appear phase iiii trial patient trial trial rochearengpharmaceuticalsindd roche business report pharmaceutical development highlight major approval key marketed product actemraroactemra herceptin inthepharmaceuticalsdivisionfiledmajor mabtherarituxan newmarketingapplicationsandgainedmajor regulatoryapprovalsseetablesppandthe lucentis followingsummariespresentapprovalsfilingsand majorclinicaltrialresultsforkeymarketedproduct byindication thedecisiongivesmorepatientsaccesstoactemra actemraroactemra andfollowspositiveresultsfromaroutinepost approval injanuarytheusfoodanddrug marketingsurveillanceprogrammeactemra administrationfdaapprovedactemrafor roactemraisnowavailableinsomecountrie thetreatmentofadultpatientswithmoderatelyto worldwide severelyactiverheumatoidarthritisrawho havehadaninadequateresponsetooneormore anemia transplantation tumournecrosisfactortnfinhibitorsactemra salesoftherenalanemiamedicationmircerame thefirstinterleukinreceptorinhibitingmonoclonal thoxypolyethyleneglycolepoetinbetaroseto antibodyapprovedtotreatramaybeusedalone millionswissfrancsdemandformircerawhich orincombinationwithmethotrexateorotherdisease isnowavailableinovercountriesworldwide modifyingantirheumaticdrugsinjunetheeuro iscomingmainlyfromthepredialysissegmentand peancommissionextendedtheproductsexiste newpatientcommencementscombinedsalesof marketingapprovaltoincludetreatmentwith thegroupsestablishedanemiamedicinesroche roactemraplusmethotrexatetoreducetherateof neorecormonandchugaisepoginepoetinbeta progressionofjointdamageandimprovephysical declinedtobillionswissfrancsroche functioninpatientswithrheumatoidarthritisthe pharmaceuticalsoverallshareoftheeuropeanane newindicationwhichisbasedontwoyeardatafrom miamarketremainedstabledespiteincrease aglobalphaseiiistudylithecamejustovera biosimilarcompetitionduemainlytothestrongper yearafterthemedicinesinitialeuapprovalfurther formanceofmircerainthemajoreucountrie reinforcingitsvalueasaneffectivetreatmentfor andarobustmarketsharebyvolumeforneorecor rainjanuarythefdaapprovedactemrafor monintherenalindicationadeclineinsale asimilarindicationinhibitionandslowingof ofepogininjapanwasduemainlytocompetitionin structuraljointdamageimprovementofphysical thedialysismarketandalowernationalhealth functionandachievementofmajorclinicalresponse insurancereimbursementpricefactorswhichout inadultswithmoderatelytoseverelyactivera weighedincreaseddemandforthemedicinein basedonasupplementalbiologicslicenseappli thepredialysissegment cationsblasubmittedbygenentechinmarch atbillionswissfrancsforthefullyearsale revenuefromcellceptmycophenolatemofetilfor filing inoctobergenentechsubmittedasecond thepreventionofsolidorgantransplantrejection sblatothefdaandrochesubmittedanaccel remainedsignificantthesalesdecreaseofwa eratedassessmentapplicationtotheeuropean dueprimarilytothelossofpatentexclusivityin medicinesagencyemaseekingtoextendthe theunitedstatesintheresultinglossesto approvedindicationsofactemraroactemrato competitionfromgenericversionswerepartlyoffset includetreatmentofsystemicjuvenileidiopathic bysalesgrowthinjapanandtheinternational arthritissjiabothapplicationsarebasedonposi region tivedatafromtheglobalphaseiiitenderstudy therearecurrentlynoapprovedtherapiesintheeu orusforsjiaadebilitatinganddifficulttotreat rochearengpharmaceuticalsindd pharmaceutical roche business report diseasethataffectsthewholebodyandrepresent thefdasnoticeofopportunityforhearingwe anareaofhighunmetmedicalneed believethiswouldprovideanopportunitytopresent ourviewsthatthedataareclinicallymeaningful avastin andmeettheapplicablelegalandregulatorystan sinceitsinitialapprovalinintheunitedstates dardsforcontinuedapprovaluntiltheconclusion foradvancedcolorectalcanceravastinhasmade oftheseproceedingsavastinremainsfdaapprove antiangiogenictherapyafundamentalpillarofcancer foruseincombinationwithpaclitaxelformetastatic treatmentavastinisapprovedinmanycountrie hernegativebreastcanceratthesametimethe forthetreatmentofadvancedstagesofcolorectal fdaissuedcompleteresponsesforallotherpende breastnonsmallcelllungandkidneycanceritis applicationsconcerningavastininmetastaticbreast alsoavailableintheusandothercountriesforthe cancersayingthattheapplicationsfailedtosupport treatmentofpatientswithglioblastomaatypeof theextensionoftheproposedindicationsforfirst braincancernearlyamillionpatientshavebeen linetreatmentincombinationwithdocetaxelbased treatedwithavastinsofarmorethanongoing onavadoandincombinationwithstandardchemo rochesponsoredorsupportedorindependently therapybasedonribbonandforsecond conductedclinicaltrialsareinvestigatingtheuseof linetreatmentincombinationwithstandardchemo avastininovertumourtypesincludingcolorec therapybasedonribbonthesedecisionsdo talbreastnonsmallcelllungbraingastricovarian notaffecttheavailabilityofavastinforitsapprove andothersanddifferentsettingsadvancedor usesinothertypesofcancerintheunitedstates earlystagedisease approval infebruarythechinesehealthauthor breast cancer indecemberfollowingareview itiesapprovedavastinforthetreatmentofmetastatic ofallrelevantdatatheeuropeancommitteefor colorectalcanceritsfirstindicationinthisimportant medicinalproductsforhumanusechmpsup market portedthecontinuedfirstlineuseofavastinin combinationwithpaclitaxelchemotherapydescrib filing indecemberrochefiledanapplication ingitasavaluabletreatmentoptionforpatient withtheeuauthoritiesforapprovalofavastin sufferingfrommetastaticbreastcancerpaclitaxelis asfrontlinetreatmentforovariancancerbasedon thechemotherapymostfrequentlyusedandalso theresultsofthephaseiiigogandicon mostfrequentlypartneredwithavastintocontrolthe trialsseebelowclinical milestone diseasethecommitteealsoconsideredcombina tionsofavastinwithtwoothertypesofchemother clinical milestone twolargephaseiiitrial apybasedondatafromtheavadoandribbon involvingsomepatientshavedemonstratedthe trialsthechmprecommendedthatthecombination potentialofavastininovariancancerresultsfrom withdocetaxelberemovedfromtheavastinlabel gogwerepresentedattheannualmeetingofthe andthatthecombinationwithcapecitabinexeloda americansocietyofclinicaloncologyascoin notbeapprovedadecisionbytheeuropeancom junethetrialmetitsprimaryendpointofextending missionontheserecommendationsisexpectedearly progressionfreesurvivaltheperiodapatient inthechmpopiniondoesnotaffectthe liveswithoutthediseasegettingworseinwomen otherapprovedusesofavastinintheeuropeanunion withpreviouslyuntreatedadvancedovariancancer foradvancedcolorectalkidneyandlungcancer iconafurthertrialwithavastininovariancancer reportedpositiveresultsinearlyjulythedata alsoindecemberthefdaannouncedanumber werepresentedattheeuropeansocietyformedical ofregulatorydecisionsconcerningtheuseofavastin oncologyesmoconferenceinoctoberinaddition formetastaticbreastcancerintheusthemost totheeufilingindecemberrocheplanstouse importantoftheseistheagencysdecisiontoinitiate theresultsofbothtrialstosupportaregulatoryappli theprocesstowithdrawthecurrentconditional cationforthisadditionalindicationintheusin acceleratedapprovalforavastinforfirstline treatmentofmetastaticbreastcancerrocheand clinicaltrialresultsledtoanumberofadjustments genentechhaverequestedahearingpursuantto intheavastindevelopmentprogrammeinas rochearengpharmaceuticalsindd roche business report pharmaceutical major regulatory filing clinical datum support product filing indication andor dosage form country actemra lithe year datum rheumatoid arthritis reduction inhibition progression usa roactemra joint damage improvement physical function rheumatoid arthritis sign symptom china refile progressive joint damage tender systemic onset juvenile idiopathic arthritis usa avastin ribbon metastatic breast cancer secondline treatment usa icon gog metastatic ovarian cancer herceptin toga advance herpositive gastric cancer usa china herceptin toga advance herpositive gastric cancer japan xeloda mabthera prima advanced follicular lymphoma firstline maintenance usa rituxan follow induction treatment mabtherarituxan switzerland plus chemotherapy rave ancaassociate vasculitis usa mircera renal anemia china cordatus correction symptomatic anemia adult chronic switzerland kidney disease need dialysis oncemonthly administration tarceva emerge datum metastatic nonsmall cell lung cancer egfr clinical trial activate mutation firstline treatment ongoing clinical experience xeloda xeloxa adjuvant colon cancer combination oxaliplatin switzerland datum public advanced refractory gastric cancer patient japan domain candidate curative surgery xelox metastatic colorectal cancer combination oxaliplatin china refile include supplemental indication phaseiiitrialswithavastininstomachavagast meaningfulprogressionfreeandoverallsurvival andprostatecalgbcancerdidnotmeet benefitinbothfirstandsecondlinetreatment theirprimaryendpointsofextendingoverallsurvival avastinhasshownapositivebenefitriskratioin rochehasdecidednottopursueregulatoryfiling theseandallotherapprovedmetastaticcancer fortheseindicationsaphaseiiiprogrammeinve indication tigatingtheadditionofavastintostandardtreat mentwithmabtherarituxanpluschemotherapy herceptin fordiffuselargebcelllymphomaanaggressive approval theeuropeancommissionapprove formofnonhodgkinslymphomawasdiscontinue herceptinincombinationwithchemotherapyforuse afterasafetyandefficacyanalysisshowedanunfa inpatientswithmetastaticstomachgastriccancer vourablebenefitriskassessmentfollowingeval exhibitinghighlevelsofherinjanuary uationofphaseiiidataavantrochehasdiscon approvalsforthesameindicationwerereceivedin tinueddevelopmentofavastininadjuvantcolorectal switzerlandinmayandtheusinoctoberfollowe cancertheresultsanddecisiononadjuvantcolo priorityreviewbythefda rectalcancerdonotaffecttheuseofavastinin themetastaticadvancedcolorectalcancersette filing injunethejapanesehealthauthoritie wherethemedicinehasdemonstratedaclinically gavepriorityreviewstatustoanapplicationsub rochearengpharmaceuticalsindd pharmaceutical roche business report major regulatory approval clinical datum support product filing indication andor dosage form country actemra option rheumatoid arthritis sign symptom usa roactemra radiate ambition lithe month datum lithe year datum rheumatoid arthritis reduction inhibition progression switzerland joint damage improvement physical function usa avastin avf metastatic colorectal cancer china global artist china herceptin toga advance herpositive gastric cancer usa switzerland lucentis cruise bravo macular edema follow retinal vein occlusion usa mabthera cll firstline chronic lymphocytic leukemia usa rituxan reach relapse refractory chronic lymphocytic leukemia usa prima advanced follicular lymphoma firstline maintenance switzerland follow induction treatment mabtherarituxan plus chemotherapy reflex rheumatoid arthritis inhibition progression joint damage improvement physical function mircera cordatus correction symptomatic anemia adult switzerland chronic kidney disease need dialysis oncemonthly administration tarceva saturn nonsmall cell lung cancer firstline maintenance usa chemotherapy xeloda xeloxa adjuvant colon cancer combination oxaliplatin include supplemental indication january mittedinmarchbychugaiforapprovalofherceptin lucentis foradvancedherpositivestomachcancerin approval injunetheusfoodanddrugadmin junerochesubmittedanapplicationforapproval istrationfdaapprovedlucentisforthetreatment ofthesameindicationinchina ofpatientswithmacularedemaswellinginthe retinafollowingretinalveinocclusionrvothe clinical milestone indecemberpatientenrol approvalfollowedasixmonthpriorityreviewby mentwascompletedforaphaseiiistudywithanew thefdarvooccurswhenbloodflowthrougharet subcutaneousformulationofherceptininwoman inalveinbecomesblockedcausingswellingmacu withherpositivebreastcancerherceptiniscur laredemaandhemorrhagesintheretinawhichmay rentlygivenintravenouslyovertominute resultinblurringorvisionlossinallorpartofone theinnovativesubcutaneousformulationwhichis eye basedonhalozymesenhanzetechnologysee pisexpectedtotakelessthanfiveminute mabtherarituxan oncology toadministerandmayallowpatientswithher approval infebruarythefdaapprovedrituxan positivebreastcancertoreceivetreatmentintheir combinedwithfludarabineandcyclophosphamide physiciansofficeorathomewithouthavingto chemotherapyforpeoplewitheitherpreviously gotoahospital untreatedfirstlineorpreviouslytreatedrelapsed rochearengpharmaceuticalsindd disease area oncology indication secondline herpositive metastatic breast cancer trial emilia tdmg patient recruit december study site country jone participant emilia study tdm houston rochearengpharmaceuticalsindd work wayne tdm medical director genentech south san francisco rochearengpharmaceuticalsindd tdm antibodydrug conjugate create value patient mean build good treatment well future nonspecific chemo herceptin trastuzumab adc target chemo therapy agent new standard therapy specifically care herpositive tumour cell metastatic breast cancer point attack cancer cell chemotherapy trastuzumab chemo tdm healthy cell attack healthy monoclonal antibody attack cancer cell cancerous cell trastuzumab specifically conventional target herpositive chemotherapy burden tumour cell therapeutic antibody target specific cancerrelate biomarker receive fda approval herceptin trastuzumab launch revolution treatment breast cancer continue build breakthrough tra tuzumabdm tdm novel antibodydrug conjugate adc develop tdm treat herpositive breast cancer tdm combine powerful anticancer approach medicine trastuzumab antibody component trastuzumab block signal herpositive cancer cell aggressive send message patient immune system destroy cancer cell deliver potent chemo therapy agent directly tumour cell induce cell death tdm offer patient herpositive breast cancer effective treatment stable linker spare burden effect conventional chemotherapy emilia phase iii registration trial compare singleagent tdm treatment combine lapatinib hertargete drug plus capecitabine xeloda chemotherapy woman advance herpositive breast cancer trial test tdm combination roche pertuzumab nextgeneration hertargeting antibody therapy rochearengpharmaceuticalsindd pharmaceutical roche business report orrefractorycdpositivechroniclymphocytic mabtherarituxan inflammation leukemiabasedontheresultsoftheclland approval rochereceivedregulatoryapproval reachtrialsfollowingregulatoryapplicationsby inoctoberfortwoadditionstotheexistingeu rocheandgenentechinthefirstquarterinocto marketingauthorisationformabtherainrheumatoid bertheeuropeanmedicinesagencyema arthritisbasedprimarilyondatafromthereflex approvedmabtheraasmaintenancetreatmentfor studytheindicationswereexpandedtoinclude peoplewithfollicularlymphomawhohavere inhibitionofprogressionofjointdamageandim spondedtoinductiontherapythefdaiscurrently provementofphysicalfunctionandinformation reviewinggenentechssblaforthesameindica onenhancedtreatmentresponsesinseropositive tionandhassetanactiondateinlatejanuary rapatientsseebelowclinical milestone bothsubmissionswerebasedontheresultsof wasaddedtotheproductsprescribinginformation theprimastudywhichshowedthatcontinue mabtherarituxanfortwoyearsmaintenance filing inoctoberbasedondatafromthephase therapyinpatientswhorespondedtoinitialtreat iiiiiravestudygenentechandbiogenidec mentwithmabtherarituxanpluschemotherapy submittedasupplementalbiologicslicenseappli nearlydoubledprogressionfreesurvivalcompared cationtothefdaforapprovalofrituxanforanca withthosewhodidnotreceivemaintenance associatedvasculitisagroupofrareseverelife treatment threateningautoimmunediseasescharacterisedby inflammationofbloodvesselsleadingtoorgan clinical milestone basedonpositiveresult damagetherearecurrentlynoapprovedtherapie fromaphaseibstudyinpatientswithfollicularlym fortheconditionandtreatmentassociatedtoxicitie phomainjulyrochedecidedtoadvanceanew arecommonwiththeunapprovedstandardofcare subcutaneousformulationofmabtheraalsobase cyclophosphamide onhalozymesenhanzetechnologyintophase iiidevelopmentsubcutaneousadministrationha clinical milestone ananalysisofsamplesfrom thepotentialtosignificantlysimplifytreatment patientswithrawhoparticipatedintwophaseiii byshorteningadministrationtimetolessthanten trialswaspresentedattheeuropeanleagueagainst minutesandimprovingpatientcomfortaphase rheumatismeularannualcongressinjuneit iiitrialisexpectedtostartinthefirstquarterof showedthattestingforspecificbloodmarkersatthe positivedatafromaphaseiiistudyofmabthera timeofdiagnosiscouldhaveasignificantimpact rituxaninpatientswithadvancedfollicularlym ontreatmentdecisionsandleadtoimprovedpatient phomawhodidnothavesymptomsasymptomatic qualityoflifeapproximatelyofrapatient diseasewerepresentedattheannualmeete haveatleastoneoftwocharacteristicbiomarker oftheamericansocietyofhematologyindecember producedbyautoreactivebcellsrheumatoid thestudyshowedthatimmediateadministration factorrfandanticycliccitrullinatedpeptideanti ofsingleagentmabtherarituxanasinductionther ccpintheirbloodsuchpatientsarereferred apyfollowedbycontinuedmaintenancetreatment toasseropositivedatafromapooledcohortofthe withmabtherarituxandelayedtheneedforchemo twostudiesshowedthatwhilebothseropositive orradiotherapyandextendedprogressionfree andseronegativepatientsbenefittedfromtreatment survivalcomparedwithwatchfulwaitingtheseare withmabtherarituxantheresponsewasenhance thefirstphaseiiidatatoshowthatinitialuse intheseropositivepopulationadditionalbiomarker ofmabtherarituxanmonotherapyasinductionfol analysesfromotherphaseiiistudiesarepending lowedbymaintenancecanprovideclinicalbenefit mabtherarituxanisthefirstandonlyselectivebcell forpatientswithasymptomaticfollicularlymphoma targetedtherapyavailableforra adiseasethatiscommonlytreatedonlywhen symptomsappearanapproachknownaswatchful tarceva waiting approval inapriltheusfoodanddrugadmini trationfdaapprovedtarcevaasamaintenance treatmentforpatientswithlocallyadvancedormeta staticnonsmallcelllungcancernsclcwhose rochearengpharmaceuticalsindd roche business report pharmaceutical egfractivatingmutationswouldcontinuetobenefit fromtreatmentwithtarcevainlaterlinesoftherapy roche innovative new clinical milestone resultsfromarandomise molecular entity latestage phaseiiistudyoptimalpresentedatthe europeansocietyformedicaloncologyesmo development include congressinoctoberdemonstratedthatfirstline potential personalise healthcare treatmentwithtarcevaextendedprogression freesurvivalinpatientswithadvancednsclcwith medicine plan egfractivatingmutationstomorethanoneyear almostthreetimeslongerthanpatientswhoreceive companion diagnostic test conventionalchemotherapyinterimresultsfrom asecondtrialinvestigatingtarcevainthisindication eurtacareexpectedinthefirstquarterof asmanyasofasianpatientswithlungcancer diseasehasnotprogressedafterfourcyclesof andanestimatedoflungcancerpatientsin platinumbasedfirstlinechemotherapyinaprilthe westerncountrieshavethisdistinctformofnsclc europeancommissionapprovedtarcevaasmono therapyformaintenancetreatmentinpatientswith xeloda advancednonsmallcelllungcancernsclc approval inmarchtheeuauthoritiesapprove whosediseaseremainslargelyunchangedknown xelodaincombinationwithoxaliplatinacom asstablediseaseafterplatinumbasedinitial binationknownasxeloxfortheadjuvantpost chemotherapybothapprovalsarebasedondata surgicaltreatmentofpatientswithearlycolon fromthephaseiiisaturnstudywhichshowe cancertheapprovalwasbasedonresultsfrom thatcomparedwithplacebotarcevasignificantly thenoxeloxastudyoneofthelarg improvedoverallsurvivalinpatientswithstable studiesofpatientswithstageiiiearlycoloncancer diseasepatientswithadvancednsclcandstable whichshowedthatpatientstakingxeloximme diseaseafterinitialchemotherapyhavetumour diatelyaftersurgeryliveddiseasefreeforlonger thatprogressfasteraremoreresistanttofurther comparedwiththosetreatedwithachemotherapy linesofchemotherapyandhaveapoorerprognosis regimenconsistingoffluorouracilplusleucovorin comparedwithpatientswhohaveacompleteor partialresponsetoinitialchemotherapy filing injapanchugaifiledmarketingapplica tionswiththeministryforhealthlabourand filing injunerochesubmittedanapplicationto welfareinmarchforapprovalofxelodacombined theeuropeanmedicinesagencyematoextend withherceptinforthetreatmentofadvance thecurrentmarketingapprovalfortarcevatoinclude herpositivestomachcancerandinseptember firstlinetreatmentofpatientswithadvancednsclc forxelodainadvancedorrefractorygastric withegfractivatingmutationstheapplication stomachcancerinpatientswhoarenotcandi issupportedbyemergingdatafromclinicaltrialsand datesforcurativesurgery ongoingclinicalexperienceincludingnewdata fromtheoptimaltrialpresentedatesmosee clinical milestone adataanalysiscomplete belowtarcevaistheonlyepidermalgrowthfactor injuneshowedthatnoaphaseiiitrialinves receptoregfrinhibitorapprovedforusein tigatingxelodaincombinationwithdocetaxelfor maintenanceandsecondlinetreatmentsetting theadjuvantpostsurgicaltreatmentofwomenwith inpatientswithadvancedormetastaticnsclc earlybreastcancerdidnotmeetitsprimaryend irrespectiveofthepresenceofegfractivate pointofextendingdiseasefreesurvivalbutdidmeet mutationsalicencefortarcevaforuseinthefirst thesecondaryendpointofextendingoverallsur linesettingwouldallowphysicianstopersonalise vivalrochehasdecidednottopursueregulatory earlytreatmentaccordingtoegfractivatingmuta filingsforthisindication tionstatuswhilepeoplewithnsclcwithout rochearengpharmaceuticalsindd pharmaceutical roche business report research development lationsrochesresearchonantibodydrugconju gatesasameansoftreatingcancerisanother rochespharmaceuticalsdivisioniscommitte exampleofahighlytargetedapproachwiththe todiscoveringandcommercialisinginnovativemedi potentialofimprovingoutcomeswhilereducing cinesthatrepresenttruemedicalvalueinarea thesideeffectsoftreatmenttdmforher ofhighunmetneedtoensureastrongflowofsuit positivebreastcanceristhemostadvance ablecandidatemoleculesintoitsdevelopmentpipe oftheseprojectsformoreinformationseebelow linerochehasbuiltauniqueinnovationnetworkof oncologyandalsoppandofthisreport independentresearchanddevelopmentcentresin additiontorocheandgenentechitincludeschugai aspartofthegroupsoperationalexcellencepro injapanandallianceswithmorethanpartner grammethepharmaceuticalsdivisionisprioritising organisationsworldwidethispromotesadiversity itsrdinvestmentsinordertodedicateresource ofresearchapproachesandenablesaccesstonew toprojectswiththehighestpotentialfollowing technologiesandpromisingdrugcandidate acomprehensiveportfolioreviewrochedecidedto discontinuerdactivitiesinrnainterference closecooperationbetweenthepharmaceutical consolidateinternalfunctionalresourcesandreduce divisionandrochediagnosticsisakeystrategic thenumberofpharmaresearchandearlydevel advantageforourcompanyitensuresthatdiagno opmentsitesfromtoseventherebyreduce ticsexpertiseisseamlesslyintegratedintoallpart fixedcostsandmakingfundsavailableforadditional ofthepharmaceuticalrdprocessthisiscentral externalresearchpartnershipsandpromisingnew torochesgoalofadvancingpersonalisedhealthcare programmesenteringphaseiiclinicaldevelopment phcanapproachthatseekstotailortreatment tospecificpatientsubpopulationsbasedongrowe atthebeginningofthedivisionsrdpipe scientificunderstandingofbiologyanddiseaseat lineincludedprojectsinclinicaldevelopment themolecularlevel phaseitoiiiandfiledforregulatoryreviewof theseinvolvednewmolecularentitiesnmes tworecentexamplesoftheprogressthatrocheis andinvolvedadditionalindicationstwelve makingtowardsphcinthedevelopmentoftherapie nmesareinlatestagedevelopmentseetable fordifficulttotreatdiseasesarergmetmab ptwentytwoprojectsinvestigatingadditional forlungcancerandrgbrafinhibitorfor indicationsforexistingproductsareinphaseiii malignantmelanomarochediagnosticsisdevelop thepharmaceuticalspipelineisshowninthefoldout ingdiagnostictestsdesignedtoguideappropriate insidethefrontcoverofthisreportfurtherdetail useofbothcompoundsintheirtargetpatientpopu areavailableatwwwrochecom roche genentech project roche genentech project research early development phase iii marketing application discovery phase january file january inflammation oncology metabolic metabolic cns ophthalmology virology ophthalmology inflammation cns oncology rochearengpharmaceuticalsindd roche business report pharmaceutical targetherpositivetumoursseepdatafrom arandomisedphaseiitrialtdmgwithtdm additional nme advance inpreviouslyuntreatedherpositivemetastatic breastcancerpresentedattheesmoconferencein latestage development octobershowedefficacycomparabletoherceptin pluschemotherapythestandardofcarealongwith metmab lung cancer lebriki asignificantlyreducedsideeffectburdenfinal zumab asthma resultsfromthisstudyareexpectedin hepatitis ocrelizumab twophaseiiiregistrationstudiesinmetastatic herpositivebreastcancerareongoingandwe plantosubmitglobalmarketingapplicationsin emiliainvestigatingtdminpretreate oncology patientsisexpectedtoyielddataonprogression rochesclinicaldevelopmentpipelineinoncology freesurvivalinandoverallsurvivalin includesnewmolecularentitiesthepharma marianneacomparativetrialoffirstlinetreat ceuticalsdivisionisfurtherstrengtheningitsoncol mentwitheithertdmaloneortdmplus ogyportfoliothroughnewtargetedtherapeutic pertuzumabversusherceptinpluschemotherapy optionsandexpandingintonewindicationssix beganinjulybothtrialsareinvestigatingtherapeu oncologynmesarenowinlatestageclinicalteste ticoptionsthattargetherpositivetumour whilesparingpatientstheburdenandsideeffect pertuzumabrgisaherdimerisationinhib ofconventionalchemotherapy itorthatisbeingstudiedwiththecurrentstandard ofcareherceptinpluschemotherapyinher rgplxcollaborationwithplexxikon positivebreastcancerdatafromaphaseiitrial isafirstinclassmoleculedesignedtoselectively neosphereinvestigatingpertuzumaband inhibitacancercausingmutatedformofthebraf herceptinplusdocetaxelchemotherapyinher proteinfoundinapproximatelyhalfofmetastatic positiveearlybreastcancerwerepresentedat melanomatumourspromisingresultsfromaphase thesanantoniobreastcancersymposiuminde iiclinicaltrialbrimwerepresentedinnovember cembertheresultsshowedthatthetwoantibodie attheinternationalmelanomaresearchcongress plusdocetaxelgivenintheneoadjuvantsette thedatashowedthatrgshranktumour beforesurgeryimprovedtherateofcomplete inoverhalfofpatientswithpreviouslytreatedbraf tumourdisappearanceinthebreastbymorethan vemutationpositivemetastaticmelanoma halfcomparedwithherceptinplusdocetaxelchemo medianprogressionfreesurvivalinthestudywa therapybasedontheencouragingefficacyresult monthstypicallyprogressionfreesurvivalfor fromneospherepertuzumabwillalsobestudie thesepatientsisapproximatelytwomonthsaphase asadjuvantpostsurgicaltherapyinherpositive iiitrialbriminpreviouslyuntreatedbraf earlybreastcancerthephaseiiiclinicalprogramme mutationpositivemetastaticmelanomapatientsmet inthissettingisscheduledtostartinlate itsprimaryendpointsinjanuarywithan resultsandrelatedregulatoryfilingsareexpecte interimanalysisshowingsignificantlyimprovedover infromaphaseiiistudycleopatraeval allandprogressionfreesurvivalinpatientswho uatingtheadditionofpertuzumabtoherceptinand receivedrgcomparedwiththosetreatedwith chemotherapyinthefirstlinetreatmentofpatients dacarbazinethecurrentstandardofcareroche withadvancedmetastaticdisease moleculardiagnosticsisdevelopingacompanion diagnosticcobasbrafvmutation trastuzumabdmtdmrgisanovel testseepptoidentifypatientswhose antibodydrugconjugatethatcombinesthethera tumourscarrytheabnormalbrafgeneandare peuticeffectoftrastuzumabtheactivesubstance thereforeappropriatefortreatmentwithrg ofherceptinwithintracellulardeliveryofdm ahighlypotentchemotherapyagenttospecifically rochearengpharmaceuticalsindd pharmaceutical roche business report new molecular entity ongoing plan latestage study compound indication status expect file pertuzumab herpositive metastatic phase iii start breast cancer line trastuzumabdm herpositive metastatic phase iii start quarter breast cancer second line braf metastatic melanoma phase iii trial firstline treatment meet primary inhibitor endpoint january hedgehog advanced basal cell pivotal phase start quarter pathway inhibitor carcinoma chronic lymphocytic phase iii start fourth quarter leukemia nonhodgkin chronic lymphocytic leukemia lymphoma metmab solid tumour lip decision prepare phase iii post lebrikizumab asthma lip decision prepare phase iii post aleglitazar cardiovascular risk reduc phase iii initiate quarter post tion type diabete dalcetrapib dyslipidemia cardio phase iii enrolment complete second quarter vascular high risk hcv hepatitis lip decision prepare phase iii lymerase inhibitor glycine negative symptom phase iii start november reuptake inhibitor schizophrenia subopti mally control positive symptom schizophrenia ocrelizumab multiple sclerosis phase iii planned start quarter ppm post rrm ppm second quarter rrm lifecycle investment point decision commence latestage development lead submission marketing application rggdccollaborationwithcurisis cellsbyactivatingotherimmunecellstoattack anovelcompoundtargetingthehedgehogsignalle thecancercellsandbyinducingdirectcelldeath pathwaywhichisthoughttobeimplicatedin intwophaseiistudiespresentedattheamerican severalcancersapivotalphaseiistudywithreg societyofhematologyannualmeetingindecem istrationpotentialiscurrentlyinvestigatingrg bertreatmentwithrgproducedpromise asapotentialtreatmentforadvancedbasalcell responseratesinverydifficulttotreatpatientswith carcinomabccrgisalsobeingevaluate eitherindolentoraggressivenhlwhohadnot inaphaseiistudyasatherapyforoperablebcc respondedtomultiplepriortreatmentsinclude inthefourthquarterrochedecidedtodiscontinue mabtherarituxanfurtherclinicaldataforrg developmentofthecompoundinovarianandcolo innhlandcllareexpectedinphaseiii rectalcancerduetolackofbenefitinphaseiitrial studiesofrgversusmabtherarituxanin aggressiveandindolentnhlarescheduledtostart rggaisthefirsttypeiiglycoengineere anticdmonoclonalantibodybeinginvestigate inlatestageclinicaltrialsasapotentialtreatmentfor rgmetmabisauniquemonoclonalantibody nonhodgkinslymphomanhlandchroniclym thatbindsspecificallytothecmetproteinreceptor phocyticleukemiacllithasbeenspecifically themetpathwaycanbeinappropriatelyactivate designedtoenhancethedestructionofcancerousb incancerandleadtoinvasivegrowthnewphaseii rochearengpharmaceuticalsindd disease area metabolic cardiovascular disease indication risk reduction patient type diabetes trial alecardio patient study site country ragnar participant alecardio aleglitazar trial stockholm rochearengpharmaceuticalsindd implication anita operation program leader roche basel rochearengpharmaceuticalsindd aleglitazar create value patient mean focus unsolved issue patient type diabete blood glucose aleglitazar dual ppar coagonist develop control long big concern roche compound patient diabete die heart disease potential reduce cardiovascular morbidity stroke inability control blood glucose mortality specifically highrisk patient patient experience acute coronary aleglitazar excellent example translational syndrome acs event heart attack die medicine biochemical parameter animal datum year currently drug market biomarker efficacy safety consistently specifically effectively control high risk support hypothesis later prove cardiovascular disease clinical setting increase risk heart attack stroke alecardio innovative global randomise associate control phase iii clinical trial patient test hypothesis alegli healthy people tazar reduce cardiovascular morbidity mortality patient suffer people heart attack stroke recent acs event people people heart attack stroke risk demonstrate multiple effect aleglitazar year conventional trial people reduction blood glucose level year trial aleglitazar highrisk subpopulation blood glucose blood fat hypertension focus reduce cardiovascular risk people type diabete save life rochearengpharmaceuticalsindd pharmaceutical roche business report datapresentedattheannualeuropeansocietyfor metabolic cardiovascular disease medicaloncologyesmoconferenceinoctober rochehasninenewcompoundsindevelopmentfor showedasignificantincreaseinprogressionfree metabolicandcardiovasculardiseasesdalcetrapib survivalforpatientswithhighmetexpressingnon rgjttlicensedfromjapantobaccois smallcelllungcancernsclcwhoweretreate anovelcholesterylestertransferproteincetp withmetmabplustarcevabasedonthisdatain modulatorbeingtestedforitsabilitytoreducecardio septemberrocheadvancedthecompoundintolate vasculareventsinpatientswithstablecoronary stagedevelopmentforthesecondandthirdline heartdiseasefollowingarecentacutecoronarysyn treatmentofnsclcaphaseiiistudyinpatient dromeeventthephaseiiidalheartprogramme withhighmetexpressingnsclcisexpectedto isontrackrecruitmentforthephaseiiidalout startinrochetissuediagnosticsisdevelope comestrialhasbeencompletedwithover acompaniondiagnostictesttoidentifypatients participantsenrolledresultsfromtwophaseiib withhighmetexpressingnsclcwhoaremostlikely studiesdalvesselanddalplaqueareexpected torespondtotreatmentwithrgseepp inandrecruitmentforafurtherphaseiiistudy aphaseiistudytoinvestigatetheaddition dalplaqueisongoingthesesupportingstudie ofmetmabtochemotherapywithorwithoutavastin areinvestigatingthepotentialimpactofdalcetrapib forthetreatmentoftriplenegativemetastaticbreast treatmentonatheroscleroticplaqueburdenuse cancerisexpectedtoenrolitsfirstpatientinthe imagingtechniquesandfunctionaltest firstquarterof aleglitazarrgisaninnovativeinvestigational inflammation autoimmune disorder treatmentdesignedtoreducetheincidenceand rochehaseightnewcompoundsindevelopment impactofcardiovascularmortalitynonfatalheart forchronicandprogressiveautoimmuneandinflam attackandstrokeinpatientswitharecentacutecor matorydiseasessuchasrheumatoidarthritisra onarysyndromeandtypediabetesaglobalphase andasthmafiveofwhichareinphaseiiclinicaltest iiiprogrammealecardiobeganrecruitment inglebrikizumabisahumanisedmonoclonalanti earlyinaleglitazarhasthepotentialtobethe bodydesignedtobindspecificallytointerleukin firsttherapytospecificallyreducecardiovascular aproteinthoughttoplayakeyroleintheairway riskinpeoplewithtypediabete inflammationhyperresponsivenessandobstruction experiencedbyasthmapatientsthecompound taspoglutidergbimlicensedfrom isbeingdevelopedforthetreatmentofmoderateto ipsenisaonceweeklyhumanglucagonlikepep severepersistentasthmapatientrecruitmentfor tideglphormoneanalogueindevelopment twokeyphaseiitrialsmollyandmillyhasbeen forthetreatmentoftypediabetesinseptember completedbasedonpromisingphaseiiresultswith rochecommunicateditsdecisiontostopadminister lebrikizumabinpatientswhosesymptomsremaine ingtaspoglutidetopatientsinglobalphaseiii uncontrolledoninhaledcorticosteroidswithor clinicaltrialsbasedonhigherthanexpectedpatient withoutasecondcontrollerrochehasdecidedto discontinuationratesobservedinanalysesofdata advancethemoleculeintolatestageclinicalteste fromthetemergeprogrammeandalsodueto inmayrocheandbiogenidecannouncedtheir theantibodymonitoringplanimplementedtoaddress decisiontodiscontinuedevelopmentofocrelizumab serioushypersensitivityreactionsaftercareful rgforrheumatoidarthritisrafollowe assessmentoftherelevanceofthetemergesafety adetailedanalysisoftheefficacyandsafetyresult andefficacydatatosupportfutureregulatory fromtheraprogrammethecompaniesconclude approvalintypediabetesincludingconsideration thattheoverallbenefitriskprofileofocrelizumab ofthecurrentportfolioevaluationinitiative wasnotfavourableinratakingintoaccount rochehasdecidedtodiscontinuethetaspoglutide currentlyavailabletreatmentoptionsinclude temergedevelopmentprogramme mabtherarituxandevelopmentofocrelizumab asatherapyformultiplesclerosisiscontinuing seep rochearengpharmaceuticalsindd roche business report pharmaceutical therearecurrentlynoapprovedtreatmentsthe firstofsixplannedtrialsbeganinnovember new class asthefirstinanewclassofmedicinesrg hasthepotentialtoredefinethetherapeutic medicine approachtoarangeofpsychiatricdisordersand deliverclinicalbenefitsbeyondthoseachievable potential redefine thera withcurrenttreatmentoption peutic approach range inoctoberrocheandbiogenidecreportedposi psychiatric disorder tiveresultsfromaphaseiitrialwiththehumanise anticdmonoclonalantibodyocrelizumab rginpatientswithrelapsingremittingmul tiplesclerosisrrmsoneoftheleadingcause virology ofneurologicaldisabilityinyoungadultsdatapre rochecurrentlyhastwodirectactingantiviralagent sentedattheannualmeetingoftheeuropean inlatestagedevelopmentforhepatitiscthenucle committeefortreatmentandresearchinmultiple osidepolymeraseinhibitorrgpartneredwith sclerosisectrimsshowedthatcomparedwith pharmassetandtheproteaseinhibitordanoprevir placeboocrelizumabsignificantlyreducedsignsof rgbothoftheseoralagentsarebeinginve diseaseactivityasmeasuredbybrainlesionsand tigatedincombinationwithpegasysandribavirin annualisedrelapseratewithnoopportunisticinfec andincombinationwitheachotherinaninterferon tionsreportedtwophaseiiistudieswillbegininthe freeregimenrginterimphaseiibresult secondquarteroftoexplorethedrugsefficacy showedgoodefficacyandtolerabilitywithnoevi inrrmscomparedwithinterferonthecurrent denceofviralresistanceafterthreemonthstherapy standardofcareaphaseiiistudyinvestigatingthe incombinationwithpegasysandribavirinaphasei potentialofocrelizumabinpatientswithprimary trialinformofrganddanoprevirasan progressivemultiplesclerosisppmsisplannedto interferonfreecombinationshowedsignificantviral startinthefirstquarterofinoctobergenen suppressionaphaseiiiprogrammewithrg techandbiogenidecamendedtheircollaborationon isexpectedtobeginininoctoberroche antibodiestargetingcdandagreedthatgenen acquiredtheglobalrightstodanoprevirtoincrease techwillhaveresponsibilityforthefurtherdevelop thestrategicflexibilityofthegroupshepatitisc mentofocrelizumabinmultiplesclerosisintheus portfolio central nervous system therocheportfoliohasnovelcompoundsin developmentfordisordersofthecentralnervoussy temincludingschizophreniamultiplesclerosisand otherseriousconditionsoneofthesecompoundsis rganovelglycinereuptakeinhibitorbee developedforthetreatmentofschizophreniaanarea ofhighunmetmedicalneedpromisingdatafrom aphaseiiproofofconceptstudywithrgin patientswithnegativesymptomsofschizophrenia werepresentedattheannualmeetingoftheamer icancollegeofneuropsychopharmacologyin decemberaglobalphaseiiiprogrammehasbeen initiatedtoinvestigatergincombination withantipsychoticsinpatientswitheithernegative symptomsorsuboptimallycontrolledpositive symptomsofschizophreniaindicationsforwhich rochearengpharmaceuticalsindd pharmaceutical roche business report focus unmet medical breast cancer themostcommoncanceramong womenworldwideovermillionwomenarenewly need diagnosedandoverdiefromthedisease eachyearasthereareseveraldifferenttypesof cancer accordingtothelatestinternational breastcancerknowledgeoftumourcharacteristic agencyforresearchoncanceriarcestimatein isimportantfortreatmentdecisionssome overmillionpeopleworldwidewerediag ofwomenwithbreastcancerhavetumourswith nosedwithcancerandsomemilliondiedofthe abnormallyhighlevelsofaproteinknownasher diseasetheiarcanticipatedthenthatcancer herpositivetumoursareparticularlyaggressive wouldsurpassheartdiseaseastheleadingcause fastgrowingandlikelytorecur ofdeathworldwideintheagencyalsofore caststhatbytherewillbeovermillionnew lung cancer themostcommonformofcancer casesandmilliondeathsperyearfromcancer worldwideandtheleadingcauseofcancerdeath ineuropealoneoneinthreepeoplecanexpectto thereareanestimatedmillionnewcasesannually developcancerintheirlifetimecancerisnotone nonsmallcelllungcanceristhemostcommon diseasebutagroupofmorethandistinctdisor formaccountingforapproximatelyofallcase derseachwithitsownmedicalchallenge malignant melanoma thedeadliestandmost nonhodgkin lymphoma agroupofover aggressiveformofskincancerthelifeexpectancy cancersthataffectthelymphaticsystemthisclass ofpeoplewithadvancedmelanomaisusually ofcancercurrentlyaffectsovermillionpeople shortwithlessthanoneinfourexpectedtobe worldwideandsomenewdiagnose aliveoneyearafterdiagnosiseveryyearan aremadeeachyearfollicularlymphomaaccount estimatedpeopleworldwidediefromthe foraboutoneinfourofallcasesofnonhodgkin diseasethenumberofnewcasesindevelope lymphomaitcanoccuratanytimeduringadulthood countriesisexpectedtodoubletoperyear thoughpeoplearetypicallydiagnosedduringtheir byapproximatelyofmelanomascarry sixtiesanditaffectsasmanymenasitdoeswomen activatingmutationsinthebrafproteinakeycom ponentoftherasrafsignallingpathwayinvolve chronic lymphocytic leukemia themostcommon innormalcellgrowthandsurvivalthesemutation typeofleukemiainadultsaccountingfor causethepathwaytobeoveractivewhichmay ofallformsofleukemiatheincidenceofcllin leadtoexcessivegrowthandcanceritisestimate westerncountriesisapproximatelyper thatapproximatelyofallsolidtumourscarry anditistwiceascommoninmenasinwoman brafvmutation colorectal cancer cancerofthelargeintestine pancreatic cancer aparticularlyaggressivedis orrectumwhichaccountsforovermillionnew easethatisextremelydifficulttotreatitkillsahigher casesaroundofallnewlydiagnosedcancer proportionofpatientsinthefirstyearafterdiagnosis worldwideeachyearitisthesecondmostcommon thananyothercancerthefifthleadingcauseof causeofcancerdeathsineuropeandthethird cancerdeathsinthedevelopedworldpancreatic mostcommonworldwide cancerclaimsnearlyliveseveryyear kidney cancer thistypeofcancerisnewlydiag nosedinaroundpeopleandcause deathsworldwideeveryyearratesthatareexpecte toincreaserenalcellcarcinomaaccountsfor ofallkidneycancer exclude nonmelanoma skin cancer easily treat lifethreatening rochearengpharmaceuticalsindd roche business report pharmaceutical gastric stomach cancer stomachcanceristhe hepatitis thehepatitisbandcviruse secondmostcommoncauseofcancerrelate hbvhcvwhicharecommonlytransmitte deathsintheworldandthefourthmostcommonly throughbloodtobloodcontactcauseacuteand diagnosedcanceritaccountsforovermillion chronicliverdiseasepotentiallyleadingtoliver newcasesandsomedeathseachyearthe failurecirrhosislivercanceranddeathworldwide vastmajorityofcasesoccurinasiawherewith millionpeoplearethoughttobechronically lungcanceritistheleadingmalignancyadvance infectedwithhbvahighlyinfectiousvirusthatis metastaticstomachcancerisassociatedwitha responsibleforanestimatedonemilliondeath poorprognosisthemediansurvivaltimeafterdiag annuallymorethanmillionpeoplearoundthe nosisismonthswithcurrentlyavailablether worldareinfectedwithhcvandthreetofour apiesearlydiagnosisofthisdiseaseischallenge millionnewcasesoccureachyearhepatitiscis becausemostpatientswithearlystagediseasedo themainreasonforlivertransplantationarecent notshowsymptom studyonthehcvrelatedburdenofdiseasein europeancountriesestimatedthatbetweenseven agerelate macular degeneration amd andninemillionpeopleoroverofthepopula majorcauseofgradualorsuddenpainlesscentral tionareinfectedwithhcv visuallossintheelderlyandaleadingcauseof visionlossinpeopleagedandolderthereare autoimmune disorder occurasaresultofamis twoformsofamdwetanddryallcasesbegin takenimmuneresponsetothebodysowntissues asthedryformbutprogresstothewet thecausesareunknownrheumatoidarthritismul formwhichcanresultinsuddenandseverecentral tiplesclerosisandlupuserythematosusareamong visionlossinwetamdnewbloodvesselsgrow themostcommonautoimmunedisorderswhichaffect undertheretinaandleakbloodandfluidcause millionsofpeopleworldwide deteriorationofthemaculatheportionofthe eyeresponsibleforfinedetailedcentralvisionmore rheumatoid arthritis anautoimmunedis thanmillionamericanshavetheadvancedform easecharacterisedbyinflammationthatleadstostiff ofthiscondition swollenandpainfuljointsultimatelyresultingin irreversiblejointdamageanddisabilitymorethan anemia occurswhenthenumberofredblood millionpeopleworldwideandtwiceasmany cellsorthehemoglobinmoleculestheycontain womenasmensufferfromrainadditiontoinflam fallsbelownormalresultingininsufficientoxygen mationofthejointssuchasthehandsfeetand reachingorgansandtissuesitisseeninupto wristsracancausefatigueheartdiseaseand ofpatientswithchronickidneyrenaldisease increasethelikelihoodofdevelopingothercomplica whichaffectsmorethanmillionpeopleworld tionssuchasosteoporosisanemiaandproblem wideinadditionanemiaaffectsthreeoutoffour withthelungsandeyesitcanshortenlifeexpec cancerpatientsundergoingchemotherapypatient tancybyyearsbcellsatypeofimmunecell withuntreatedanemiamayneedbloodtransfusions areknowntoplayakeyroleintheinflammation thepotentiallongtermeffectsofanemiainclude associatedwithraseveralkeycytokinesorprotein cardiovasculardiseaseinrenalpatientswhilein arealsoinvolvedincludinginterleukiniltnf patientswithcanceritisassociatedwithdiminishe alfaandinterleukinililhasbeenidentified qualityoflife ashavingapivotalroleintheinflammationprocess rochearengpharmaceuticalsindd pharmaceutical roche business report multiple sclerosis anoftendebilitate glossary autoimmunediseaseinwhichnerveimpulsespassing throughthecentralnervoussystemaredisrupte adjuvant treatment treatmentgivenaftersurgical duetodamagetothebrainandspinalchordthis removalofatumourtolowertheriskofrelapse leadstounpredictableandhighlyvariablesymptom rangingfromabnormalsensationsandreducedcoor diseasefree survival thelengthoftimeafter dinationtopainparalysisvisualimpairmentanda treatmentforaspecificdiseaseduringwhich declineincognitiveandotherfunctionsaccorde apatientsurviveswithnosignofthedisease towhoestimatesapproximatelymillionpeople worldwidearelivingwiththedisorderwhichis firstline treatment theinitialtreatmentgiven usuallydiagnosedinadultsagedbetweenand afterdiagnosisincludingthefirsttreatment yearsrelapsingremittingmultiplesclerosis givenaftermetastaticcancerhasbeendiagnose rrmsthemostcommonformischaracterisedby acuteexacerbationswithfullorpartialrecovery maintenance treatment treatmentgiventopre betweenattacksprimaryprogressivemultiplescle ventadiseasegettingworseortopreventacancer rosisppmsischaracterisedbyneurological fromrecurringwhenithasdisappearedfollowing disabilityfromonsetwithsymptomsgraduallywor initialtherapy eningovertime metastatic disease cancerthathasspread diabete recognisedasaglobalepidemicby fromtheoriginalsiteofatumourtootherpartsof theworldhealthorganizationtheinternational thebodyalsoreferredtoasadvanceddisease diabetesfederationestimatesthatsomemillion peopleworldwidewillhavediabetesby neoadjuvant treatment treatmentgivento accordingtothewhotypeadultonsetdiabete reducethesizeofatumourbeforesurgicalremoval accountsforaroundofallcasesuncontrolle isattempte typediabetescanleadtoseverecomplication suchascardiovasculardiseasestrokeblindness overall survival thetimefromthestartof amputationsandkidneyfailureresultinginsignifi treatmentuntilthepatientdies canthealthcareburdenstosociety progressionfree survival thelengthoftime schizophrenia aseverementaldisorderthat duringandaftertreatmentduringwhichapatient distortsthewayapersonthinksactsexpresse liveswithoutthediseasegettingworse emotionsperceivesrealityandrelatestoother accordingtowhoestimatesschizophreniaaffect secondline treatment treatmentgivenifthe approximatelymillionpeopleworldwideandis initialorfirstlinetreatmentdoesnotworkorif usuallydiagnosedinadultsagedbetweenand thecancerstopsrespondingtoit yearsthesymptomsofschizophreniaarebroadly categorisedaspositivenegativeandcognitiveposi tivesymptomsarepsychoticbehaviourssucha hallucinationsanddelusionsnegativesymptom includeapathysocialwithdrawallackofdrive andreducedabilitytofeelpleasureineverydaylife cognitivedeficitsincludedifficultyconcentrate orfollowinginstructionsdifficultycompletingtask memoryproblemsanddisorganisedthinke persistentnegativesymptomsareamajorcauseof burdenforpatientsandcaregiver rochearengpharmaceuticalsindd diagnostic sale grow ahead market market share gain key segment immunoassay tissue diagnostic effort enhance operational efficiency continue division contribute high operating profit business area launch new product help drive market growth rochearengdiagnosticsindd diagnostic roche business report diagnostic division brief sale million chf core operating profit million chf number employee key figure change change millions chf chf local currency sale sale professional diagnostic diabetes care molecular diagnostic apply science tissue diagnostic core operating profit operate free cash flow research development core basis diagnostic leadership team december daniel oday chief operating officer roche diagnostic manfre baier apply science colin brown dirk ehler professional diagnostic paul brown molecular diagnostic roland diggelmann asiapacific peter finckh platforms support christian hebich finance service michael heuer emea europe middle east africa latin america david lapr operation annette luther communications kent kost quality regulatory hany massarany tissue diagnostic wataru ogawa japan jack phillips north america burkhard piper diabetes care clausjoerg ruetsch legal cris wilbur human resource robert yates business development june december rochearengdiagnosticsindd roche business report diagnostic diagnostic division sale region rochesdiagnosticsdivisionistheworldsleade supplierofin vitrodiagnosticsivdsperformedin europemiddle alaboratoryoratthepointofcareonbloodtissue eastafrica andothersamplesfrompatientsivdtestsareacrit japan icalsourceofobjectiveinformationhelpingdoctor asiapacific detectdiseasesselectappropriatetreatmentsand monitorpatientsresponsestocareinadditionsci latin america entistsusethedivisionsresearchproductstogain abetterunderstandingofthecausesofdiseaseand north america todiscovernewtreatmentsinovercountrie italic growth rate local currency rochediagnosticsservescustomersspanningthe entirehealthcarespectrumfromhospitalsand commercialmedicallabstophysicianstopatient withconditionsrequiringthemtoselftestthe nologiesandsimplifyprocessesmeetingthe divisionoffersawiderangeoftechnologiesallowe requirementsofallcustomersregardlessoflab thedetectionandanalysisofdnarnaand sizelocationortestingexperience proteinsonalargebaseofinstrumentsinstalle demonstrate medical valueisbecoming worldwidealreadyamongthebroadestinthe themaindriverofdifferentiationinthediagnostics industryrochesivdtestmenuissteadilyexpand marketcontributingtotherevaluationofivds inganddrawingonthelatestscientificadvances despitetheirfundamentalimpactonthemajority inrochehadapproximatelyashareofthe ofclinicaldecisionsivdscurrentlyaccountfor globalivdmarketwhichisvaluedatanestimate lessthanofmedicalspendingandareclearly billionusdollarsinannualsale undervaluedtherearetwomaincategoriesof diagnosticsthatcontributetobetterhealthcare decisionsstandalone diagnosticsoffervalue strategic priority byenablingthepreciseandtimelydiagnosis ofdiseasesandfacilitatingearlyscreeningfordis scientificprogressnewtechnologiesandchange easepredispositionandprognosisexample demographicsareamongthetrendsexpande includethemolecularhumanpapillomavirushpv thehealthcaremarketontheotherhandthereis testinscreeningforcervicalcancerthemrsa mountingpressureonhealthcarebudgetsand testtodiagnoseinfectionwithmethicillinresistant costsworldwidediagnosticscancapitaliseonall staphylococcus aureusandthepigfandsflt thesetrendsbytranslatingscientificinsightsinto immunoassaysintestingforpreeclampsia productsthatbringpatientsrealmedicalbenefitand companion diagnosticsareteststhatenable atthesametimecontributetosignificantcost doctorstoidentifythepatientsmostlikelyto savingsenablingpreciseandtimelydiseasediagno benefitfromaparticulartreatmentortomonitor sisandtreatmentstobetargetedatthepatient responsestoitrochealreadymarketscom mostlikelytobenefitisofgreatvaluebothforthe paniondiagnosticsforanumberofindication wellbeingofthepatientandinallocatingmedical withmoreinlatestagedevelopmentseelist resourceswheretheywillbemosteffective deploy diagnostic test drug develop thediagnosticsdivisionsstrategicprioritie mentiscrucialtohelpincreaserdproductivity improve testing efficiency isonepillarofthe anddevelopmoretargetedmedicinesroche divisionsstrategyrochesautomateddiagnostic diagnosticsiscollaboratingcloselywiththe systemsembodydecadesofengineeringinno pharmaceuticalsdivisionandexternalpharma vationtestingcomponentsvisualisationandana lysisunitsandworkflowmanagementsystems havecontinuouslyimprovedtoincludenewtech market size base company independent report rochearengdiagnosticsindd diagnostic roche business report roche companion diagnostic market late development disease area disease drug diagnostic test technology application virology cmv valcyte cmv viral load pcr monitor hbv pegasys hbv viral load pcr monitoring antiviral hbv pegasys peginterferon hbsag levels immunoassay monitor alphab mercksp hcv pegasys peginterferon hcv viral load pcr monitor alphab mercksp hcv polymerase inhibitor hcv viral load pcr monitor hcv protease inhibitor hcv viral load pcr monitor hiv antiviral hiv viral load pcr monitor hiv abacavir hlab pcr screen glaxosmithkline genotype oncology breast cancer herceptin lapatinib expression ihc ish selection glaxosmithkline gene amplification breast cancer tamoxifen erpgr expression ihc selection hormonal therapie breast cancer pertuzumab expression ihc ish selection gene amplification breast cancer tdm expression ihc ish selection gene amplification cancer compound merck mutations microarray selection colon cancer cetuximab merck kras mutation pcr selection panitumumab amgen therascreen colon cancer cetuximab merck kras mutation pcr selection panitumumab amgen gastric cancer herceptin expression ihc ish selection gene amplification melanoma braf inhibitor braf mutation pcr selection nsclc gefitinib astrazeneca egfr mutations pcr selection tarceva therascreen nsclc tarceva egfr mutations pcr selection gefitinib astrazeneca nsclc metmab meet expression ihc selection nsclc transgene muc expression ihc selection pancreatic hent expression ihc selection cancer clovis oncology inflammation asthma lebrikizumab serum periostin level immunoassay selection cea ige rheumatoid mabtherarituxan anticcp immunoassay selection arthritis sle rontalizumab ifninduce gene pcr selection osteoporosis bonvivaboniva bcrosslap immunoassay monitoring bisphosphonate pnp level transplantation cellcept mpa level immunoassay monitor black type market grey type development available market monitor monitor patient response particular treatment screening screen patient particular genetic variation hlaassociate hypersensitivity abacavir selection selection patient eligible particular treatment selection patient eligible early treatment anticcp antibodie cyclic citrullinate peptide braf bisoform rapidly grow fibrosarcoma oncogene cea carcinoembryonic antigen cmv cytomegalovirus hbv hepatitis hbsag hbv surface antigen hcv hepatitis human epidermal growth factor receptor hiv human immunodeficiency virus hent human equilibrative nucleoside transporter egfr epithelial growth factor receptor estrogene receptor ihc immunohistochemistry ish situ hybridisation ifn interferon kras member ras family oncogene mpa mycophenolic acid nsclc nonsmall cell lung cancer pcr polymerase chain reaction pnp procollagen type nterminal propeptide pgr progesterone receptor rheumatoid factor sle systemic lupus erythematosus schere plough rochearengdiagnosticsindd roche business report diagnostic roche topselle diagnostic sale millions chf accuchekavivanano cobase cobasc cobastaqman ventanaihcreagent accuchek cobas module cobas modules cobas ampliprep immunohistochemistry monitoring system modular analytic modular analytic cobas taqman situ hybridisation elecsy cobas integra market segment market segment market segment market segment market segment blood glucose monitoring immunoassay clinical chemistry virology hepatitis advanced tissue stain hepatitis hiv business unit business area business area business area business area diabetes care professional diagnostic professional diagnostic molecular diagnostic tissue diagnostic rochearengdiagnosticsindd diagnostic roche business report industryleade portfolio diagnostic test instrument clinical testing life science research coaguchekx cobastaqscreendpxt cobasbpoc accuchekcombo magnapurelc coaguchek cobas ampliscreen cobas system blood accuchek insulin magna pure cobas taqscreen gas hospital blood delivery system lightcycler glucose system market segment market segment market segment market segment market segment coagulation monitor blood screen intensive care insulin delivery system dna purification gene expression business area business area business area business unit business area professional diagnostic molecular diagnostic professional diagnostic diabetes care apply science image scale yearonyear sale growth local currency rochearengdiagnosticsindd roche business report diagnostic partnersonnewmedicinesandtheirusein bothmatureandemergingemeaeconomie personalisedsettingsseealsother section helpedbystrongperformancesbyprofessional diagnosticsanddiabetescareprofessionaldiag tofurtheraccelerate growth emerge seven nosticsandtissuediagnosticsweretheprimary country thedivisionisexpandingit growthdriversinnorthamericainjapan localorganisationsandinvestinginprogramme overalldivisionalsalesgrewfasterthanthemarket tobringproductstolocalmarketsmorequickly withprofessionaldiagnosticsstrongperformanceoff thedivisionintendstofurtherimprove prof settingcontinuingchallengesindiabetescare itabilitythroughacombinationofstrongsale increasedinvestmentandstrongdemandforimmu growthandefficiencyinitiativestargetingvirtually noassaysandotherleadingedgerocheproduct everyareaofoperationsthisreportcontain contributedtorobustabovemarketgrowthinthee informationontheprogressmadein emergingmarketswhichinaccounte foralmostoftotaldivisionalrevenue result main business onaswissfrancbasisthedivisionscoreoperate profitforincreasedinlocalcur development renciestomillionswissfrancswhilethecore operatingprofitmarginadvancedpercentage inthediagnosticsdivisionrecordedsalesof pointstotheseincreaseslargelyreflectthe billionswissfrancsanincreaseofinlocal strongperformanceofrocheskeydiagnostic currenciesoverinswissfrancsin productsaswellasongoinginitiativestoimprove dollarsthiswassignificantlyabovetheestimat operationalexcellenceformoreinformationonthe edivdmarketgrowthrate divisionsoperatingresultsseethefinancereport thedivisionlaunchedatotaloftestswhichex pandedtheimmunoassaymenuininfectiousdis diagnostic sale increase easesextendedthemoleculartestpanelinvirology significantly ahead market andfurtherstrengthenedthetissueassayport folioinoncologyinadditioninstrumentswere launchedinkeymarketsfacilitatingmaximum efficiencyinstateofthearttestinginclinicallabo allfivedivisionalbusinessareascontributedtosale ratoriesresearchcentresandpointofcareunit growthledbyprofessionaldiagnosticsanddiabete seetableofproductlaunchesonin careimmunoassaysandbloodglucosemonitore thedivisionplanstolaunchkeyproductsinclud systemsremainedthesebusinessesprimarygrowth ingtheusintroductionofaccuchekcombofor driversstrongdemandforadvancedtissuestain themanagementofbloodglucoseindiabetesthe ingproductscontinuedtofuelabovemarketgrowth cobashpvtestforcervicalcancerscreen intissuediagnosticsvirologywasthemaincon ingandthecobasbrafmutationtestinmela tributortosustainedsalesgrowthinmoleculardiag nomaseetableofproductlauncheson nosticsstrongsalesofcellanalysisandgenomics systemswereappliedsciencesmaingrowthdriver datafromthreeclinicalstudieswerepresentedat instrumentplacementswereagainupsignificantly majorscientificcongressesathenaalargeregis forthedivisionasawholeandwereamajorgrowth trationtrialinvestigatingthebenefitsofhpvteste driverinallsegment salesagainoutpacedthemarketinallregion country brazil russia india china south korea growthwasverystronginasiapacific mexico turkey particularlyinchinaandsouthkoreadriven state growth rate local currency market growth base company independent report mainlybyprofessionaldiagnosticsdespiteprice end september challengessalesoutperformedthemarketin emea europe middle east africa rochearengdiagnosticsindd diagnostic roche business report inscreeningforcervicalcancerprotectaran zerlandandthediabetescarerdactivitieson domisedtrialstudyingthentprobnpbiomarker insulindeliverysystemsfromburgdorfswitzerland guidedapproachintreatmentofheartfailure tomannheimgermanythedivisionbelieve andthesteptrialaimingatimprovementofdiabete thatthesemeasureswhicharepartofthegroup managementthroughstructuredtestingallthree wideoperationalexcellenceprogrammwillenable trialsdemonstratedthehighmedicalvalueofroche ittoenhancesystemintegrationleverageexist diagnosticproductsseer sectionon ingcapacitiesandreduceinfrastructurecostswhile maintainingthefocusoncustomersandinnovation operation thedivisionregularlyassessesthemixofinsource andoutsourcinginitsmanufacturingandsupply rochediagnosticsbusinessareasbasareinno chainoperationsingeneralactivitieswhichinvolve vationenginestranslatingourgrowingunderstand proprietarytechnologyorenablerochetoleverage ingofdiseasesintonewproductsandapplication internalexpertiseareinsourcedoperationsare thebaheadquartersitesinrotkreuzswitzerland outsourcedwhenthisofferseconomiesofscaleor professionaldiagnosticsmannheimgermanydia otheradvantageswhileensuringthecontinuedinteg betescarepleasantonusamoleculardiagno rityofrochesproductsandservicesinrecentyear ticspenzberggermanyappliedscienceand thelevelofoutsourcinghasgrowninlinewithsale tucsonusatissuediagnosticsarethedivision mainrdsiteswithadditionalcentresofexcel lencelocatedinbranfordusalifesciences business development madisonusanimblegenandindianapolisusa diabetescareinseptemberrocheopenedanew collaborationswithacademiaresearchinstitutesand diagnosticsoperationscomplexforrdandpro otherprivateandcommercialorganisationsgive ductioninpenzberganewimmunoassayproduction rochediagnosticsrapidaccesstorelevantmedical unitinmannheimwasinauguratedinoctober scientificandtechnologicaladvancesintellectual propertyipexchangeisastrategiccomponentof inalifecyclemanagementapproachwasin rochesabilitytooffercustomersthemostextensive troducedtoestablishastrongerconnectionbetween portfoliooftestsandtechnologiesyearafteryear eachbaanditsmarketslifecycleteamsareac inlicensingisanimportantopportunityforrocheto countableforthedevelopmentfilingapprovaland accessmarkersandtechnologieswhereasout launchofnewproductstomaximisetheirvalue licensingofipcanhelpestablishnovelmarkersand fromlaunchtoobsolescenceinadditiontwonew technologiesfromrochemorerapidlyinthemarket globalcrossbafunctionshavebeencreatedto placebyinvolvingmoreplayerstodevelopand helpmaintainthefocusonproductprofitabilityand educatethemarketitisthusvitalforrochediagno processefficiencyglobaloperationswilldrive ticstohaveexcellentinternalprocessestoidentify operationalexcellenceinmanufacturingsupply iprapidlyandtomaintainclosecontactwithpartner chainanddirectprocurementwhileglobalquality companiesforbothinandoutlicensingagreement regulatorywillensuresubmissionqualityandreduce timetoapprovaltheestablishedglobalplatform inrochecompletedmajoracquisitionsin andsupportfunctionwillcontinuetoplayakeyrole diabetescaremedingoltdandtissuediagnos ininstrumentandsoftwaredevelopmentandcus ticsbioimageneincandenteredintoanumber tomerservice ofresearchandtechnologycollaborationsindiabete carewithintercomponentwaremoleculardiag asannouncedinnovemberoverthenexttwoto nosticswiththegermancancerresearchcentre threeyearsrochediagnosticsintendstotransfer andappliedsciencewithibmanddnaelectron theproductionofchemicalrawmaterialsand icsmoreoverthedivisionsignedoverlicense analyticsservicesfrommannheimtopenzbergboth agreementsapproximatelyhalfoftheminlicense ingermanybloodgasandelectrolytesmonitor iptobroadenrochesinnovationbaseseebusiness ingactivitiesfromgrazaustriatorotkreuzswit area highlightsformoredetail rochearengdiagnosticsindd find disease area virology oncology indication hpv risk factor cervical cancer trial registration trial athena participant study site country usa chantal potential participant athena trial basel rochearengdiagnosticsindd soon rita head assay development roche pleasanton rochearengdiagnosticsindd cobas hpv test create value patient mean prove medical value diagnostic test rigorous clinical trial biomarker identification clinical validation collaboration research group academia industry development education diagnostic test healthcare professional regulatory approval sensitivity specificity reimbursement health successful economic diagnostic test market demonstrate medical value roche athena trial enrol persistent infection highrisk human papilloma woman screen participant virus hpv leading cause cervical cancer cervical cell change pap smear cobas hpv implicate case screen dna test highrisk hpv geno enable early identification removal precancer type result reveal ous lesion dramatically reduce incidence woman aged year old test positive hpv mortality cervical cancer worldwide notype find cer study show pap smear sam vical precancer despite normal pap smear test cobas hpv test ple cell cervix currently com enable physician identify woman mon test detect cervical cancer cervical precancer miss adequate sensitivity pre cytology cancerous lesion miss single pap smear thousand woman ultimately diagnose cervical cancer normal pap smear result rochearengdiagnosticsindd diagnostic roche business report business area highlight andcobasuasemiautomatedurineteststrip analysertherolloutofthenewcobasbpoc professional diagnostic bloodgasanalysercommencedineuropeandseveral professionaldiagnosticsisaleadingsupplierof marketsinlatinamericaandasiapacifictarget instrumentstestssoftwareandservicesforclinical ingspecificallyatthepocsegmentandcapableof laboratoriesanddecentralisedtestingproductsto deliveringmanyvitalresultsintimecriticalsitua supportclinicaldecisionmakingatthepointofcare tionsthisinstrumentisanimportantadvancein pocinithadashareofagrowing bloodgasanalysistheleadingsegmentinhospital globalmarketworthbillionusdollar poctestingtheuslaunchofcobasbpoc isexpectedin professionaldiagnosticsfullyearsalesgrew abouttwiceasfastastheglobalmarketrise stronggrowthincoagulationmonitoringreinforce millionswissfrancsandoutpacingmarket rochesleadingpositioninthissegmentcontinue growthinallregionsimmunoassayswereakey strongdemandforportabletestingsystemssucha growthdriverwithsalesupinfora thetopsellingcoaguchekxssystemandexpande decadethissegmenthasconsistentlygrownatdou medicarecoverageforhomecoagulationteste bledigitratesthankstoastronginstalledbase intheuswerekeyfactorscontributingtogrowth andaneverexpandingtestmenusalesofclinical studieshaverepeatedlyshownthatselftestinghelp chemistryandcoagulationmonitoringproduct patientsonanticoagulantstokeeptheirmedica grewandrespectively tionwithinthetherapeuticrangeandcanminimise theriskofcomplication inprofessionaldiagnosticslaunchedeightnew ornextgenerationimmunoassaysintheusor deliveringonthepromiseofpersonalisedhealth marketsrecognisingthecemarkincludingsixtest caretheprotecttrialpresentedattheamerican todiagnoseormonitorinfectiousdiseaseshepa heartassociationmeetinginnovemberdemon titisaandchivherpessimplexvirushsvand stratedasignificantreductionintotalcardiovascular hsvandrubellaseetableofproductlaunche eventswhenheartfailuretherapywasguidedby onthreenewornextgenerationclinical concentrationsofthecardiacbiomarkerntprobnp chemistryproductswerealsointroducedince becauseofthisstrongclinicalbenefitthetrialwa successful marketsinprofessionaldiagnosticswillexpand stoppedearlytoallowallpatientsaccesstothisnew diagnostic test market itsimmunoassaymenufurtherwithnewassay treatmentstrategyseer sectionon coveringarangeofdiseaseareasincludinginfec tofurtherstrengthenitscardiologyportfolioroche tiousdiseasesandoncology signedacrosslicenseagreementwithalereinc givingeachpartysemiexclusiveworldwiderightsfor demandforthecobasmodularanalyserserie natriureticpeptidebiomarkersprovenfortheirdiag remainedstronginfirstlaunchedinthis nosticusefulnessinavarietyofcardiovascular platformforhighthroughputtestingisnowavailable diseasesincollaborationwiththeamericancollege inallkeymarketsincludingtheusfollowingthe ofcardiologyprofessionaldiagnosticsisdeveloping introductionofthecobaseimmunoassaymodule awebportalforbiomarkersallowingphysiciansto highvolumelaboratoriesarenowabletofullycon accessthelatestinformationoncardiacbiomarker solidatetheirserumworkareasrocheoffersacom andencouragingitsapplicationinclinicalpractice prehensiveportfolioofstandardisedintegratedsys temsforclinicallaboratoriesofalltypesandsize diabetes care fromthestandalonelowvolumecobasandthe diabetescaredevelopsandcommercialisesblood mediumvolumecobastothecobas glucosebgmonitoringandinsulindeliverysystem modularanalyserseriesforhighvolumelaboratorie thatenablepeoplewithdiabetestomanagetheir conditionmoreeffectivelythegoalofdiabetesther intheusprofessionaldiagnosticsalsolaunchedthe apyistomaintainthebglevelsinanearnormal cobaspandppostanalyticalunitswhich rangeandthusavoiddiabetesrelatedcomplication automatethestorageandretrievalofsampletube diabetescarenotonlyoffersindividualproduct rochearengdiagnosticsindd roche business report diagnostic innovationsbutcombinesthesetoformintegrate acquiredmicropumpspecialistmedingoenhance solutionsthatencompassallareasofdiabetesman itsportfoliowithaninnovativemicropumpthis agementitistheindustryleaderwithashare acquisitionwillenablerochetobringintegrate ofaglobalbgmonitoringmarketworthover billion insulindeliverysystemstoabroaderrangeofpeople usdollar withdiabetesandofferusersawiderrangeof optionstosuittheirneed indiabetescaressalesroseto mil lionswissfrancsthiswaswellabovetheglobal diabetescareremainscommittedtoexploringand marketgrowthrateinanenvironmentthatremain developingnewdiabetesmanagementconcepts challengingduetotheuncertaineconomicrecov asdemonstratedbythestructuredtestingprotocol eryandgeneralpricepressuresalesofbgmonitor stepclinicalstudyintypediabeticpatient ingsystemsweredrivenbyaccuchekaviva notusinginsulinpresentedattheannualmeete andaccuchekperformawhichshowedstrongdou oftheeuropeanassociationforthestudyofdia bledigitgrowthsupportedbystrongmarketup beteseasdinseptemberthestepstudyshow takeofthesleekversionsaccuchekavivananoand thatglycemiccontrolcanbesignificantlyimprove accuchekperformananoespeciallydesignedfor whentherapyisadjustedonthebasisofstructure younghighfrequencytestersbytheendof bgmonitoringandpatternanalysisseer sec thesedeviceswereavailableincountriesacross tionon europelatinamericaandasiapacifictheaccu chekmobilealsopostedsignificantsalesgrowth thevisualisationandassessmentofbgandin thisbgmonitoringsystemsstripfreetechnologyis sulindataarepivotaltoeffectivediabetesmanage particularlyappreciatedbyinsulindependentpa mentyetsharingthedatacontinuestoposesig tientswhomeasuretheirbloodglucosefrequently nificantchallengesforpeoplewithdiabetesand andthusbenefitmostfromenhancedtestingcon healthcareprofessionalsaliketoaddressthisissue venienceintroducedintheaccuchekmobile diabetescareispartneringwithehealthspecialist isnowavailableincountriesineuropeand intercomponentwaretodevelopawebbaseddiabe asiapacificintheeumaltoseindependentstrip tesmanagementsolutionthatimprovestheinter chemistriesfortheaccuchekavivaaccuchek actionbetweenpatientsandtheircaregiversbase performaaccuchekcompactandaccuchek onsecurelysharedwellstructuredinformation mobileproductlinesreceivedregulatoryapproval injuneandwereimmediatelyrolledout molecular diagnostic moleculardiagnosticsdevelopsandcommercial diabetescarepostedstronggrowthineuropelatin isesadvanceddiagnosticandbloodscreene americaandasiapacificwithsignificantcontri platformsandtestsbasedonrochesproprietary butionsfromemergingmarketsintheussalesde realtimepolymerasechainreactionpcrtech creasedslightlyunderperformingthemarket nologywithamarketsharerocheistheleader whichremainednegativelyimpactedbythemacro inthehighlycompetitivemoleculardiagnostic economicenvironmentresultinginpricepressure marketvaluedatbillionusdollarsandgrowing andslowvolumegrowthusandjapaneseregu thisyearmarksthethanniversaryofpcrs latoryapprovalsforthemaltosefreestripchemistrie debuttothescientificcommunitypcrsunique expectedinwillenablethelatestaddition abilitytoexponentiallyamplifysmallamountsoftarget totheaccuchekportfoliotobelaunchedintheus dnahasresultedinnumerousdiagnostictech andjapanandareanticipatedtoboostsalesin niqueswhichwouldotherwisebetootimeconsum thesekeymarket ingorimpossibletoperform insulindeliverysystemsposteddoubledigitsale moleculardiagnosticscontinueditssteadyper growthdrivenmainlybycontinuedstronguptakeof formanceinwithsalesadvancingto thenewinteractiveinsulinpumpsystemaccuchek millionswissfrancsgrowthwasledbyvirol combonowavailableincountriesineurope ogywhichcurrentlyaccountsforabouthalf latinamericaandasiapacificinmaydiabetescare ofthebusinessareassalesdemandforthecobas rochearengdiagnosticsindd diagnostic roche business report systemlaunchedinlatewasstrongwith ofhumanpapillomavirushpvdnatestinginclud thesystemnowinstalledincountriesineurope inggenotypingoverconventionalcytologic asiapacificlatinamericaandcanadacobas paptestingseer sectiononsupporte offersfullautomationformidtohighthroughput bytheathenaresultsrochefiledthehpvtestin testingthemenucurrentlyincludesdualtargettests theusinjunewithapprovalexpectedinthesecond forchlamydia trachomatisandneisseria gonorrhoeae halfofthistestreceivedcemarkcertification andascreeningandgenotypingtestforhuman inlateandexperiencedastrongmarketuptake papillomavirushpvregionallynorthamericasales incemarketsthroughouttofurtherexpand showedgoodgrowthwhilesalesheldsteadyin itstestingpotentialincervicalcancerrocheentere theeulatinamericaandasiapacificpostedexcel intoaresearchcollaborationwiththegermancancer lentdoubledigitgrowthstrongcontributionfrom researchcenterdkfzrecentfindingsbythe theemarketswasledbyrussiaandmexico dkfzindicatethattherelativeamountsofspecific rnamarkersinhpvinfectedcellsenablehighly inmoleculardiagnosticsaddedfournewor accuratediscriminationofcervicalcancerandhigh nextgenerationteststoitsportfolioinvirologyand gradefromlowgradelesionsandthusfacilitate infectiousdiseasesthankstothefirstofitskind morespecificpredictionofwomensriskfordevel dualpcrtargethivviralloadtestwhichgreatlyim opingcervicalcancer provestheabilityofphysicianstomakeinforme treatmentdecisionsmoleculardiagnosticswon moleculardiagnosticsisbuildingabestinclass amajorcontractinsouthafricaforoverhalfamil oncologyportfoliobysecuringrelevantintellectual liontestsperyearrochesnextgenerationhbv propertydevelopingrobustassaysandproviding testwhichreceivedthecemarkinisnowalso completein vitro diagnosticssolutionscoveringsam availableintheusthistestenablesbroadergeno plepreparationthroughtoresultsanalysesand typedetectionandincreasedworkflowflexibilityin reportinginrocheobtainedaworldwideco themanagementofhbvinthebloodscreeningseg exclusivelicencefromjohnshopkinsuniversity mentthefirstduplexassayforsimultaneousde andqiagenforthedevelopmentofdiagnosticassay tectionofparvovirusbandthehepatitisavirus forthebiomarkerphosphoinositidekinasepik wassuccessfullylaunchedintheeuandother thepikpathwayplaysamajorroleinseveral marketsrecognisingthecemarkcontributingtoim cancersincludingcolorectalgastricbreastand provedsafetyofhumanplasmaproductsfdaap endometrialandiscurrentlyacentralfocusof provalofthistestisexpectedinthelightcycler cancerdrugdevelopmentrochehasalsoobtaine mrsaadvancedtestrochesflagshipproductin alicensefromgenzymecorporationtodevelopa thehospitalacquiredinfectionsmarketwasapprove testforepidermalgrowthfactorreceptoregfr andlaunchedintheusinjulystudiesindicatethat mutationsasacompaniondiagnosticfortarcevain thetestsspeeditidentifiesmethicillinresistant recentstudiespatientswithnonsmallcelllung staphylococcus aureusmrsacarriersinlessthan cancernsclccarryingmutationsintheegfrgene twohoursversusonetothreedaysusingconven showedenhancedresponsetoandmaybenefit tionalculturebasedmethodscanhelpsignificantly mostfromtreatmentwithtarcevatheegfrmutation reducethespreadofthispotentiallydeadlymicrobe testalongwithfurtheroncologytestsforthebraf inhospitalsscreeningformrsaisoneofthefast vmutationandkrasmutationsareschedule estgrowingsegmentsinthenorthamericanmolec forlaunchoncobasin ulardiagnosticsmarketthetestwaslaunchedinthe euandothermarketswhichrecognisethecemark applied science inseetableofproductlauncheson appliedsciencesuppliesscientistsinacademiaand thebiotechandpharmaceuticalindustrieswith datafromathenaarochesponsoredusregistra instrumentsreagentsandtestkitsforabroadrange tiontrialassessingtheutilityofthecobashpv ofresearchapplicationsthegloballifescience testinscreeningforcervicalcancerwerepresente researchmarketvaluedatbillionusdollarsgrew attheinternationalpapillomavirusconferencein approximatelyinappliedsciencehas montrealthedataconfirmtheincreasedaccuracy roughlyshareofthismarket rochearengdiagnosticsindd choose disease area central nervous system indication schizophrenia trial phase iii trial patient study site country kenneth participant clinical trial new york rochearengdiagnosticsindd wisely daniela research project leader central nervous system cns roche basel rochearengdiagnosticsindd firstinclass gri schizophrenia create value patient mean courage need great fail available therapy effective positive symptom effective negative symptom significant effect potential treat suboptimally control positive symptom positive symptom occur stable phase few effect acute episode new mechanism action affect nearly million people worldwide schizo glycine reuptake inhibitor gri develop phrenia severe mental disorder distort roche drug treat negative way person think act express emotion symptom schizophrenia represent entirely ceive reality relate lifelong novel approach normalise glutamate neu disease cure average shorten rotransmission increase synaptic level glycine life expectancy year high risk target important pathway psychiatric suicide cardiovascular pulmo disorder potential firstinclass nary event negative symptom compound type treatment schizophre usually great impact quality life nia addition combination current patient unable live independently hold job treatment potential treat suboptimally con establish personal relationship manage troll positive symptom little increase day social situation drug develop treat effect novel mode action negative symptom fail clinical trial valu able therapeutic application psychiatric available treatment offer modest benefit disorder rochearengdiagnosticsindd diagnostic roche business report appliedsciencepostedgrowthonsalestotalle quencingisalreadyonthehorizonandpromisesthe millionswissfrancsgrowthdriverswerethe nextleapinperformanceinjunerocheandibm cellanalysissegmentthankstoincreaseddemand signedanagreementtodevelopananoporebase forsolutionsinoncologyandstemcellresearch singlemoleculesequencertodirectlyreadand genomicsformerlyreportedassequencingandmi decodehumandnabasedonibmsdnatransistor croarraybusinessesandcustombiotechdueto technologythisapproachpromisesgainsincost recoveryoftheglobaleconomysalesofthemagna efficiencythroughputscalabilityandspeedcom pureandlightcyclerproductlinesforsamplepre paredwithothersequencingtechnologiescurrently parationandquantitativepcranalysisdeclineddue availableorindevelopment todramaticallylowerdemandforinfluenzaahn virustestingallregionsshowedsalesincrease nimblegencomplementeditsofferingonthecyto exceptlatinamericawherethenegativeeffectof geneticsmicroarrayworkflowsysteminclude decreasedhntestingwasparticularlypronounced arraysforsimultaneousanalysisofmultiplesample salesinasiapacificwereexceptionallystrong instrumentsreagentsaswellasanalysisandvi ledbychinaandindia sualisationsoftwarenowprovidingacomprehensive solutionforhighresolutioncytogeneticanalyse salesforcellanalysissystemsremainedrobust ofchromosomalabnormalitie fuelledbyfullintegrationoftheinnovatisproduct portfolioandsteadilyincreasingdemandfor appliedsciencetookfurtherstepstowardstransition xcelligenceautomatedrealtimecellanalyser ofitsproductsfrompureresearchuseintoroutine rtcainseptemberappliedscienceexpande diagnostictoolsivdsapreinvestigationaldevice thisproductlinebylaunchingthertcahtin exemptionpreidesubmissionfornimblegen strumentforhighthroughputanalysisandthe microarrayplatformhasbeenfiledwiththefdait rtcacardioinstrumentforlabelfreecardiotoxic approvalistheprerequisiteforobtainingfda itytesting clearanceforrochescytogeneticmicroarray foruseasivdsthesemicroarrayswhichdetect doubledigitincreasesinsequencingreagentand chromosomalabnormalitiescouldspearheada microarrayssalesfuelledgrowthingenomic producttransitionintoivdsandarecurrentlyunder helpedbystrongworldwidedemandforthe developmenttodemonstratetheirmedicalvalue gsjuniordnasequencerlaunchedinmaythis anddiagnosticutility mediumthroughputbenchtopversionofthegenome sequencerflxsystembridgesthegapbetweenlow tissue diagnostic andhighthroughputsequencingandofferssolution tissuediagnosticsventanamedicalsystemsin innearlyeveryfieldofbiologicalresearchthank northamericaistheworldsleadingsupplier toitssizeefficiencyandcompetitivepriceitput oftissuebasedcancerdiagnosticsitsinstrument nextgenerationsequencingtechnologywithinthe andreagentsystemsareusedinhistologycytol reachofthousandsofresearchersaroundtheworld ogyanddrugdiscoverylaboratoriesworldwidein theunithadashareofthetissuediag inresponsetotheworldwidesurgeinresearch nosticsmarketwhichisvaluedatoverbillionus projectsinvolvingresequencingofthehumangenome dollarsandgrewapproximately tostudydiseasesinlargepopulationsapplie scienceismakingadditionalinvestmentstodevelop tissuediagnosticssignificantlyoutpacedthe systemstargetingthisapplicationinnovember marketinrecordingsalesofmillionswiss appliedscienceenteredintoanexclusivepartnership francsanincreaseofcomparedtotheyear withdnaelectronicsforthedevelopmentofa earlierperiodadvancedtissuestainingimmuno lowcosthighthroughputdnasequencerthesys histochemistryihcandin situhybridisation temwillcombinelifescienceslongread ishwasthemaingrowthdriverreflect sequencingtechnologywithdnaelectronicsinex ingstrongreagentsalesandrobustuptakeof pensivehighlyscalablemethodforelectrochemical thefullyautomatedbenchmarkultrasystemfor detectionmoreoverthethirdgenerationofse simultaneousihcandishtestingonasingle rochearengdiagnosticsindd roche business report diagnostic platformthissystemwhichisnowavailablein hasbeenverystrongparticularlyindevelope countriesworldwidesetsnewstandardsintermsof marketsvantageanadvancedworkflowmanage randomslideaccessuserfriendlinessandhigh mentsystemforimprovedproductivityandpatient qualityresultsthebusinessareaperformedstrongly safetylaunchedincontinuedtogain worldwidegrowingtwotofourtimesasfastas momentumwithsalesmorethandoublingcompare themarketineuropelatinamericaandasiapacific totheyearearlierperiod salesintheseregionsbenefitedfromintensifie commercialisationeffortsoutsidetheussynergie tissuediagnosticscompletedtwoacquisition withrochepharmaceuticalsinhertestingin bioimageneincaleaderindigitalpathologyanaly breastandgastriccancerandtheintroductionof sisandworkflowwithproductsenablinggeneration benchmarkgxataneconomicpriceinemerg ofhighresolutionwholeslidedigitalimagesfrom ingmarket glassmicroscopeslidesaswellassoftwaretoview analyseandmanagetissueimagescomplemente intissuediagnosticslaunchednewanti andstrengtheningtheofferinginimageanalysis bodiesforihctestingtosupportthediagnosisof andinformationmanagementandmariposabio variouscancertypesseetableofproductlaunche scienceaninnovatorinthefieldofantibodyproduc onsixdnaprobesforishtestingwere tiontosupportrochesproductionofbestin addedtothemolecularassaymenuintheeuand classantibodie othermarketsrecognisingthecemarkincludingtwo newmoleculardnatestsforthehumanepidermal growthfactorreceptorhergeneenabling research development accuratetimelyassessmentofthelikelihoodofre sponsetotreatmentwithherceptininbreastand inresearchanddevelopmentrdcostscore gastriccanceradnaprobetargetingtheinsulin basisinthediagnosticsdivisiontotalle mil likegrowthfactorreceptorigfrgenewa lionswissfrancsadeclineofinlocalcurrencies addedtotissuediagnosticsnonsmallcelllung comparedtordcostsasapercentageof cancerbiomarkerpanelwhichalsoincludesassay salesdecreasedtoinlinewithoveralldivisional foregfrandmetstrengtheningitspositionin strategythefocuswasondevelopingnextgene prostatecancertestingtissuediagnosticssecure rationplatformstoimprovetestingefficiencyandon theexclusiverightsfromasymmetrxincforuse developingnewtestsanddemonstratingtheirme ofthepbiomarkerandlaunchedtwodnaprobe icalvaluewithrobustclinicaldataclinicalvalidation enablingthedeterminationoferggenomicrear isrelativelynewintheivdindustrybesidessignif rangementsonasingleslidewhilethepbiomark icantinvestmentitrequiresexpertiseinclinicaldevel eristhegoldstandardforthedifferentialdiagno opmentandincreasedinteractionwithnontradi sisofprostatecancererggenomicrearrangement tionalcustomerssuchaspayersandhealthcare havebeenshowntobeareliableprognosticmarker professionalsseefeatureonbeingableto ofprostatecancerspecificmortalityincertain drawonrochepharmaceuticalslongstandingex patientgroup pertiseinclinicalvalidationgivesrochediagnostic anadvantageovermostotherivdcompanie theadvancedstaininginstrumentportfoliowas bolsteredworldwidewithtwonewadditionsdis inthreemajorclinicaltrialsdemonstratingthe coveryultraanautomatedihcandishplatform significantmedicalvalueofrocheproductswere designedforuseintheresearchsettingandoffere presentedatscientificcongresse improvementsineaseofuseworkflowandsystem flexibilityandbenchmarkgxalowvolumeauto datafromtheathenatrialwerepresentedatthe matedtissuestaininginstrumentdesignedforcancer internationalpapillomavirusconferenceinmontreal diagnosticsprofessionalswhowanttoexpand injulythisrochesponsoredusregistrationtrial theirtestmenuandadoptautomationwithreduce thelargesteverperformedinthisindicationaimedto investmentwithplacementsinovercountrie assesstheutilityofthecobashpvtestin bytheendofacceptanceofbenchmarkgx screeningforcervicalcancerthedataclearlycon rochearengdiagnosticsindd diagnostic roche business report firmedtheincreasedaccuracyofhumanpapilloma therapyadjustmentscontributessignificantlytoa virushpvdnatestingoverconventionalcytologic reductionofhbacvaluesimprovesglycemic paptestingoutofwomenenrolledinthis controlandhelpstoreducediabetesspecificpsy trialoneintenofthoseagedyearsorolderwho chologicaldistressanddepressionwhilesmbg testedpositiveforhpvgenotypesorwere iswidelyacceptedasacorecomponentofeffective foundtohavecervicalprecancerdespitenormalpap diabetesmanagementinpeopleoninsulintherapy teststhecobashpvtestdetectshigh thevalueofsmbghassofarremainedcontroversial riskgenotypesofhpvtwelveasapooledresultand forinsulinnaivepeoplerepresentingalargepart genotypesandindividuallyasdemonstrate ofallpeoplewithtypediabetes byathenathistesthelpsphysicianstorecognise andtreatprecursorsofcervicalcancerearlierpossi inadditiontothemedicalvalueofivdtestsapplie blybeforeitspreadsinthebodyeachyeararound intheclinicdiagnosticstodayplayanumberof halfamillionwomenworldwidearediagnosedwith criticalrolesindrugdevelopmentfromidentifye cervicalcancerandmorethansuccumb newtherapeutictargetsandscreeningoutun tothedisease promisingdrugcandidatestoselectingappropriate patientpopulationsforclinicaltrialssomemay finalresultsofprotectprobnpoutpatienttai alsobecomecompaniondiagnosticsforpatientselec loredchronicheartfailuretherapyaprospective tionresponsepredictionortherapeuticmonitor randomisedclinicaltrialinpatientswerepre ingeverydrugunderdevelopmentatrochehasit sentedattheamericanheartassociationcongress ownassociatedbiomarkerprogrammeanddiag inchicagoinnovemberbythemainstudyinve nosticsexpertiseandadvicearemadeavailablefor tigatorsfromharvarduniversityandmassachusetts eachoftheseprogrammesinthediagnostic generalhospitalpromotinganewparadigmin andpharmaceuticalsdivisionsincludingpre themanagementofheartfailuretheresultsdemon gredpharmamedicinesandchugaicollaborate stratedthatntprobnpguidedheartfailurecare onmorethan projectsacrossalldiseaseareas wasassociatedwithasignificantreductionin ofinterestatrochemorethanhalfoftheseproject totalcardiovasculareventssuchasworsene wereinoncologyfollowedbyinflammationcns heartfailureheartfailurehospitalisationandcardio virologyandmetabolicdiseasesinadditionthe vasculardeathascomparedwithstandardtreatment diagnosticsdivisioncollaboratedwithseveral asheartfailureranksamongthemostcostlychronic otherpharmaceuticalcompaniestodevelopcom conditionsindevelopedcountriesreducingthe paniondiagnosticsforkeybiomarkersparticularly riskofcardiovasculareventsnotonlycontributesto inoncology betterpatientoutcomesbutisalsolikelytoreduce healthcarecoststherochentprobnptestis availableatthepointofcareandinlaboratorie worldwidewhereitrunsonthecobasplatformsitis estimatedthatasmanyasmillionpeopleworld widehaveheartfailurewithnewcasesdiag nosedeachyearintheusaloneandamortality ratethatexceedsthatofmanycancer thestepstructuredtestingprotocolstudya prospectivemonthclinicaltrialinnoninsulin treatedpeoplewithtypediabeteswaspresent edattheannualmeetingoftheeuropeanassociation forthestudyofdiabeteseasdinstockholmin septemberthestudydemonstratedthattheuseof thisnewdiabetesmanagementapproachincluding structuredselfmonitoringofbloodglucosesmbg datavisualisationpatternanalysisandderive rochearengdiagnosticsindd roche business report diagnostic product launch diagnostic division major product launch business area product product description market timeline professional immunoassay hiv combi min improve combined testing apac diagnostic virology infectious hivantigen hivantibodie enable reliable latam disease early detection hiv infection hsv igg hsv igg quantitative detection apac igg antibodie hsv latam rubella igm diagnose rubella infection woman antihcv presumptive diagnosis hcv infection anti hav diagnose hav immunoassay free hcg pappa evaluate risk trisomy apac disease area pregnancy latam stat ntprobnp evaluate risk heart failure clinical chemistry nextgeneration test hbac ferritin new apac product multicontrol clinchem latam cobas module immunoassay module immunoassay cobas modular throughput testshour high volume laboratory analyser series cobas poc system multiparameter blood gas analyser use apac point care laboratory latam cobas clinical chemistry immunoassay module high cobas cobas volume laboratorie module cobas modular analyser series cobas semiautomate urine test strip analyser cobas cobas postanalytical unit automate storage retrieval barcode primary secondary sample tube diabete care maltoseindependent accuchek aviva accuchek performa apac strip chemistries accuchek mobile accuchek compact latam molecular molecular test cobas ampliprepcobas taqman dual target hiv test diagnostic virology infectious simultaneous detection region disease hiv genome lightcycler mrsa advanced test automate realtime pcrbase test mrsa cobas taqscreen dpx test simultaneous quantitative detection parvovirus qualitative result hav cobas ampliprepcobas taqman hbv test newgeneration hbv viralload test enable broad genotype detection improve workflow flexibility apply science nimblegen cgx highresolution analysis chromosomal abnormality multiplex array capable analyse sample simultaneously junior economic benchtop nextgeneration sequence system small laboratory nimblegen cytogenetic complete solution highresolution cytogenetic analysis workflow system include instrument array analysis visualisation software rtca cardio instrument realtime cell analysis functional monitoring cardiotoxicity arrhythmic effect rtca instrument realtime highthroughput labelfree impedancebase cell analysis rochearengdiagnosticsindd diagnostic roche business report major product launch business area product product description market timeline tissue diagnostic antibodie antiecadherin antip basal cell cocktail antip ihc testing cancer antikeratin antip catenin anticyclin anticd antick anticam anticd anticd antick antihent antimoc antigpc antick antibody ihc antihelicobacter pylori test infectious disease dna probe ish ddish probe sish probe igfr probe testing cancer topa probe perg probe perg probe benchmark economical lowvolume automate advanced tissue apac staining discovery ultra automate advanced tissue stain research set black type new productfirst market launch grey type new productlaunch additional market apac asiapacific european union latam latin america united states worldwide ddish dual colour dual hapten ish hav hepatitis hbac hemoglobin hbv hepatitis hcg human chorionic gonadotropin hcv hepatitis hiv human immunodeficiency virus hpv human papillomavirus hsv herpe simplex virus ihc immunohistochemistry ish situ hybridisation mrsa methicillinresistant staphylococcus aureus ntprobnp nterminal fragment btype natriuretic peptide pappa pregnancyassociate plasma protein rtca realtime cell analyser sish silver ish stat short turnaround time test emergency rochearengdiagnosticsindd roche business report diagnostic key product launch plan business area product product description market timeline professional immunoassay total vitamin measure vitamin diagnostic great precision aid detect ovarian cancer cobas module clinical chemistry module throughput testshour cobas modular highvolume laboratory analyser series cobas poc system multiparameter blood gas analyzer use point care laboratory diabete care accuchek mobile lcm nextgeneration stripfree blood glucose monitoring system integrated lance device significantly small current version enhance functionality accuchek nano sleek version highfrequency user accuchek combo interactive insulin delivery system combine insulin pump blood glucose monitoring system broad data management capability molecular molecular test cobas braf mutation test identification diagnostic oncology infectious mutation braf gene disease cobas kras mutation test identification mutations kras gene cobas egfr mutation test identification mutation egfr gene cobas hpv test detect hpv hpv individu ally highrisk genotype pool result apply science type hla primer hla genotype junior system flx set system flx titanumxl new sequence chemistry enable extended read length flx system sequence kit cgh ultrahigh resolution array cgh validation combine cghsnp array cghsnp validation million million feature discovery variation gene copy number single nucleotide tissue diagnostic erpr antibody ihc support diagnosis breast cancer test benchmark ultra dual colour ish support diagnosis breast cancer probe ish testing futureview nextgeneration detection system benchmark platform deliver great specificity flexible detection option improve turnaround time black type new productfirst market launch grey type new productlaunch additional market european union united states worldwide braf bisoform rapidly grow fibrosarcoma oncogene cgh comparative genomic hybridisation egfr epithelial growth factor receptor erpr estrogene receptorprogesterone receptor human epididymis protein human epidermal growth factor receptor hla human leukocyte antigen hpv human papillomavirus ihc immunohistochemistry ish situ hybridisation kras member ras family oncogene snp single nucleotide polymorphism rochearengdiagnosticsindd diagnostic roche business report glossary situ hybridisation ish amethodofstaine biologicaltissuesamplestoidentifythepresence biomarker acharacteristicthatcanbemeasure andcopynumberofspecificgenesorgeneticmuta andevaluatedasanindicatorofanormalbiological tionsincellsusedinthediagnosisofcancerand processadiseaseprocessoraresponsetoathera otherdisease peuticinterventionelevatedlevelsoftheprotein herincancerforexampleareabiomarkerfora micropump insulin delivery anextgeneration highprobabilityofresponsetoherceptin insulinpumpsmalllightweightdiscretetowear thatdeliversinsulinwithouttubingitcombineskey cell analysis methodsofmeasuringthepropertie featuresofdurableinsulinpumpswiththeb ofcellsincludingtheirsizeandshapecellular attributesoftubefreepatchpumpsprovidingflex parameterssuchasthepresenceofspecificprotein ibilityandfreedomforabroaderrangeofinsulin andcellularprocessessuchasproliferationand dependentpeoplewithdiabete growthcellanalysistechnologiesplayanimportant roleindrugdevelopmentandproduction microarray adevicefordetermininggenetic changesthatmaycontributetohumandiseaseor mark certification certificationthatanin vitro influencetreatmentresponsehighdensitymicro diagnosticivdproductcomplieswithallsafety arraysevaluatethousandsofdnaandrna healthandenvironmentalrequirementsforuseinthe sequencesatonce europeanunioncertifieddiagnosticsarereferre toasceivds pointofcare poc testing diagnosticteste performedatornearthesiteofpatientcareusing clinical chemistry abranchofdiagnosticscom transportableoftenhandheldinstrumentsandtest prisingteststhatdetectandmeasurechangesin kitsresultsareavailableimmediatelyhelpingto thechemicalcompositionofbodyfluidsandtissues speedclinicaldecisionmake todiagnoseorpredictthecourseofadisease polymerase chain reaction pcr alaboratory dna sequence methodsofdeterminingthe methodwidelyusedinresearchandindustrytomake orderofnucleotidesmolecularbuildingblocksin millionsofcopiesofadnasequenceofinterest geneticmaterialknowinganindividualsdna veryquicklyrealtimepcrsimultaneouslyamplifie sequencecanprovideinsightsintogeneticchange copiesandquantifiesthetargeteddnamolecule whichcontributetohumandiseaseorinfluence treatmentresponsehighthroughputtechnologie virology inmoleculardiagnosticstestingtodetect readthousandsofsequencesatonce certainseriousandprevalentviralinfectionseg hivandhepatitiscortomonitortheirtreatment immunoassay alaboratorytestthatdetectsor measuresatargetsubstanceinasampleusingan immunochemicalreactioninwhichanantibody bindstoaspecificantigenthetargetcanbeadrug aproteinoravirusforexample immunohistochemistry ihc amethodofstain ingbiologicaltissuesamplestodeterminethepres encelevelandlocationofspecificproteinsincell usedinthediagnosisofcancerandotherdisease rochearengdiagnosticsindd corporate governance roche commitment stakeholder reflect operate business focus value creation management culture conform modern standard corporate governance group policy communicating transparently remuneration report roche success depend ability dedication people recognition form basis remuneration policy system rochearengcorporate governanceindd corporate governance roche business report corporate governance rochecomplieswithallrelevantcorporategover attheagmonmarchtheboardofdirector nancerequirementsinparticularwithallapplicable willproposeshorteningthetermofofficeofnewor lawstheswissstockexchangesixswiss directorsforreelectionfromthreetotwoyearsand exchangedirectivesincludingthecommentaries theboardwillnominatepiusbascherabrunogehrig theretoandtheswisscodeofbestpracticefor lodewijkjrdevinkandandreasoeriforreelec corporategovernancepromulgatedbytheswiss tiontotheboardandpaulbulckepeterrvoserand businessfederationeconomiesuissethecompany christophfranzforelectionasnewmembersofthe internalgovernanceframeworkparticularlyitsarti board clesofincorporationandbylawsembodiesallthe principlesneededtoensurethatthecompanysbusi walterfreyhasdecidedtoretireasmemberofthe nessesaremanagedandsupervisedinamanner boardofdirectorsaftertenyearsofdistinguishe consistentwithgoodcorporategovernanceinclud servicetheboardofdirectorsthankswalterfrey ingthenecessarychecksandbalance forhislongstandingengagementandhismanycon tributionstorochewhichstartedalreadywithhis ourprintedannualreportcontainsselectedlinksto activitiesasamemberoftheboardofrochepharma therochewebsitewwwrochecomreadersare agingermanyfromtobeforebecome thusprovidednotonlywithasnapshotofourcom aboardmemberofrocheholdingltdin panyatthereportingdatebutarealsodirectedto sourceswhichtheycanconsultatanytimeforup wolfgangruttenstorferdecidedtoresignasamem todateinformationaboutcorporategovernance beroftheboardofdirectorsofrocheholdingltd atrochewhereaseachannualreportcoversasin afterfouryearsofservicetheboardofdirector glefinancialyearendingdecemberourwebsite thankswolfgangruttenstorferforhisvaluablework containsinformationofamorepermanentnaturea andcontributiontoroche wellasthelatestrochenewsthecompanysarti clesofincorporationbylawsandthecurriculavitae ofthemembersoftheboardofdirectorsandthe corporate executive corporateexecutivecommitteearepublishedonour committee website startingonjanuarypascalsoriotmemberof board directors thecorporateexecutivecommitteesinceapril anddanielodaywereappointedascoodivision atthendannualgeneralmeetingagmof rochepharmaceuticalsandcoodivisionroche rocheholdingltdonmarchshareholder diagnosticsandasanewmemberofthecorporate reelecteddeannejuliusandbeatricewederdi executivecommitteerespectively mauroasmembersoftheboardofdirectorsfora termofthreeyearsasprovidedbythearticle erichhunzikerchieffinancialofficerchiefinfor ofincorporationpeterbrabeckletmatheandhorst mationofficeranddeputyheadofthecorporate teltschikhavedecidedtoretireasmembersofthe executivecommitteehasdecidedtoretirefrom boardofdirectorsaftermanyyearsofdistinguishe rocheattheendofmarchandplanstofocus servicearthurdlevinsonandwilliammburn onanumberofboardmembershipstheboardof wereelectedasnewmembersoftheboardfora directorsofrocheholdingltdthankserichhunziker termofthreeyearsasprovidedbythearticlesof forhismanyyearsofexceptionalserviceandout incorporationatitsorganisingmeetingimmediately standingcontributionstothegroupssuccess followingtheagmtheboardofdirector hasapproveditscommitteesstructureanditscom theboardofdirectorshasappointedalanhippeto mitteesmembershipsasshownon succeederichhunzikeraschieffinancialofficer httpwwwrochecomaboutrochecorporategovernancehtm rochearengcorporate governanceindd roche business report corporate governance board director december leave franz humer prof bruno gehrig andr hoffmann andreas oeri prof pius baschera prof sir john irving bell william burns lodewijk vink deanne julius walter frey arthur levinson wolfgang ruttenstorfer prof beatrice weder mauro rochearengcorporate governanceindd corporate governance roche business report board director year birth term end elect board director franz humer chairman prof bruno gehrig vicechairman andr hoffmann vicechairman prof pius baschera prof sir john irving bell william burns lodewijk vink walter frey deanne julius arthur levinson andreas oeri wolfgang ruttenstorfer prof beatrice weder mauro new propose member board director nominate paul bulcke election peter voser annual general meeting march christoph franz secretary board directors gottlieb keller honorary chairman board directors fritz gerber corporate governance sustainability committee audit committee remuneration committee presidiumnomination committee nonexecutive director committee chairperson january rochearengcorporate governanceindd roche business report corporate governance corporate executive committee december leave severin schwan pascal soriot daniel oday erich hunziker silvia ayyoubi gottlieb keller richard scheller jeanjacques garaud dan zabrowski osamu nagayama stephan feldhaus perolof attinger rochearengcorporate governanceindd corporate governance roche business report corporate executive committee year birth position corporate executive committee severin schwan ceo roche group erich hunziker chief financial officer deputy head corporate executive committee pascal soriot coo division roche pharmaceutical daniel oday coo division roche diagnostic gottlieb keller general counsel silvia ayyoubi head human resource april alan hippe chief financial officer enlarge corporate executive osamu nagayama president ceo chugai committee richard scheller head genentech research early development gre jeanjacques garaud head roche pharma research early development pre dan zabrowski head roche partnering stephan feldhaus head group communication secretary corporate executive committee perolof attinger kpmg klynveld peat marwick goerdeler reporting year statutory auditor kpmg roche holding ltd auditor charge john morris chief compliance officer urs jaisli alanhippewilljoinrocheasamemberofthe effectiveauguststephanfeldhauswas corporateexecutivecommitteeasofapril appointedheadgroupcommunicationsandmember oftheenlargedcorporateexecutivecommittee asofjanuaryjeanjacquesgaraudwa reportingtoseverinschwanandreplacingperolof appointedasheadofrochepharmaresearchand attingerwhotookoveranewlycreatedposition earlydevelopmentpredandtogetherwithdan asheadceoofficeandsecretarytothecorporate zabrowskiasheadofrochepartneringbothwere executivecommitteereportingtoseverinschwan appointedasnewmembersoftheenlargedcorpo rateexecutivecommittee rochearengcorporate governanceindd roche business report corporate governance information relate capital structure informationonrochescapitalstructureispro corporate governance videdinthefinancereportnotestothefinancial statementsofrocheholdingltdpage group structure shareholder andadditionaldetailsarecontainedinthe rochesoperatingbusinessesareorganisedinto articlesofincorporationofrocheholdingltd twodivisionspharmaceuticalsanddiagnostic changesinequityaredetailedinthefinance thepharmaceuticalsdivisioncomprisesthetwo reportnotestothefinancialstatementsof businesssegmentsrochepharmaceuticalsand rocheholdingltd chugaiwhereasgenentechastheformerthird thecompanyhasasharecapitalof segmenthasbeenintegratedintorochepharma swissfrancsdividedintofullypaid ceuticalsthediagnosticsdivisionconsistsof bearershareswithanominalvalueofswiss thefollowingfivebusinessareasappliedscience franceachtherearenorestrictionsontheexer diabetescaremoleculardiagnosticsprofes ciseofthevotingrightsofthesesharesupon sionaldiagnosticsandtissuediagnosticsbusi depositsharescanbevotedwithoutanyrestric nessactivitiesarecarriedoutthroughgroup tion subsidiariesandassociatedcompaniessignificant thereisnoauthorisedorconditionalcapital subsidiariesandassociatedcompaniesareliste inadditionnonvotingequity inthefinancereportnotetotherochegroup securitiesneshavebeenissuedinbearerform consolidatedfinancialstatementssubsidiarie theydonotformpartofthesharecapitaland andassociate confernovotingrightseachnesconfersthe majorshareholdersarelistedinthefinance samerightsasonesharetoparticipateinavail reportnotesandtotherochegroup ableearningsandinanyliquidationproceed consolidatedfinancialstatementsequity followingrepaymentofthesharecapitalroche attributabletorocheshareholdersandrelate nesandtherightspertainingtheretoinclude partiespagesandandinnoteto theprovisionsprotectingtheinterestsofnes thefinancialstatementsofrocheholdingltd holdersaredescribedinofthearticlesof significantshareholders incorporationofrocheholdingltd andrhoffmannvicechairmanoftheboardof informationondebtinstrumentswhichhavebeen directorsandandreasoerimemberoftheboard issuedandonoutstandingbondsisprovidedin ofdirectorsandchairmanoftheboardscorporate thefinancereportnotetotherochegroup governanceandsustainabilitycommitteeserve consolidatedfinancialstatementsdebt intheirrespectivecapacitiesontheboardandit committeesasrepresentativesoftheshareholder additionalinformationonemployeestockoption groupwithpooledvotingrightsandreceivethe isprovidedinthefinancereportnotetothe remunerationsetforthintheremunerationreport rochegroupconsolidatedfinancialstatement onandinthefinancereportnote employeestockoptionsandotherequitycom totherochegroupconsolidatedfinancialstate pensationplans mentsrelatedpartiesandnote rochehasissuednooptionsapartfromemployee tothefinancialstatementsofrocheholdingltd stockoptionsstocksettledstockappreciation boardandexecutiveremuneration rightsssarsandoptionsissuedinconnection nootherrelationshipsexistwiththeshareholder withdebtinstrument withpooledvotingright neithertheoptionsawardedtoemployeesnor therearenocrossshareholding thedebtinstrumentswhichhavebeenissuedhave anyeffectonrochessharecapital httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm rochearengcorporate governanceindd corporate governance roche business report board director corporate executive theboardofdirectorshasestablishedasystem committee ofcontrolswhichiscontinuouslymonitoredbythe informationoneachmemberoftheboardof auditcommitteeandbythecorporategover directorsincludingtheyearsinwhichtheywere nanceandsustainabilitycommitteeandconsist electedandtheyearsinwhichtheirtermsend ofthefollowingelement andoneachmemberofthecorporateexecutive reportonfinancialandoperatingrisk committeeislistedonpagestocurricula riskmanagementsystem vitaeandotherinformationincludinginformation systemofinternalcontrolsoverfinancial onboardmembershipsareavailableonthe reportingseepagesandinthe internet financereport theannualgeneralmeetingelectsthemember internalaudit oftheboardofdirectorsinstaggeredelection groupcomplianceofficerandcompliance inwhicheachnomineeisvotedonseparatelysee officersinsubsidiarie ofthearticlesofincorporationofroche safetyhealthandenvironmentalprotection holdingltdandtheminutesofthendannual department generalmeetingofrocheholdingltdheld corporatesustainabilitycommittee march scienceandethicsadvisorygroupseag withtheexceptionoffranzbhumerwilliamm forissuesrelatingtogeneticsandgenetic burnsandarthurdlevinsonnoneofthemem engineeringestablishedin bersoftheboardofdirectorshasbeenamember eachyearseveralblackoutperiodsareimpose ofrochescorporateexecutivecommitteeor duringwhichsenioremployeesareprohibitedfrom servedinanexecutivecapacityatanygroupsub tradingincompanystockthefollowingblackout sidiaryduringthethreefinancialyearsprecede periodsareineffectfor thecurrentreportingperiod decembertofebruary theinternalorganisationoftheboardofdirector apriltoapril andthedivisionofauthorityandresponsibilitie junetojuly betweentheboardandmanagementtheremit octobertooctober oftheboardcommitteesandtheinformation blackoutperiodscanbechangedbythechair andcontrolmechanismsavailabletotheboard manoftheboardofdirectorsifcircumstance initsdealingswithcorporatemanagementare warrant governedbythebylaw intheboardofdirectorsmetforfive theboardofdirectorsofrocheholdingltdis meetingseachfromtohoursinlengthonce organisedsoastoensurethatthegroupsbusi forafulldaymeetingandonceforathreeday nessesareconductedresponsiblyandwitha focusonlongtermvaluecreationtothisendthe rocheboardhasdelegatedcertainresponsibili tiestoseveralcommitteestheircompositionand figure indicate actual length meeting chairpersonsasofjanuaryaredescribe include director extensive premeete preparation oneachcommitteesauthoritiesandre postmeete followup activity sponsibilitiesaredefinedindetailinthebylaw httpwwwrochecomaboutrochemanagement boardofdirectorshtm oftheboardofdirector httpwwwrochecomaboutrochemanagement allthecommitteesexceptthepresidiumare executivecommitteehtm chairedbyindependentdirector httpwwwrochecomaboutrochecorporategovernance accordingtothebylawsoftheboardofdirector articleofincorporationhtm httpwwwrochecomaboutrochecorporategovernance attherequestofanyofitsmembersaboard annualgeneralmeetingshtm meetingwithoutthechairmanpresentmaybe httpwwwrochecomaboutrochecorporategovernance convenedtherocheboardmeetsonceayear articleofincorporationhtm toassessthechairmansperformancethis httpwwwrochecomaboutrochecorporategovernance committeeshtm meetingwhichisnotattendedbythechairman httpwwwrochecomaboutrochecorporategovernance ischairedbyoneofthevicechairmen articleofincorporationhtm rochearengcorporate governanceindd roche business report corporate governance board board committee attendance corporate governance presidium nomination remuneration audit sustainability board committee committee committee committee number meeting humer gehrig hoffmann baschera bell burns vink frey julius levinson oeri ruttenstorfer weder mauro member committee board committee member march visittoamajorsubsidiarywhichincludedaboard orthefullboardinternalauditregularlybriefs ofdirectorsmeetingtheboardcommitteesmet theauditcommitteewithreferencetoongoing asfollowsin auditreportsmembersofinternalauditattend presidiumoftheboardofdirectorsnomination auditcommitteemeetingsasdoexternalaudi committeefivemeetingsapproxhour torsforinformationontheexternalauditorssee remunerationcommitteefourmeeting membersofthecorporateexecutivecommittee approxtohourseach haveamaximumordinarynoticeperiodoftwelve auditcommitteefivemeetingsapproxto month hourseach therearenomanagementcontractswhichfall corporategovernanceandsustainabilitycom withinthescopeofsubsectionannexofthe mitteethreemeetingsapproxhourseach sixdirectiveoninformationrelatingtocorporate theboardofdirectorsregularlyconductsaself governance assessmentofitsperformance themembersofthecorporateexecutivecommit remuneration shareholding loan teeareinvitedtoattendforandreportinperson alldetailsregardingremunerationshareholding onthoseagendaitemsconcerningthemwhen andloansaresetforthintheseparateremunera thesituationwarrantsmembersoftheenlarge tionreportonpagestoandinthefinance corporateexecutivecommitteemayalsobe reportnotesandtotherochegroup invitedtoattendtheboardcommitteesinvitethe chairmanoftheboardandothercorporate figure indicate actual length meeting include director extensive premeete preparation executivecommitteememberstodeliverreport postmeete followup activity atcommitteemeetingsandmayelecttocommis remuneration committee member permit sionindependentexpertreportsandcallon contribute attend remuneration committee meeting theservicesofconsultantstheriskmanagement matter concerning deliberate decide additional information provide finance report note systemissubjecttocontinuousreviewwith roche group consolidated financial statement findingsbeingpresentedtotheauditcommittee risk management rochearengcorporate governanceindd corporate governance roche business report consolidatedfinancialstatementsequityattri theirauditstheauditcommitteeoversee butabletorocheshareholdersandrelate andassessestheauditorsandmakesrecomman partiespagesandandarelistedinthe dationstotheboardforinformationonthe notesandtothefinancialstatementsof responsibilitiesoftheauditcommitteeseearti rocheholdingltdboardandexecutiveremuner cleofthebylawsthestatutoryauditor ationandboardandexecutiveshareholding participatedinfourmeetingsoftheauditcommit pagesand teein participatory right shareholder thereportsofstatutoryauditorsontheconsoli theparticipatoryrightsofshareholdersare datedfinancialstatementsandonthefinancial definedinrochesarticlesofincorporationas statementscanbefoundonpagesand rochesharesareissuedtobearerthereare respectivelyofthisyearsfinancereport norestrictionsonadmissiontoannualgeneral meetingswiththeexceptionthatsharesmust kpmgreceivedthefollowingremunerationfor bedepositedwithinaspecifiedperiodbeforethe theirservicesasstatutoryauditorsofrochehold dateofameetingandanadmittancecardmust ingltdandotherrochecompanie beissuedintheshareholdersnameasprovide inofthearticlesofincorporationanyshare holdercanelecttoberepresentedbyanother millions chf shareholderatanannualgeneralmeetingthe auditing service articlesofincorporationcontainnorestriction auditrelated service ontheexerciseofvotingrightsandtheonlyquo tax consultancy service rumrequirementsarethosestipulatedin total inconformitywiththeswisscodeofobligation underofthearticlesofincorporationshare thestatutoryauditorsareelectedeachyearby holdersrepresentingshareswithanominalvalue theannualgeneralmeete ofatleastmillionswissfrancscanrequestthe placementofitemsontheagendaofanannual ernstyoungltdreceivedthefollowingremuner generalmeetingthismustbedonenolaterthan ationfortheirservicesastheauditorsofchugai daysbeforethedateofthemeete change control defensive measure millions chf thearticlesofincorporationcontainnoprovision chugai audit onthemandatorybidruleswisslawapplie consulting service therearenochangeofcontrolclausesthose provide chugai componentsofremunerationbasedonrochene total wouldbeterminatedintheeventofanacquisi genentech chugai tionandvestingperiodrestrictionsonpreexist ingawardswouldberemovedsothatallsuch optionscouldbeexercisedimmediately information policy asprovidedbyofthearticlesofincorpora relationship statutory auditor tioncorporatenoticesarepublishedinthe attheannualgeneralmeetingofrocheholde swiss official gazette commerceandinother ltdonmarchtheshareholdersvotedto dailynewspapersdesignatedbytheboardof appointkpmgagkpmgasstatutoryauditor informationonhowlongtheauditorsandauditor httpwwwrochecomaboutrochecorporategovernance inchargehavebeenservinginthesecapacitie articleofincorporationhtm isprovidedonthestatutoryauditor httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm participateinauditcommitteemeetingsthey httpwwwrochecomaboutrochecorporategovernance preparewrittenandoralreportsontheresultsof articleofincorporationhtm rochearengcorporate governanceindd roche business report corporate governance directorsbasler zeitung finanz und wirtschaft nonapplicabilitynegative disclosure lagefi temps neue zrcher zeitung itisexpresslynotedthatanyinformationnot rochereportsitshalfyearandfullyearresultsin containedormentionedhereinisnonapplicable businessreportspublishedinprintandonline oritsomissionistobeconstruedasanegative formatsandatmediaeventsinadditiondetaile declarationasprovidedinthesixswissexchange firstandthirdquartersalesfiguresarepublishe corporategovernancedirectiveandthecom eachyearinaprilandoctoberthemostcurrent mentarythereto listofpublicationdatesisavailableinenglishand germanontheinternet allrelevantinformationanddocumentsinclude allmediareleasesinvestorupdatesandpresen tationstoanalystandinvestorconferencesare availableontheinternetfurtherpublicationscan beorderedbyemailfaxortelephone baselwebmasterrochecom tel fax thecontactaddressforinvestorrelationsis hoffmannlarocheltdinvestorrelation groupfinancebaselswitzerland tel fax additionalinformationincludingdetailson specificcontactpersonsisavailableonthe internet chief compliance officer thechiefcomplianceofficerwithhiscompliance officersnetworkiscommittedtoensuringthatthe rochegroupcodeofconductisconsistently compliedwiththroughouttherochegrouphe alsoservesasacontactpersonforshareholder employeescustomerssuppliersandthegeneral publiconissuesrelatingtotheimplementation ofandcompliancewiththiscodeemployeesand otherpartieswhobecomeawareofviolationsof therochegroupcodeofconductcanbringthem totheattentionoftheirmanagersorsupervisor orreportthemtothechiefcomplianceofficer ursjaislidirectphonenumber emailursjaislirochecom suchdisclosureswillbetreatedconfidentiallyin additionasoftheendofemployeesmay anonymouslyreportirregularitiesorcomplaint intheircorrespondingmotherlanguageviaa speakuphotlinethechiefcomplianceofficer httpwwwrochecommediahtm reportsregularlytothecorporategovernance httpwwwrochecominvestorshtm httpwwwrochecominvestorscontactshtm andsustainabilitycommittee httpwwwrochecomaboutrochecorporategovernance codeofconducthtm rochearengcorporate governanceindd remuneration report roche business report remuneration report summary abalancedmixoflongandshorttermremunera rochessuccessdependsontheabilitiesanddedica tioncomponent tionofitspeoplerecognitionofthisformsthebasis marketcompetitiveness ofourremunerationpolicyandsystem basepaybonusesblockednonvotingequitysecuritie oneoftheprimaryaimsofourremunerationpolicyis nesawardsofstocksettledstockappreciation toencouragealongtermfocusandalignmanage rightsssarsandaperformanceshareplanpsp mentsinterestswiththeinterestsofrochesshare supporttheseprinciplestheseremunerationcom holdersandholdersofrochesnonvotingequity ponentsarelinkedtoourcompanysfinancialperfor securitiesne manceandcommercialsuccessandthusalignthe interestsofrocheemployeeswiththoseoftheshare thisremunerationreportwillbesubmittedsepa holder ratelyforapprovalattheannualgeneral meeting theamountoftheseparatecomponentsofremunera theremunerationofcorporateexecutivecommittee tionforeachindividualmemberofthecorporate membersandotherseniorrocheexecutivesis executivecommitteeisshownintheindividualdescrip comprisedof tionoftheremunerationofthecorporateexecutive basesalaryfixed committeeinthisreport bonusvariable stocksettledstockappreciationrights base pay ssarsvariable basepaycashpaymentlevelsaredetermine performanceshareplanpspawardsvariable accordingtomarketdataoftheworldsbiggestphar underthepspnoneswillbeawarded maceuticalscompaniesforspecificpositionsand thessarsgrantedin individualemployeesabilitiesexperienceandperfor andhavestrikepricesabovethenesprice manceovertimepayincreasesarelinkedtoindividual asofdecemberandhavenovaluefor performanceandalsotakeintoaccountprevaile therecipientsthiscanchangeifrochesfuture marketconditionsandthecompanysoveralleconomic nespriceimprove situationbasepayandpayincreasesareconclusively therehasbeennochangeinthebaseremunera monitoredanddeterminedbytheremuneration tionoftheboardofdirectorssince committee pleaseseetherestofthisreportforfulldetail bonus bonusescashpaymentareawardedinrecognition remuneration policy ofindividualcontributionstovaluecreationwhich rochefundamentallyreneweditsremunerationpolicy gobeyondnormaljobexpectationsandtheyare inandrevieweditinreconfirmingthe meanttobeanincentivetocreateorstrengthennew keyprinciplesitispartofaframeworkofemployee businessopportunitiesandstriveforoutstanding policiesaimedatmotivatingandretainingcurrent resultsbonusamountsarelinkedtogroupordivi employeesattractingtalentednewonesandhelpe sionalbusinessperformanceconsideringprofit allrocheemployeestoperformatconsistently highlevelsourremunerationpolicyisdesignedto stock optionsstocksettle stock appreciation right fostervaluecreationandreinforceacultureof ssar performanceandinnovationanditappliestonon finance report note roche group managerialemployeesaswellastomanager consolidate financial statement relate party note financial statement roche thekeyprinciplesunderpinningthispolicyare holding ltd board executive remuneration board focusonvaluecreation executive shareholding payforperformance peer set abbott laboratories amgen astella enablingemployeestoshareinthecompany astrazeneca bayer becton dickinson biogen idec bristolmyers squibb eli lilly gilead glaxosmithkline success johnson johnson merck novartis pfizer fairnessandtransparencyinremunerationdecision sanofiaventis takeda rochearengremuneration reportindd roche business report remuneration report variable remuneration element bonus ssar psp relation fix base pay member corporate executive committee bonus ssar psp individual target value max relation value base annual base pay base pay measure january year cycle minimum maximum relation value cash payment value development value development base pay determine determined performance ne performance ne grant grant performance criterion group objective group individual contribution group performance divisional business remuneration tsr relation performance committee decision tsr performance individual objective discretion peer set consider profit sale growth opac operate profit capital charge split group objective individual objective salesgrowthopacoperatingprofitaftercapital performance share plan chargeperformanceandtotheachievementof themembersofthecorporateexecutivecommittee individualandfunctionalmeasurableandqualitative andothermembersofseniormanagementcur performanceobjectivesforreasonsofcompeti rentlysomeindividualsworldwideparticipate tivenessrochedoesnotdisclosedetailsofindividual intheperformanceshareplanpspthepsp objectivesofthemembersofthecorporateexec wasestablishedinforperiodsofthreeyear utivecommitteetheremunerationcommitteeofthe eachandisbasedonathreeyearcomparison boardofdirectorshasdefinedthecorporateex ofthetotalshareholderreturntsrwithcom ecutivecommitteemembersbonusesindecember petingcompaniesintherewerethreeover basedonresultsachievedfor lappingperformancecyclespsp pspandpspofwhichpsp stocksettle stock appreciation right ssar closedon december stocksettledstockappreciationrightswere introducedonjanuarythusestablishinga detailsforthepspcalculationandaddi uniformsystemofremunerationthroughoutroche tionalinformationaresetforthinremuneration ssarsentitleholderstobenefitfinanciallyfrom ofmembersofthecorporateexecutivecommittee anyincreaseinthevalueofrochesnonvotingequity performanceshareplanpsp securitiesbetweenthegrantdateandtheexer cisedateawardsareallocatedindividuallyuponthe remuneration board director remunerationcommitteesdecisionatitsowndi corporate executive committee cretiondetailedinformationisavailableon eachyeartheremunerationcommitteewhichis andto entirelycomprisedofindependentexternalmember oftheboardofdirectorssetsremunerationforthe rochearengremuneration reportindd remuneration report roche business report membersoftheboardofdirectorsandthecorporate nerationofthechairmanoftheboardofdirector executivecommitteecashpaymentsbonuse themembersofthecorporateexecutivecommittee optionsstocksettledstockappreciationrightsand takingintoconsiderationpersonnelchange policydecisionsaboutpensionbenefitstheterm oftheperformanceshareplanaredeterminedannually thefollowingpagesprovidedetailedinformationon bytheboardofdirectorsactinguponrecommen theremunerationearnedbyeachmemberofthe dationsfromtheremunerationcommitteetheremu boardofdirectorsandbyeachmemberofthecor nerationcommitteecontinuouslytrackssalarytrend porateexecutivecommitteefor inthemarketoftheworldsbiggestpharmaceutical companiesandreportstotheboardofdirectorsin remuneration formationonthiscommitteesremitpowersandit remuneration member board proceduresformakingremunerationdecisionscanbe director inthemembersoftheboardof foundinthebylawsoftherocheboardofdirector directorsreceivedtheremunerationincashshown followingtherevisionoftheremunerationpolicy includingmarketcomparisonswiththeworldsmajor httpwwwrochecomaboutrochecorporategovernance articleofincorporationhtm pharmaceuticalcompaniestheremuneration list member position committee committeehasdeterminedthebonusesandremu membership chairmanship remuneration member board director additional compensation remuneration committee memberschairs chf chf additional special compensation humer remuneration chairman board director gehrig hoffmann baschera bell burns vink frey julius levinson oeri ruttenstorfer weder mauro remuneration member board director additional compensation remuneration committee memberschairs chf chf additional special compensation brabeckletmathe teltschik ith exception member presidium vicechairmen board member receive chf year committee serve chf year committee chair high total remuneration member board director page remuneration serve vicechairman board prorate remuneration period march december prorate remuneration period january march rochearengremuneration reportindd roche business report remuneration report inthetableremunerationofmembersoftheboard forhisconsultingworkandforhisboardmember ofdirectorsonfortheirboardactivitie shipofgenentechamountingtousdollar remunerationofallmembersoftheboardofdirec swissfranc torswillagainremainunchangedfor forthemembersoftheboardofdirector besidethecashpaymentsthenonexecutivemem receivedremunerationtotallingswiss bersoftheboardofdirectorswerenotawardedany francsswissfranc sharesnonvotingequitysecuritiesstocksettle stockappreciationrightsssarsstockoption noadditionalremunerationwaspaidtomembersof orrestrictedstockunitsrsusin theboardofdirector horstteltschikreceivedhonorariaamountingto remuneration member corporate eurosswissfrancsforservingon executive committee thegeneralprovision theboardsofseveralrochesubsidiariesingermany assigningauthorityfordecisionsoncorporateexec utivecommitteeremunerationtotheremuneration williammburnsreceivedhonorariaamountingtoa committeeandtotheboardofdirectorsareoutline totalofusdollarsswissfrancs onpagestoofthisremunerationreport forservingasamemberoftheboardofdirectorsof chugaipharamaceuticalcoltd stock optionsstocksettle stock appreciation right ssar sincehiselectiontotheboardofdirectorsofroche remuneration member board director holdingltdarthurdlevinsonreceivedpayment remuneration member corporate executive committee base pay chf annual salary annual salary annual salary schwan ayyoubi hunziker keller oday soriot total member corporate executive committee duetoobligationsfromhisformerrocheassignment bonus intheusdanielodayreceivedthefollowingpay allmembersofthecorporateexecutivecommittee mentsinmortgagesubsidyusdollar willreceivethebonusasacashpaymentdue swissfrancsforfinancialtaxservice forpaymentattheendofapril usdollarsswissfrancsdanieloday receivedinadditionswissfrancsforthe ondecemberthestocksettledstock schoolingofhischildren appreciationrightsgrantedin forthemembersofthecorporateexecutive committeereceivedremunerationtotalling remuneration member corporate executive swissfrancsswiss committee exclude ahvivalv franc rochearengremuneration reportindd remuneration report roche business report bonus bonus bonus bonus total total total chf chf chf schwan ayyoubi hunziker keller oday soriot total member corporate executive committee include additional compensation successful integration genentech amount swiss franc pay stocksettle stock appreciation right ssar ssar ssar ssar value chf value chf value chf schwan ayyoubi hunziker keller oday soriot total member corporate executive committee stock optionsstocksettle stock appreciation right ssar lackschole value describe stock optionsstocksettle stock appreciation right ssar value accord annual report andmostofwhichcanbeexercisedfollow eachyearintherewerethusthreecyclesin ingtheendofthevestingperiodinfebruary progresspsppspandpsp hadnovaluefortherecipient asinthepreviousyearforthepsp thepspendedon decem membersofthecorporateexecutivecommittee berwithoutanyawardsoftargetedne additionallyreceiveannualexpenseallowancesof swissfrancstotallingswissfranc undertheprovisionsofthisplananumberofnon votingequitysecuritieshavebeenreservedfor performance share plan psp theparticipantsineachcyclethenumberofse themembersofthecorporateexecutivecommittee curitiesactuallyawardedwilldependonwhether andothermembersofseniormanagementcurrently andtowhatextentaninvestmentinrochesecuritie someindividualsworldwideparticipateinthe sharesandnesoutperformstheaveragereturn performanceshareplanpsp inthepspmovedtooverlappingthreeyear strike price table stock option ssar performancecycleswithanewcyclebeginne rochearengremuneration reportindd roche business report remuneration report onaninvestmentinsecuritiesissuedbyapeerset attheendofthepspcyclebasedona ofcomparatorcompaniescomparisonsarebase threemonthmovingaverageatconstantexchange onthesecuritiesmarketpricesanddividendyield rateswithdistributeddividendstotallingbil ieontotalshareholderreturntsrtoreducethe lionswissfrancsbillionswissfrancs effectofshorttermmarketfluctuationssecurity billionswissfrancsbillion pricesareaveragedoverthethreemonthsoctober swissfrancsthetsroftherochesecuritie todecemberpriortothestartofaperformance nesandsharesrankedcomparedwithits cycleandoverthethreemonthsoctobertodecem peersetofcompaniesoperatinginthesamein berattheendofthecycleifrochesecurities dustrythereforeaccordingtothetermsoftheplan performaswellasorbetterthanthoseofofthe theparticipantsreceivednoneoftheoriginally peersetandinadditionrochestsrincrease targetednesseetablebelowfordetail atleastduringacycletheboardofdirector canelecttoincreasethemaximumnesaward indirect benefit byasmuchastwofoldintheeventthataninvest employercontributionsmadeintosocialsecu mentinrochesecuritiesunderperformsthe rityschemespensionplansandagroupwide averagereturndeliveredbythepeercompanie employeestockpurchaseplanrocheconnectin fewerornoneswillbeawarde respectofmembersofthecorporateexecutive committeeareshowninthetableindirectbenefit inneswerereservedundertheplanformem inon bersofthecorporateexecutivecommitteeas showninthetablebelowtheboardofdirectorswill rocheconnectisavoluntarystockpurchaseplan decideontheactuallevelofnesorcashequivalent offeringemployeestheopportunitytobuyroche awardsforthecyclesand nonvotingequitysecuritiesnesuptoanamount afterthecloseoftheandfinancialyear equaltooftheirannualsalaryatadis respectivelytheaimofthepspistoprovide anincentivetoparticipantstoachievesteadyvalue growth footnote performance share plan psp total estimate value psp award ne ne award award award target number target number target number ne psp ne psp ne psp psp psp value chf value chf value chf schwan ayyoubi hunziker keller oday soriot total member corporate executive committee total estimate value psp originally target ne award psp estimate value calculate yearend price december chf nonvoting equity security ne base number ne originally target subject change number value ne awardable plan december december respectively spread relevant period time year board director vote actual allocation ne originally target december december respectively accord tsr achieve rochearengremuneration reportindd remuneration report roche business report indirect benefit payment pension fundsmgb ahvivalv roche connect tax consulting service chf chf chf chf schwan ayyoubi hunziker keller oday soriot total mgb stiftung der hoffmannla roche mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit ahvivalv swiss social security programme provide retirement disability unemployment benefit countnespurchasedunderthisplanaresubjectto high total remuneration member aholdingperiodwhichisfouryearsinswitzerland board director franzbhumerasthechairmanwasthememberof remuneration emolument loan theboardwiththehighesttotalremunerationfor inpensionsandtwopaymentsfortaxconsult seeremunerationofmembersoftheboardof ingservicestotallingswissfrancswere directorsthechairmansremuneration paidtofourformercorporateexecutivecommittee consistsofbasesalaryandbonusawardsaschair members manoftheboardafterthehandoverofhisexecu tivefunctionasceoattheannualgeneralmeeting membersofthecorporateexecutivecommitteehave onmarchhedidnotreceiveanyadditional amaximumnoticeperiodoftwelvemonthsincon ssarsornesfromnewpspcyclesandwa nectionwiththenewcompanyandpersonnelstruc nolongerenrolledinanyrochestockoptionplan turemembersofthecorporateexecutivecommittee orssars canreceivecompensationamountingtooneannual basepayincaseofterminationofthecontractbythe accordingtotheannouncementintheannual companyterminationthroughnofaultandnotbase reporttheboardofdirectorsreducedthe onlackofperformanceuntiltheageofsixty chairmansbasesalaryintomillionswis high total remuneration member board director chf chf salary bonus total pension fundsmgb roche connect total value detailed calculation remuneration chairman ceo annual report stiftung der hoffmannla roche mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit nclude additional compensation committee member chf payment tax consulting service chf chugai advisory mandate usd chf include employer contribution ahvivalv chf rochearengremuneration reportindd roche business report remuneration report high total remuneration member corporate executive committee chf chf salary bonus total ssar blackschole value grant minus pension fundsmgb roche connect estimate value target award ne accord performance share plan awardsvalue nes total total value detailed information annual report blackschole value describe stock optionsstocksettle stock appreciation right ssar mgb stiftung der hoffmannla roche mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit basic rule detailed calculation remuneration member corporate executive committee performance share plan footnote respectively include annual expense allowance chf payment tax consulting service chf exclude employer contribution ahvivalv payment francsasof aprilanddeterminedatthe security holding directorsandrhoffmann endofthathistotalremunerationincluding andandreasoeriandmembersofthefounder bonusescontributionstopensionfundsandad familieswhoarecloselyassociatedwiththembelong ditionalcompensationexpenseallowancewill toashareholdergroupwithpooledvotingright dependingontheachievementofobjectivesnot attheendofthisgroupheldshare exceedthemaximumamountofmillionswiss ofissuedsharesdetailedinformation francstheshareholdersagreedtothismaximum aboutthisgroupcanbefoundinthefinancereport amountwiththeapprovaloftheremuneration notetotherochegroupconsolidatedfinancial reportattheannualgeneralmeetingon statementsrelatedpartiesandin marchtheeffectivetotalremuneration thenotetothefinancialstatementsofroche wasbelowofthedeterminedmaximumand holdingltdsignificantshareholdersin lowerthan additionasofdecemberthemembers oftheboardofdirectorsandpersonscloselyasso high total remuneration member ciatedwiththemandthemembersoftheexecutive corporate executive committee committeeandpersonscloselyassociatedwith severinschwanasceowasthememberofthecor themheldsharesandnesasshowninthetableon porateexecutivecommitteewiththehighesttotal remunerationforseeremunerationofmem bersofthecorporateexecutivecommitteeaf stock optionsstocksettle stock apprecia tion right ssar atdecemberfranz bhumerandwilliammburnsbeingtheonly noadditionalremunerationwaspaidtocurrentor membersoftheboardofdirectorsholdingoption formermembersofthecorporateexecutivecommit andasofjanuaryssarsduetotheir tee formerpositionsandthemembersofthecorporate executivecommitteeheldoptionsandstock settledstockappreciationrightsssarsfirst rochearengremuneration reportindd remuneration report roche business report introducedonjanuaryasshowninthetable thestrikepricesexpirydatesandgrantvalue stockoptionsandssarson foroptionsandssarsareshowninthetableon thenumbersofoptionsandssar alloftheoptionsshowninthetablewereissuedby ascalculatedatthetimeofissuehavebeenentered rocheasemployeestockoptionseachoption asvaluesinthetableremunerationofmember entitlestheholdertopurchaseonerochenonvote ofthecorporateexecutivecommitteecstockset equitysecuritynesataspecifiedstrikeprice tledstockappreciationrightsssarson atgrant underthetermsofthismultiyearoptionplan thestrikepriceforoptionsshownwastheclose priceforrochenesonthelastdayoftrade priortotherocheannualmediaconferenceallof theoptionsshownarenontradableonethird oftheoptionsaresubjecttoavestingperiodofone yearonethirdhaveavestingperiodoftwoyear andonethirdavestingperiodofthreeyear unvestedoptionslapsewithoutcompensation ifemploymentisterminatedvoluntarilyforreason otherthanretirementwhilevestedoptionsmust beexercisedwithinalimitedperiodoftimeifemploy mentisinvoluntarilylayofforredundancyjob eliminationorreductioninforceterminatedgrante butunvestedoptionsvestimmediatelyandmust beexercisedwithinsixmonthsortheyareforfeite thefairvalueoftheoptionsiscalculatedatthe dateofissueusingtheblackscholesformulaandas iftheoptionsweretradablewithandeduction fortheaveragetwoyearvestingperiod thessarsshowninthetableonwere introducedbyrocheonjanuaryinplaceof stockoptionsssarsentitleholderstobenefit financiallyfromanyincreaseinthevalueofroche nesbetweenthegrantdateandtheexercisedate thestrikepriceforssarsunderthetermsofthis multiyearplanwastheclosingpriceforrochene onthefirstdayoftradingaftertherocheannual mediaconferenceallssarsvestwithinthreeyear ofthegrantdateieonethirdvestattheendof oneyearonethirdattheendoftwoyearsandone thirdattheendofthreeyearsvestedssar mustbeexercisedconvertedintoneswithinseven yearsofthegrantdateandunexercisedssar lapsewithoutcompensationthefairvalueofthe optionsiscalculatedatthedateofissueusingthe blackscholesformulaandasiftheoptionswere tradablewithandeductionfortheaveragetwo yearvestingperiod rochearengremuneration reportindd roche business report remuneration report security holding december close relative share ne security holding number number numbertype number board director humer ssar rogtpk trackerplus cert zrcher kantonalbank roche genussschein rog underlie valor isin gehrig hoffmann ubs longshort certificate link roche bearer share roche nonvoting equity securities valor isin baschera bell burn stock option ssar vink american depository receipts adr rhhby isin frey julius nes levinson oeri ubs longshort certificate link roche bearer share roche nonvoting equity securities valor isin ruttenstorfer weder mauro total nes corporate executive committee schwan ne stock option ssar ayyoubi stock option ssar hunziker stock option ssar keller ne ssar oday ssar soriot ssar total ne share hold shareholder group pool voting right list rochearengremuneration reportindd remuneration report roche business report stock option ssar number stock option ssar hold current member corporate executive committee december ssar issue total corporate execu tive committee schwan ayyoubi hunziker keller oday soriot total corporate executive commit tee member humer burn strike price chf market price ne december chf expiry date grant value option start ssar chf blackschole value minus ssar stock option franz humer receive additional ssar franz humer receive stock option ssar member corporate executive committee wiliam burn receive additional ssar william burn receive stock option ssar member corporate executive committee rochearengremuneration reportindd corporate responsibility dow jones sustainability index name roche supersector leader healthcare second consecutive year sustainability core business practice positioning reflect commitment run business way ethical responsible create longterm value stakeholder year progress longterm diversity energy goal introduce new programme increase access product rochearengcorporate responsibility partindd corporate responsibility roche business report corporate responsibility brief wefocusondevelopingnewmedicinesanddiag thesixthannualsustainabilityworkshopattende nosticsthataddressunmetmedicalneedandhelp bysustainabilityexpertsfromaroundthegroup patientsleadlongerbetterlivesdiscovere accesstomedicinesanddiagnosticsandthevalue anddevelopingtheseproductsremainsourgreat ofourproductsandservicesremainedhighon responsibility theagendathisyearwhileaworkinggroupdis cussedournewkpis thenatureofourbusinessmeanswealwaysthink longtermittakeseighttotwelveyearstobringour web medicinestomarketsobeingsustainableiscritical sustainability principle foroursuccessaswellasforourcustomerssup wwwrochecomprinciple csc charter wwwrochecomcsrcommittees pliersandpartnersweaimtobalancetheneedsof kpi wwwrochecomsuskpipdf individualssocietyandtheenvironmentinourwork andtobearewardingemployerthatattractstalente peopleourvaluesofintegritycourageandpassion guideemployeestodotherightthingintheirwork approach roche management sustainability wefocusonthecorporateresponsibilityissuesthat aremostrelevanttoourstakeholdersandhavethe board director greatestpotentialtoimpactourbusinesswemonitor ourprogressusingkeyperformanceindicatorskpis corporate foreachissueduringwerevisedourkpisto executive alignthemwithourstrategicframeworkensurethey committee supportourlongtermbusinessstrategyandgoal andfurtherintegrateresponsiblebehaviourthrough outthebusiness board committee corporate governance sustainability theupdatedkpismeasurethevaluewecreatefor fourmainstakeholdergroupsemployeespatient investorsandsocietywereportagainstseveralof corporate sustainability committee csc thesekpisplusadditionalperformancemeasure core team work team throughoutthisannualreportandonourwebsite inwewerenamedsupersectorleaderin healthcareforthesecondyearrunninginthedow key material sustainability topic jonessustainabilityindexesdjsiinrecognition ofourcommitmenttosustainablepracticesweuse thisindexandotheranalysestoevaluateourperfor manceandtoidentifyareaswherewecanimprove orlearnfromother manage corporate responsibility network colleague atrochecorporateresponsibilityisanintegralpart relevant corporate divisional function ofeveryonesworkandiscoordinatedbyourcor poratesustainabilitycommitteecscasshownin thediagramthecscidentifiesandassessessig nificantsocialethicalandenvironmentalrisksand opportunitiesanddevelopsandrevisescorporate positionsandguidelinesonrelatedtopicsitmetfor mallyfourtimesinandinseptemberhoste rochearengcorporate responsibility partindd roche business report corporate responsibility stakeholder engagement weaimtocreatevalueforourstakeholdersthrough believeintwowaydialoguewherebothpartieslearn themedicalbenefitsourproductsprovideour fromeachotherthetableshowsexamplesfrom dailybusinessactivitiesandspecificactivitieswith andthereisfurtherinformationonourwebsite eachgroupweregularlyseekstakeholdersview whenformulatingbusinessstrategysettingprioritie web includingthoserelatingtocorporateresponsibil stakeholder engagement itycrandthroughoutproductdevelopmentwe wwwrochecomstakeholderengagement stakeholder engagement stakeholder group example engagement result engagement patient run workshop patient group well understand patient need patient group country include france germany help manage disease review inform consent form consent form easy patient read patient advocacy group egan understand healthcare market research need assessment improve understand customer need professional hcp country hcp participate american hcp virtual conference service hcp society clinical oncology virtual conference government participate industry initiative topic development effective public health poli regulator biosimilar cie regulation share learning industry develop guideline misuse com roche wada sign memorandum pound world antidope agency understand healthcare payer work payer develop method development tool assess cost evaluate compare effectiveness effectiveness medicine improve understanding payer develop pricing toolkit computer value product service model association payer employee groupwide programme promote increase awareness understand strategic framework strategic framework global ran management town hall meeting work force major site investor attend investor meeting improve investor understanding busi conference ness model strategy latestage pipeline supplier work key supplier commit minimise supply chain risk business partner new supplier code conduct extend supplier audits business critical begin align supplier audit protocol service provider indirect spend psci member nongovernmental work access medicine index ensure recognition access organisation rank programme engage amnesty international launch project chinese ministry declaration bern organ health establish organ donation donation china system community donate time money expertise help reduce health inequality cause aids orphans malawi maintain positive relationship clean water uganda community contribute local community support generation scientist initiative roche genetic education programme medium corporate press release trade maintain positive medium image protect news update reputation rochearengcorporate responsibility partindd corporate responsibility roche business report patient excellenceinscienceisfurtheringourunderstande ourhealtheconomistsandreimbursementmanager ofthemechanismsofdiseaseweareusingthis workwithnationalandlocalhealthauthoritiesto knowledgetodevelopmedicallydifferentiatednew demonstratetheeconomicandhealthbenefitsofour therapiesandhelpimprovepatientsqualityoflife productsandserviceswithineachhealthcaresys furthermorebyfittingtreatmentstopatientsand temweengagewithpayersandprovidersthrough achievingbetteroutcomespersonalisedhealthcare outaproductslifecycleandprovideguidanceon makesmoreefficientuseofhealthcarebudget howtoassessthevalueofourproductsandservice throughevaluationssuchashtasinmarketssuch wecanincreasethiscontributiontosocietyby astheukwehavedevelopedmodelsthatassessthe demonstratingthemedicalandeconomicvalue costsandclinicalconsequencesofcertainthera ofourproduct piescomparedwithdifferenttreatmentoptionsto helpingtoimproveglobalaccesstohealthcare helppayersandhealthcareprovidersmakein runningsafeandethicalclinicaltrial formedchoice ensuringpatientsafety buildingrelationshipswithpatientsgroup weworkwithpayerstoagreepricingarrangement listeningandrespondingtocustomersview thatsuittheirneedsourapproachconsidersa rangeofoptionsforreachingamutuallyagreeable value medicine diagnostic pricesuchasvolumebasedandotherdiscount healthcarepayershavetobalancemedicalneedand pricecappingcostsharingandpaymentbyresult clinicalimpactwiththecostofnewmedicinesand thisworkwasparticularlyimportantformain theallocationofscarcebudgetsthishasledtothe tainingaccesstoourproductsinwhenmany developmentofavarietyofmethodsfordetermin governmentsfocusedonreducinghealthcare ingappropriatecoverageandreimbursementrate budgetsorrestrictingtheirgrowthtohelpmanage byexaminingtheclinicaleconomicsocialand publicfinance ethicalimplicationsofamedicaltechnologythese arebroadlytermedhealthtechnologyassess ourpositionsonpersonalisedhealthcareassesse mentshtasdifferentprovidersusedifferenthta thevalueofourproductsandservicesandprice resultinginvaryinghealthcareprioritiesdelivery describeourapproachinmoredetailandareavailable andaccesslevel onourwebsite itisessentialthatpayerscanassessourproduct global access healthcare usingobjectiveconsistentandopenprocesse theprovisionofhealthcareisasharedresponsibility whichconsiderthefullcycleofcareaswellasclini andlackofaccesstomedicinesanddiagnosticsis calandeconomicvalueforindividualpatientsand oneofmanysystemiccausesofhealthcareinequality forsocietyforthisreasonwehaveaglobaldepart otherbarriersincludelackofdiseaseawareness mentthatsetsandmaintainspricesforourportfolio lowlevelsofdiagnosisandlimitedhealthcareinfra throughouttheproductlifecycleitalsoensuresour structureandbudget clinicaltrialsassessthecosteffectivenessaswell asefficacy wehaveanimportantroletoplayintacklingthe globalhealthcarechallengeweworkwithgovern whensettingthepriceforanewtestordrugwelook mentshealthcareprovidersthemediapatient atthemedicalbenefititprovidesandcompareit groupsandnongovernmentalorganisationsngo lifecyclevaluewiththeavailablealternativesmanyof toincreaseaccessandtacklethesewiderproblem ourproductshelpreducetreatmenttimesandthe needforsurgeryorpalliativecareminimisehospital healthneedsindevelopingcountriesandemerging stayspreventdiseasefromreturningandspeed marketsdifferfromthoseinthedevelopedworld patientsreturntoworktheassociatedsavingsare wecreatetailoredprogrammestoboostaccesstoour alsotakenintoaccountadditionallyweconsider productsplusresearchanddevelopmentrd localreimbursementmodelspopulationsizeand modelsforthediscoveryofnewproductsforthese prevalenceofthediseaseandlevelofunmetneed regionswearecommittedtofindingsustainable rochearengcorporate responsibility partindd roche business report corporate responsibility andimpactfulwaystomakealongtermdifferenceto healthcaretheillustrationshowssomeofourpro grammestoincreaseaccesstohealthcareandthere arefurtherdetailsonourwebsite new drug lead select access need theworldhealth oneworld health investigate organizationwholistsmanyofourdrugsas potential new treatment childhood diarrhoea essentialmedicinestheseandourotherproduct areavailablethroughdoctorshospitalslaborato riesandpharmaciesinovercountriesmainly inthosewithestablishedhealthcaresystem howeveraroundathirdoftheworldspopulation doesnothaveadequateaccesstohealthcare patient receive free medicine genentech access care foundation poorercountriessufferthehighestlevelsofdisease andhavetheweakesthealthcaresystemsmanyface acriticalshortageofhealthcareprofessionalsand facilitiesaswellaslowlevelsofunderstandingofthe causespreventionandtreatmentofdiseasewe aimtoprovidesustainableaccesstohealthcarein infant test hiv thesecountriesbasedon amplicare initiative sustainablepatentandpricingpolicie partnershipswithgovernmentsngosandother educationtrainingandknowledgetransfer rdintodiseaseswithunmetmedicalneed wehavenotfiledorenforcedpatentsforanyofour medicinesintheleastdevelopedcountriesldcs definedbytheunitednationssincein employee participate annual children weexpandedthispolicytoincludethelowincome walk support care centre provide educational countrieslicsdefinedbytheworldbankcover opportunity aid orphan malawi local community activity inganothersixcountriesinadditionwedonotfile orenforcepatentsforanyantiretroviralhivmedi cinesinsubsaharanafricanssacountrie wesupplytwohivmedicinesatnoprofitpricesin theldcsandssaandweprovidethesemedicine developsnewmarketsforourproductsandservice atreducedpricesinlowermiddleincomecountrie inthelongerterm valcyteourmedicineforaidsrelatedcytomegalo virusretinitisisavailableatreducedpricesforngo inwejoinedforceswiththeinternational ledaidstreatmentprogrammesintheldcslic atomicenergyagencyiaeatolauncheducare ssaandlowermiddleincomecountrie amajornewprogrammetoimprovecancercare inafricacancerkillsmorepeopleeachyearindevel wefocusondevelopingpartnershipswithgovern opingcountriesthanaidsmalariaandtuberculo mentsandngosinthesecountriesouraimisto siscombinedyetthereisverylittleoncologyinv establishprogrammesthatraiseawarenesstrain menttheprogrammeisestablishinganonline healthcareprovidersandimproveinfrastructurethis universityofferingcomprehensivetraininginseveral approachincreasesthecapabilitiesofhealthcare areasofcancermanagementandanetworkfor systemssotheycanstarttosustainablymeetpatient doctorstoshareknowledgeandexperiencewiththeir needsthisincreasesaccesstohealthcareand peersrocheisprovidingfinancialsupportcon rochearengcorporate responsibility partindd corporate responsibility roche business report treatment course antiinfluenza medicine tamiflu donate country need sublicense agreement reach tamiflu reserve programme established develop country month employee secondment contribute skill expertise help difference health service ldc country roche file enforce patent hivinfecte patient medicine eligible noprofit reducedprice roche medicine pilot country select online university course oncology educare initiative ssa partnership iaea aid technology agreement reach company ldc ssa onsite technical help people reach year manufacture generic version rural south africa roche hiv medicine saquinavir phelophepa healthcare train employee participate annual children child support ssa monitoring orphan child give primary healthcare walk support care centre provide educational diabetes partnership plus service assistance opportunity aid orphan malawi novo nordisk change diabete act support unicef ecpp local community activity child programme aid orphan programme sultationandexpertiseinweidentifiedsuitable patientsandtheirfamiliesinwetookpartin sitesforpilotprogrammesinghanazambiatan workshopsforhealthcareworkersincameroon zaniaandugandawherewewillbegintrainingpro andugandaandparticipatedinthediabetesleader grammesin shipforumafricamorethanparticipant fromsubsaharanafricancountriesattendedthis wealsohaveanumberofprogrammesforincrease eventtodiscusstheappropriateresponsetothe accesstodiagnostictestsweareapartnerinnovo increasingburdenofdiabetesandothernoncommu nordiskschangingdiabetesinchildrenprogramme nicablediseasesinafrica alongwiththeworlddiabetesfoundationandsev eralafricangovernmentsmorethanchildrenin anumberofourpartnershipsimproveresearchinto africawereenrolledintheprogrammebytheend neglecteddiseasesofthedevelopingworldfor oftheyreceivededucationindiabetescareand exampleinwelaunchedaresearchfellowship accesstoinsulinanddiabetessuppliesprovide togetherwiththewhosprogrammeforresearch byrochewealsohelptotrainhealthcareworker andtrainingintotropicaldiseasestdrthegate rochearengcorporate responsibility partindd roche business report corporate responsibility foundationandtheinternationalfederationofphar maceuticalmanufacturersandassociationsifpma boost cancer care morocco thisfellowshipgivesresearchersfromdeveloping countriesfirsthandexperienceofstateoftheart morocco partnership lalla salma processesandtechniquestohelpimprovetheir association cancer alsc help researchandclinicaldevelopmentexpertise increase cancer awareness access treat ment lead launch national rocherankedsixthintheaccesstomedicine cancer plan indexanindependentrankingofresearch plan include construction new cancer focusedpharmaceuticalcompaniesbasedon centre expand screening programme indicatorswearepleasedwiththisscorepartic education awareness initiative ularlyastheindexfocusedondiseasesoutsideour partner alsc provide access areasofspecialtyandsodidnottakeintoaccount cancer treatment million moroccan oureducarecancerinitiativeordiagnosticsaccess live poverty line fall programme outside healthcare system alsc buy drug reduce price roche donate access emerge market improvinghealth money receive help strengthen healthcare carestandardsinmiddleincomecountriespresent infrastructure country cancer asubstantialmarketopportunityforrochethe patient receive free treatment result marketresearchagencyimsestimatesthatby partnership effort pay dividend thevalueofemergingmarketswillequalroughly market cancer treatment ofusmarketvalueandexceedthatofwestern quadruple year europeouremergingmarketsstrategyfocuse special ceremony november roche onspeedingupregulatoryapprovalsandsupporte accept international award princess marketdevelopmentprimarilyinmajoremerging lalla salma effort economiessuchasbrazilchinaindiaandrussia everycountryshealthcaresystemisatadifferent stageofdevelopmentandhasdifferentneedswe workwithgovernmentsineachcountrytohelp suchascancerhepatitiscandrheumatoidarthritis establishappropriatepoliciesprocessesandpro inwenegotiatedcommercialaccesspro grammessuchasdiseaseawarenesslocalclin grammesinmiddleincomecountriesforourhepatitis icaltrialsandtrainingforhealthcareprofessional drugpegasysaswellasforourcancerdrug avastinherceptinmabtheraandtarceva wealsodevelopspecificpricingprogrammesfor individualemergingmarketswheremanypatients forexampleindiahasahighhepatitiscinfection cannotaffordlongtermtreatmentfordisease ratecoupledwithlowlevelsofdiagnosisandlimite impact hiv access programme hivinfecte patient hivinfecte patient live living country eligible country eligible noprofit medicine reducedprice medicine rochearengcorporate responsibility partindd corporate responsibility roche business report accesstotreatmentcounterfeitmedicinespresent trialsincountrieswherewedonotplantomarketthe furtherchallengesourpharmaceuticalsanddiag medicinebeingtestedweincorporatetheinter nosticsdivisionshavesetupscreeningcampsblood nationalconferenceonharmonisationichgood banksanddialysisclinicstohelpovercomethese clinicalpracticegcpguidelinesintoourclinical problemswehavealsoengagedsupplychainsecu trialprogrammesandtrainmonitorandauditall rityexpertskezzlertoprovideencryptionsoftware thoseinvolvedtoensurecomplianceinwe thatenablesconsumerstoverifythattheirmedicine revisedtheinformationweprovidetopatientstake isgenuinewhentheybuyitusingtheirmobilephone partinrochetrialswithhelpfromtheeuropean costassistanceprogrammesareavailableinindia geneticalliancesnetworkegantomakeit basedontherecommendationofthetreatingdoctor clearerandeasiertounderstand asaresultofthesecombinedeffortsthenumber ofpatientsreceivingpegasysandourcancerdrug clinical trial hasdramaticallyincrease access develop world evenincountrie number clinical trial withadvancedhealthcaresystemsmanypeople number healthcare cannotaffordtreatmentortheinsurancetopayfor centre involve itintheunitedstatesgenentechhelpspatient number patient toaccessourmedicinesregardlessoftheirability phase iiv clinical trial topay roche genentech genentechaccesssolutionshelpsinsuredpatient navigatethecomplexitiesofhealthinsurance peoplecansearchforclinicaltrialstotakepartin coveragebyexplainingwhattheirpolicycoversand orlearnfromtheresultsofcompletedtrialsat whattheyneedtopayforandbyhelpingthem wwwrochetrialscomasofdecember findpaymentsupportprogrammeswherepossible thewebsitecontaineddetailsofprotocol inweassistedmorethanpeople andtrialresultsthesestudiescovermorethan conditionsincludingalzheimersdisease thegenentechaccesstocarefoundationgatcf asthmaaroundcancerscardiovasculardisease providesfreemedicinestouninsuredandunderin depressiondiabeteshepatitishivaidsinfluenza suredpatientswhomeetcertainfinancialandmedi andobesitythewebsitehadvisitorsin calcriteriaingatcfprovidedfreemedicines detailsofourclinicaltrialsarealsoavailable tomorethanpatients throughtheinternationalfederationofpharma ceuticalmanufacturersandassociationsifpma safe ethical clinical trial clinicaltrialsportalandtheusnationalinstitute clinicaltrialsareessentialtodemonstratethatnew ofhealthsglobalregistry medicinesaresafeandeffectiveandthatdiagnostic testsprovideusefuldatatheyalsoprovideimpor westorebiologicalmaterialusedinclinicaltrial tantinformationaboutthecosteffectivenessof suchastissueorgansbloodandotherbodilyfluid atreatmentandhowthisimprovesqualityoflifein inhumanspecimenrepositoriesorbiobank additiontrialsprovideparticipatinghospitalswith thismaterialisinvaluableforlearningmoreabout educationalfinancialandmedicalsupportandgive diseasesandexploringpossibletreatment patientsaccesstothelatesttherapiespatient theyalsocontainsensitiveinformationaboutthe receivefreetreatmentduringthetrialanduntilthe personprovidingthesamplewearededicate drugisavailablethroughthehealthcaresystemif toprotectingdonorsprivacyandensuringtheyare noapprovedalternativeexist fullyinformedabouthowtheirsampleanddata willbeusedbeforetheyagreetotakepartinatrial wehavestrictpoliciesandprocessestoensurethe weapplyequallystrictmeasurestoallpersonaldata safetywellbeingandlegalrightsofpeopletaking aboutcustomerssuppliersandemployeesinline partinclinicaltrialsinadditionwedonotperform withourdirectiveontheprotectionofpersonaldata rochearengcorporate responsibility partindd handle disease area oncology indication firstline metastatic colorectal cancer trial avex avastin elderly xeloda patient fully recruit study site country daisy michaels hospital oncology clinical research group toronto rochearengcorporate responsibility partindd jane senior international clinical trial manager roche basel rochearengcorporate responsibility partindd phase clinical trial avastin advance colorectal cancer create value patient mean postapproval trial effective medicine benefit wide population increase number patient benefit avastin tml cairo aio duration treatment nordicact dream tribe new chemotherapy combination avastin avex olivia special population result number expect patient trial nearly million patient treat avastin launch breakthrough cancer medicine develop extensive clinical trial programme cancer treatment constantly evolve oncologist try new drug combination phase clinical trial conduct medicine enter market generate valuable new insight drug thoroughly study avastin phase trial provide important additional information safety efficacy reallife set routine oncology practice use avastin special population elderly phase trial evalu ate avastin patient metastatic colorectal cancer design determine optimal duration treatment investigate new combination avastin medicine rochearengcorporate responsibility partindd corporate responsibility roche business report organ transplantation inanngoraise weinvestigateallreportedsideeffectstofindout concernsthatorgansusedintworocheclinicaltrial whetherourproductcausedthemifthereisalink inchinamayhavebeenharvestedwithoutconsent wereevaluatewhetherthebenefitsofthemedicine andpossiblyfromexecutedprisonersthetrialsinto orteststilloutweightheriskswealsohaveproce theuseoftheimmunosuppressantcellceptin duresinplacetopromptlyinformpatientsphysician organtransplantsinvolvepatientsataccre healthcareprovidersandregulatorsofanynewprod itedtransplantcentresandarebeingcarriedout uctsafetyinformationweupdateproductlabelle toestablishwhetherthestandardcellceptdosewill andinformationwithnewsafetyinformationas safelyandeffectivelypreventorganrejectionin requiredandwhennecessarywritetohealthcare peopleofchineseorigin providerswithupdatedadviceontheuseofour product forclinicaltrialsinchinawefollowthesamescien tificmedicalandethicalstandardsasinallother wehaveastrictproductrecallprocesstoensurewe countrieswesupportaworldwidebanonanyuseof canwithdrawproductsrapidlyontherareoccasion organsfromexecutedprisonersaswellasonthe thatqualityproblemsdoariseintherewereno deathpenaltyhoweverasinmanycountrieschi recallsinvolvingthepublic neselegislationpreventspharmaceuticalcompanie fromdeterminingtheoriginoftransplantorgans patient advocacy transparencyisessentialwhenpharmaceuticalcom wewillcompletethetwotrialsbuthavenoplansto paniespartnerwithpatientadvocateswedeclare carryoutfurthertransplantationtrialsinchinaat ourpatientgrouppartnershipsonourwebsitealong thisstageanyfuturetrialswillcontinuetoadhereto withashortdescriptionofthepartnershipsactivi thedeclarationofistanbulonorgantraffickingand tieswealsodeclaresignificantormeaningfulnon transplanttourismandthewhoguidingprinciple financialsupportasguidedbytheeuropeanfe onhumancelltissueandorgantransplantation erationofpharmaceuticalindustriesandassociation efpiaourpositionstatementandguidelinesfor wecontributedtochangesinchineselegislationin workingwithpatientgroupsdescribeourapproach asaresultofthesechangesthenumberof andareavailableonourwebsite transplantsfromlivingdonorshasincreasedefforts tointroduceasystemforpeopleinchinatosign theirconsenttodonateanorganarealsohavinga patient group important positiveeffectwestronglybelievethatorgando nationbyfreelyconsentingdonorsisthemosteffec partner roche tivewaytocontributetoanethicalandsustainable solutioninthisareaofmedicalpracticewewelcome insight challenge face allsupportinthisareatoimprovethesituationfor patientsinneedoforgan patient family patient safety share interest help anymedicinemaycausesideeffectsinsome patientsourpriorityistomakesurethebenefit patient understand outweightheriskswehaverobustprocessesin allcountriestomonitorhowpatientsreacttoour manage condition medicinesweregularlyanalysemedicinesagainst variousreferencedatabasestohelpusspotpoten tialsafetyrisksallproductsinclinicaldevelopment haveasafetymanagementplanandallmarkete examplesofourpatientadvocacyininclude medicineshaveariskmanagementplanreviewe runningworkshopsinfrankfurtgermanyandbrus andapprovedbymajorhealthauthoritie selsbelgiumtohelppatientgroupsimprovethe supporttheyprovidepeoplelivingwithdiseasein rochearengcorporate responsibility partindd roche business report corporate responsibility francetherochefoundationorganisedachronic chugaialsosupportseffortstoraisediseaseaware diseasemeetinginmaythiseventwhichwill nessinjunethecompanyheldaneventto nowbeheldannuallybroughttogetheralmost promotetheimportanceofearlydetectionandtreat patientspatientrepresentativesandhealthcare mentofrheumatoidarthritiswhichaffectsaround professionalstodiscusswaystoimprovequalityof peopleinjapanawarenessdaysineight lifeforpatientswithchronicdiseasethefoundation japanesecitiesbroughtattentiontotheimpor alsolaunchedanewpatienttestimonywebsite tanceofdetectingcoloncancerearlyforthesecond wwwlavoixdespatientsfrwhichpublishespatient yearrunningthecampaignusedagiantinflatable experiencesandsharesthemthroughlinksto colonwithinformationpostedonthewallsforvisitor socialnetworkssuchasfacebookandtwitter towalkthroughandlearnhowtohelpprevent coloncancerduringdailylifeindecemberchugai patient education awareness sponsoredaneventrunbythecancercharity ourresponsibilitiesdonotstoponcewehavesup medicineandhumourwhichhelpspatientsand pliedaproductwealsohelphealthcareprofessional theirfamiliestomanagethedisease andpatientstofullyunderstandtheirdiseaseand treatmentoptionshowtouseourproductscorrectly web andanyotherservicesavailableforimprovingout personalise healthcare wwwrochecomphcinrd come roche position statement phc access medicine diagnostic pricing neglect disease work patient group examplesincludetheaccuchekconnectwebsite wwwrochecompoliciesguidelinesandposition andcoachingprogrammeswhichhelpdiabetic access medicine report wwwrochecom patientstolinktheirbehaviourtotheirconditionwe accesstohealthcare programme ldc wwwrochecom alsoprovidesupportservicesforourcancermedi programmesinleastdevelopedanddevelopedcountrie cinesincludingcallsfromtrainedoncologynursesto programme develop country helppatientsmanagetheirtherapytreatmentdiarie wwwgenentechaccesssolutionscom roche trials patient safety wwwrochetrialscom torecordandlearnfromtheirexperiencespatient wwwrochecomclinicaltrial treatmentcalendarsandappointmentreminder wwwrochecommanagingmedicationsafety list patient group support ourbagofhopeprogrammepartnerswiththe wwwrochecompatientgroups accuchek connect wwwaccuchekconnectcom juvenilediabetesresearchfoundationjdrfto international federation pharmaceutical manufacturers distributebagscontaininginformationanddia association ifpma clinical trial portal betessuppliestonewlydiagnosedtypediabetic wwwifpmaorgclinicaltrial todatethisprojecthashelpednearly national institutes healths global registry wwwclinicaltrialsgov patientstoadjusttolifewiththeirconditionin rochereceivedjdrfschancellorsawardfor thiswork inadditionwehelphealthcareprofessionalsand patientgroupstoproducenewslettersandmagazine informationpacksguidesforfriendsfamilyand caregiverswealsosupplyneedleboxescounselle hotlinesandeducationprogrammesforexample wehavepartneredwiththeeuropeangeneticsalli ancesnetworktoproduceaseriesofsimpleleaflet inseverallanguageswhichanswerpatientsque tionsontopicssuchasclinicaltrialsandbiobank theseareavailableatwwwbiomedinvoallcom inweaddedleafletsonpersonalisedhealth careandthesocialandpsychologicalaspect ofdiagnosticteste rochearengcorporate responsibility partindd corporate responsibility roche business report people ourpursuitofexcellenceinscienceprovidesdirec aschangingdemographicsandtalentshortagescon tionandpurposeduringchallengingeconomictime tinuetoimpactthelabourmarketcompetitionfor morethaneverwerelyonourpeopletodevelop highlyskilledandexperiencedemployeesremainsan anddeliverinnovativeproductstopatientsandthere ongoingchallengeweareconstantlysteppingup bycontributetothefutureofhealthcare ourpracticestosourceandattractthebesttalentin thehealthcareindustry itisthecommitmentofouremployeesand theirdemonstrationofourvaluesofintegritycourage personalandprofessionaldevelopmentisveryimpor andpassionthatmakearealdifferenceinthelive tanttoouremployeesandapriorityinaninnovation ofpatient drivencompanylikeoursthisremainsthecasedur ingthesignificantorganisationalchangescurrently asacompanydedicatedtoinnovationandscience underwaywestriveforourpeopletoreachtheirfull ahighlyskilledpassionateandmotivatedworkforce potentialandsupportthemateverystage isatthecoreofwhoweareandwhatwedowe wanttobeatrulygreatplacetoworkfortodaysmost webelieveinrewardingachievementandcommit talentedpeoplebygivingthemthechancetomake mentwithfairandattractivecompensationthis theirmarkprovidinganenvironmentwheretheycan approachcontributessignificantlytoattractingreward growandrecognisingthemfortheirachievement ingrecognisingandretainingtherightpeople select external award recognition ranking rank award roche site science magazine employer survey genentech universum swiss professional survey roche basel healthmedicine sector crf institute roche germany employer engineer crf institute roche switzerland employer switzerland san francisco business times genentech good place work bay area fast company magazine genentech world innovative company san diegos good place work genentech great place work denmark roche denmark good pharma companyb multinational company good medical company science magazine employer survey roche basel fortune good company work genentech large company great place work austria roche vienna good employer employee great place work spain roche madrid well workplace jra well workplace new zealand roche auckland small medium sized business category great place work urugay roche urugay place pharmaceutical company rochearengcorporate responsibility partindd roche business report corporate responsibility peoplefromdiversebackgroundsbringarange hasbeennamedbestemployerinthehealthcare ofperspectivestotheirworkhelpingtodriveinno industrybysciencemagazineforeightofthelastnine vationthisiswhywevaluetheexperienceofall yearsandinrocherosefromthtothplace employeesandfosteraninclusiveworkingenviron inthesamesurveysurveyparticipantsgaveboth mentinwhicheveryonefeelsrespectedregardless companieshighratingsforbeinginnovativeleader ofagebackgroundorgenderwheretheycan inthehealthcareindustryandfordoingimportant developtheircareersandseethepositiveimpact highqualityresearchactivitiesinthefieldofsocial oftheirwork responsibilitywerealsoratedhighlyandcontrib utedtothepositiveresultsrochewasalsorecog thewayweimplementtheorganisationalchange nisedinrankingsbyuniversumtopemployerand takingplaceaspartofourrecentlyannounce thegreatplacetoworkinstitute operationalexcellenceprogrammewilltestourcom mitmenttoremainingagreatplacetowork championing diversity inrochesexecutivecommitteecommittedto great place work increasingthepercentageoffemaleleadersinkey rochewasrecognisedasanattractiveemployerby positionsbybykeypositionsaredefined anumberofawardsinforexamplegenentech asthoserolesthatarecriticaltobusinessdelivery drivesignificantvalueandhavethegreatestbreadth anddepthofresponsibilitykeypositionsareclosely programme ensure diversity workforce linkedtoorganisationalstructurewewilltherefore reviseourcurrentlistofaroundpositionsto reflecttherecentchangesthathavetakenplace global local leadership programme todevelopinclusive giventhecommitmenttoincreasefemaleleader leadershipbehavioursandfostera cultureofdiversity inkeypositionswehavereplacedourpreviously reportedwomeninseniorleadershipmetricbase onapproximatelypositionswiththeper sponsor employee affinity centageofwomeninkeypositionsthebaselinefor group association net thisnewmetricwaswomeninkeyposition work toprovidesupportexchange ofideasandsharelearnings indecemberwearealreadyseeingapositive impactfromthevariousactionstakentosupport womeninleadershipwithanincreaseofwomenin programme improve keypositionstoindecember standing oftheneedsofemployee withdisabilitiesandtoincrease numberofhire gender diversity mobility programme topromote woman total internationaltransferofemployee acrosstheglobe workforce woman management woman executive attraction source pro cesse standard toensure woman diversityofcandidatepool key position genderisonlyoneelementofourcommitmentto diversityandwedonottoleratediscriminationofany programme focus old employee whichvaluetheir formasstatedinourglobalemploymentpolicy expierienceandretainknowledge ourapproachistoembeddiversityinallourmain processesandobjectivesourhumanresource rochearengcorporate responsibility partindd corporate responsibility roche business report functionhasmeasuresandgoalsinallkeyprocesse applicationsforspecificjobsandregistere relatingtorecruitingdevelopingpromotingand newcandidatestotherochegrouptalent recognisingemployeestosupportadiversework pooladatabaseofjobseekersinterestedin forceandinclusiveenvironmentinthecontextof becomingrocheemployee ourdiversitygoalwehaveextendedourrangeof programmesandinitiativestoencourageandsafe advertisingrolesinternallyalsooffersgreaterop guardemployeediversityandsupportanumberof portunitiesforrocheemployeesasbyjoiningthe employeeassociationsandnetworkstheseinclude rochetalentpooltheyarenotifiedbyemaila rochebaselsfamilyandcareersandwomenin soonaswepostapositionmatchingtheirprefer leadershipgroupsgenentechwomenprofession encesandskills alsgwpandgenentechoutequalgoe strengtheningtiesacrossgenerationssenior weregularlyconductaglobalsurveytogaugethe stagesandafricanamericansinbiotechnology effectivenessofourrecruitmentservicesandtrain aaib ourrecruitersworldwideonthelatestmethodsand strategiesthroughouttheyearasmallgroupof foster innovation ourrecruitmentspecialistsattendedbusinesscon innovationisthecoreofourbusinessandisdriven ferencesandeventsattopinternationalbusiness bydiverseapproachesideasandexperiencesour schoolstogiveprospectiveemployeesthechanceto talentmanagementprocessesarealldesignedto learnmoreaboutourcompanyandforustoadd recogniseanddriveinnovationinadditionwecon targetedtalenttoourpipelineforthefuturethese ductabroadarrayofspecificandlocalisedactivi andmanyotherinitiativescombinedwiththework tiesourpharmaresearchandearlydevelopment ofourprofessionalrecruitmentteamsaroundthe researchorganisationintroducedascientificcareer globeensureourpoolofdiverseandtalentedcandi ladderinandsponsoredamajorrecognition datescontinuestogrow programmetheleosternbachawardsforinnovation inchemistrythisyeartheawardrecognise inrochescoredamongstthetopcompanie bradgravesandhisteamfornewclassesofcom ontalentattractionandretentioninthedowjones poundsintheareaofcancertreatmentresearch sustainabilityindexe organisationsatbothrocheandgenentechpartici pateininternalandexternalscienceconference thetalentselectionsurveyshowsapointin andwritepublicationsinprestigejournalsin creaseinthepercentageofrocherecruitment rochepublishedmorethansientificarticle managerswhobelievetheirnewhireperformswell ofwhichnearlywereinhighimpactjournalssuch comparedwiththeirpeersthisplacesusabove asnaturecellscienceandthenew england jour thebenchmarkinthisexternalsurveyofovermul nal medicineourpostdocfellowshipprogramme tinationalcorporationsandsuggeststhatweare awardsgrantstoourbestscientistsenablingthem successfullyattractingtoptalent toconductexploratoryresearchandstrengthening ourrdtalentpipelineseveralgenentechscien develop employee inweenhancedour tistsreceivedprestigiousexternalscienceawardsin supportforemployeestodevelopfunctionalprofe amongthemdrrichardschellerwhoreceive sionalandleadershipskillsthisyearofour thekavliprizeinneuroscienceanddrnapoleone employeestookpartincareerdevelopmentplanne ferrarawhowonthelaskerdebakeyclinicalmedi discussionsinadditionweworkwithemployee calresearchaward individuallytoguidetheirdevelopmentaccordingto theirneedsinterestsandspecialitiesconsistent attract employee toattracttalentwe globaltrainingmaterialsnowreflectourdevelopment continuetoleverageourstronganddifferentiating philosophywhichisbasedonemployeeengage employerbrandthroughcareerswebsitesin mentindividualgrowthandorganisationalsuccess countriesthesesiteshadapproximatelymillion visitorsininadditionthegenentechcareer websitehadmillionvisitswereceive exclude genentech ventana chugai rochearengcorporate responsibility partindd roche business report corporate responsibility ourleadershipdevelopmentprogrammesinstilwhat leadership pipeline itmeanstobealeaderatrocheandequipmanager toliveuptotheseexpectationstoincreasethecon sistencyoftheseprogrammesworldwideinwe number highpotential leader createdaglobalframeworkforleadershipdevelop percentage woman menttobeimplementedinphasesbythiseffort highpotential leader willbesupportedbythecontinuingrolloutofaglob percentage woman allearningmanagementsystemandwillprovide leadership programme easieraccesstolearninganddevelopmentsupport internal staffing rate key position ourbusinessisbecomingincreasinglyglobaland thisyearweintroducedapartnershipwithglobal wecompletedoursuiteofgloballeadershippro englishaservicethatprovidesonlinebusinesseng grammeswiththeintroductionofamoduleforglobal lishtrainingtheondemandservicegivesemployee employeeswithhighpotentialinthelongerterm accesstofastcosteffectiveandintensivelanguage globalprogrammesarenowavailableforhighpoten coursestodateoveremployeesfromcoun tialleadersatallcareerstageswehavealso trieshaveusedtheservice enhancedoursuiteofprogrammesbyupdatingcon tenttofocusoninclusivebehaviourandcultural ourdiagnosticsandeuropeanpharmaceuticalsaffili awarenessaswellastobuildgreatercollaboration atesofferednearlycoursesinthrough andunderstandingacrossdivisionsregionsand ourcommontrainingmodelwhetheronlineorclass functionsfinallywehaveimprovedthewaywe roombasedtrainingsessionswithalmost selectparticipantssetlearninggoalsandmeasure employeestakingpart theeffectivenessoftheprogramme learn development ourleadershipdevelopmentprogrammeprovedsuc cessfulwhenseveraloutstandinginternalleaders steppedintocriticalrolesduringtheorganisational total training changesthattookplacethisyeartheinternalfill investment rateforallpositionsisandforthetop million chf executiveposition training spend employee chf inthedowjonessustainabilityindexesrate total number rocheasthebestcompanyinthehealthcaresector training hour million forhumancapitaldevelopmentcontributingtoour average training hour positionashealthcaresupersectorleader employee number postdoc international mobility weconsiderinternational student intern experiencetobeanimportantaspectinthepro fessionaldevelopmentoffutureleadersinwe exclude chugai sawamarkedincreaseinthenumberofnewinter nationalassignmentsfromintoin develop tomorrow leader inwecon thiswaspartlyduetothegenentechintegra tinuedourprogressinidentifyinganddevelope tionandresultingexchangeoftalentedemployee highpotentialleaderscapableoftakingoncritical betweencaliforniaandotherpartsoftheworldour seniorrolesintheshortmediumandlongterm expatriatesandcrossboundaryemployeesrep resentdifferentnationalitiesandarewomen movingabroadcanbestressfulsowetrytomake theexperienceassmoothaspossibleinapril welaunchedrevisedinternationalassignment rochearengcorporate responsibility partindd corporate responsibility roche business report policiesofferingadditionalflexibilitytoassignee duringandourgoalistorolloutourglob wenowalsoofferachildcareallowanceandin allyalignedcompensationstrategysupportedby creasedspousalsupportinadditionweintroduce thenewglobalperformancemanagementprinciple astandardhealthcareprogrammeforglobalassign thenewcommonapproachwillensureourcompany eeswhichhascomeintoeffectonjanuary remainscompetitiveandsustainableandcontinue thisprogrammeofferscompetitivehealthinsurance tocreatevalueforallstakeholdersbymaintaininga toassigneesandtheirfamiliesthroughaleading stronglinkbetweenperformanceandcompensation specialistprovider wewillpreserveemployeesopportunitytosharein oursuccess rewarding recognise employee performance management inofour benefit benefitsareanimportantpartofthe employeestookpartinperformancemanagement totalrewardpackageweofferouremployeesmost discussionswiththeirmanagerstoreachashare programmesaretailoredtolocalmarketsandregu understandingoftheirperformanceobjectivesand lationsbuttypicalexamplesincludefinancialsupport achievementsthroughtheyearanddeterminecom foremployeesandtheirdependentsuponretirement pensation andincaseofillnessdisabilityordeaththesebene fitsusuallysupplementlocalstatesystemswealso asthemobilityofouremployeesincreasesandmany offerwellnessprogrammesthatencourageahealthy leadersmanageorganisationsacrosscountrybor lifestyleandbenefitsthatsupportemployeeswork dersweareworkingtoalignourperformanceman lifebalanceoverofaffiliatesofferextensiveben agementprinciplesgloballyinandthe efitsplansmostgobeyondstateschemesand newcommonapproachwillputgreateremphasison includefreeaccesstoawiderangeofmedicals anongoingdialoguebetweenemployeesandman vice agerswebelievethiscontinuoustwowayfeedback processwillcontributetotimelyinputaboutideas inweworkedtomakeaffiliatesbenefitpro forimprovementbetteremployeedevelopmentand grammesconsistentwithincountriesthiswillensure ultimatelymaximisescientificinnovationandbusi employeesaretreatedequallyandimproveefficien nessresult cybyconsolidatingvendorsintheunitedstate ourcombinedworkforceofemployeeswillall compensation ourtotalremunerationinvestment enjoythesameattractiveandcompetitivebenefit inamountedtoapproximatelybillionswiss programmesfromjanuaryintheunitedking franc domwehaveextendedourflexiblebenefitspro grammetocoverallpharmaceuticalsanddiagnostics ourbasepaypackagesrewardperformanceand employeesfromapril commitmentwhileourbonusschemesincentivise employeesforinnovationandoutstandingresult inadditionwehaveintroducedaglobalassistance thatsupportourstrategicobjectivesbonusesreflect programmetosupportemployeesandtheirfamilie bothindividualandteamachievementsaswella whiletravellingabroadthiswillprovideaccess overallbusinessperformance tomedicalandsecurityinformationandemergency assistancefromjanuary wewantemployeestoshareinoursuccessthrough rocheconnectemployeesinmostcountriescan duringwecontinuedtocloselymonitorthe purchasenonvotingequitysecuritiesatadiscount statusofourmajorpensionfundsalongsidesome ofuptoinemployeesincoun cashinjectionsweinitiatedchangesinseveral triestookpartinthisprogrammethisrepresent localpensionplanssomeofourmajorpensionfund approximatelyofeligibleemployeesandsecuri removedearlyretirementincentivesandhaveintro tiesworthmillionswissfrancswerepurchased ducedmoreflexibleretirementmodelsinanticipation inadditionallymanagersandemployee ofanageingworkforce receivednonvotingequitysecuritiesthroughthe rochelongtermplan rochearengcorporate responsibility partindd roche business report corporate responsibility align human resource process web overthecourseofgenentechandournorth employee wwwrochecomemployee americanpharmaceuticaloperationswillbeincorpo group policy position guideline wwwrochecompoliciesguidelinesandposition ratedintoourcommonhrinformationsolution global career portal httpcareersrochecom chrischrisenablesgloballyalignedprocesse employment policy wwwrochecomemploymentpolicypdf thathavebeenadjustedtoreflectthebestprac core standard wwwrochecomcommitment ticesofbothgenentechandtherestoftheroche groupcurrentlychriscoversaffiliatesand representativeofficesandofrocheemployees human right labour relation therocheemploymentpolicygovernshumanright andlabourrelationsthechiefcomplianceofficer monitorsimplementationandcompliancewiththis policyandservesasacontactforallemployee werespecttherightofemployeestofreedomofas sociationandcollectivebargainingmorethan ofouremployeesaretradeunionmembersand overaremembersoforganisationsthatfreely representthemincountrieswherethisislegal therocheeuropeforumrepresentstheinterestsof almostemployeesincountrie ourdirectiveontheprotectionofpersonaldata ensuresthatwesafeguardemployeeinformationand complywithrelevantlocallegislation adedicatedemployeerelationsofficermonitorsthe levelofemployeeengagementandensuresthat appropriateprogrammesandpoliciesareinplaceto ensurefairtransparentandrespectfultreatment ofemployeesincludingduringtheimplementation ofouroperationalexcellenceprogrammewe willmanagethisprogrammecarefullykeepingem ployeeswellinformedthroughoutsupporte themthroughthechangesandensuringthoseleav ingthecompanyaretreatedwithfairnessdignity andinasociallyresponsiblewayourlocallydefine severancepackagestypicallyincludearangeof measurestoreflectthedifferentneedsofthoseaf fectedmeasuresincludeseverancepaywith optionstoconverttotimeoutplacementservice counsellingcareersfairsandcentresretraine andredeploymentoptionsaswellasanincrease focusoninternalrecruitmentandopportunitie rochearengcorporate responsibility partindd corporate responsibility roche business report key figure employee fte function employee rocheemployspeopleincountrie service clusteredinfivemainregionsourworkforce manufacturing representsmorethannationalitieswith logistic ofemployeesworkinginrd market distribution research roche employee worldwide development fulltime equivalentsfte general administration total europe north america asia staffing rate latin america australia africa new hire total internal staffing rate external staffing rate employee fte operating division retain employee instaffturnoverincreasedfromto pharma driveroftheincreaseisthefirstwaveofemployer chugai relatedterminationsaspartofoperationalexcel diagnostic lenceinaustralialatinamericaandnorthamerica total turnover include genentech restate reflect consolidation finance total employee contract type europe north america asia regular fte latin america fix term fte australia time headcount africa time headcount regular temporary employee roche contract reason leave employeeinitiate employerinitiated neutral rochearengcorporate responsibility partindd roche business report corporate responsibility society ourresponsibilityextendsbeyondthehealthcare breakdown give area productsweprovidetopatientsandthewellbeingof ouremployeeswearealsocommittedtosupporting thewelfareofcommunitiesinwhichweoperate humanitarian social project ourdonationprogrammesseektogivebacktocom science munitiesinfourstrategicareashumanitarianand education socialprojectsscienceandeducationartsandcul arts culture tureandcommunityandenvironmentineach community areawesupportprogrammesthatmeetthecriteria environment definedbyourpolicyonphilanthropicdonation andnoncommercialsponsorshipaswellaspro grammesthatwebelievewillmakealaste launchingaprogrammeorcontributingtoacauseis tangibledifference onlythefirststepinrochessocialengagementwe carefullyconsiderwhatwewantourphilanthropyto rigorous approach achieveandcontinuallymonitorprogresstoward tocreaterealchangewehavedevelope thedesiredimpactthereforewetracktheoutcome atargetedstrategywhichhingesonfourcriteria ofourprojectsnotjusttheinitialinvestment innovativeappliescreativeandeffective solutionstosocietyschallenge sample philanthropic impact sustainabledeliversenduringeffectsin patient orphan child give adynamicresourceconstrainedworld community health primary healthcare malawi collaborativedrawsonthestrengthsand outreach course community capacitiesofrespectivepartner health worker hold south outcomedrivenprovidestangiblelongterm african village benefitstothepeopleinvolve community rebuild bore hole rehabilitate strengthen uganda wemakemostofourcontributionslocallysothat primary school classroom eachbusinessunitcanbestaddresstheneedsofit build furnish malawi owncommunityourbusinessesconceiveand education student receive implementtheircommunityactivitiestoprovidethe enhancement secondary scholarship greatestpossibleimpactgiventhespecificchal opportunity receive postsecondary lengeandavailablecapabilitie assistance malawi student enrol week someissuescallforglobalinterventioninsuch international research casesweworkwithourinternationalnetwork exchange germany ofpartnerstosupportprojectsthatwillmeetsocie united states tysmostcriticalneedstheseprojectsdonotoften makeheadlinesbutneverthelesshelptoresolve humanitarian social project fundamentalobstaclestogoodhealthsuchasalack improvingwellbeingisatthecoreofrochesphilo ofbasicmedicalsuppliesortrainedhealthcare ophyhumanitarianandsocialprojectsaccountfor professionalsbymobilisingourresourcesandexpe thelargestportionofourgivingandfocusonsup rienceacrossourfourstrategicareasweaimto portingthemostvulnerablemembersofsociety makeanotabledifference oftenchildren managing impact employeeparticipationinourprogrammesamplifie developingandmanagingourphilanthropicactivitie theirimpactforexampleemployeesfrom requirescarefulcoordinationprinciplesandpriori morethanaffiliatesparticipatedinthe tiesaresetatthegrouplevelandimplementedlo annualchildrenswalktheygeneratedovermil callybybusinessunitsandpartner lionswissfrancsincludingmatchingfundsfrom rochearengcorporate responsibility partindd corporate responsibility roche business report thecompanythisyearofthismoneywillgoto rilythroughtheteachersrochehelpedtrain supportdaycarecentresinmalawithatprovide thisyearwealsoexpandedourroche genetic foodsheltereducationandskillstrainingtoaid educationprogrammeprovidingteachingmaterial orphanstheremainingwillsupportlocal forsecondaryteachersinthebaselregionwith charitiesthatsupportvulnerablechildrenselecte fourlaboratoryworkshopsandtwotalkingscience byaffiliate workshopstheschoolbasedtrainingmodelraise understandingandinterestingenetic itisimportantthatemployeesseetheimpactoftheir effortseachyearnineofthemostsuccessfullocal art culture childrenswalkfundraisersvisittheprogrammeswe innovationcomesinmanyformsweseeastrong supporttoreaffirmourcommitmentandwitness creativeconnectionbetweenscienceandtheartsin thedifferencewemakeinmalawitheythenreturn partnershipwiththelucernefestivalthecleveland homeandactasambassadorsforthewalkandit orchestraandcarnegiehallweregularlycommission objective newworksfromcontemporarycomposersthis augustwewelcomedtheworldpremiereoftoshio accesstohealthcareshouldbeuniversalbutinmany hosokawasorchestralpiecewovendreamsand countriesthisisnotthecasewehaveanumber announcedoursixthcommissiontocomposersofia ofprogrammesthathelptobuildinfrastructurepro gubaidulinaweprovidefurthersupportforcrea videbasichealthcareortransferknowledgeand tivityandexpressionthroughmonthlyrochenjazz expertise eventswherewebringtogetherthelocalcommuni tywithworldclassmusicianstoexploremodern forexampletherochesponsoredphelophepa inventivemusicnowinitsfifthyearrochenjazz healthtraindelivershealthsuppliesandservicesto hasentertainedmorethanpeoplewithper poorandremotesouthafricancommunitiesin formancesbyensemble thetrainsthyearrocherefurbishedthe primaryhealthcoachimprovingventilationprivacy community environment anddisabledaccess webelievethatindividualwellbeingiscloselytie tohealthycommunitiesforexampleinkualalumpur science education rochehasestablishedacommunitybasedreha excellenceinscienceiscriticalforrocheweaimto bilitationprojectwithmalaysiasdepartmentofsocial inspirefuturegenerationsofscientistswhowill welfaretheprojectprovidesoccupationaltherapy drivethediscoveryofnewtreatmentsanddiagnostics forchildrenwithmentalphysicaldevelopmentalor fortodaysunmetmedicalneed emotionalconditionsinruralcommunitiesthis helpsthechildrenimprovebasicmotorfunctionsand weprovideyoungscientistswithopportunitiesto reasoningabilitiesandthereforetoleadindepen expandtheirexperienceinthefieldthroughour dentandproductivelive internationalrochepostdocfellowshipprogramin webuiltuptheprogrammetoposition web withtwoyeargrantsexpandableuptofouryear roche social programme wwwrochecomsociety basedonscientificmerittheseareforjointrd roche jazz wwwrochenjazznet roche act wwwreactrochecom projectswithpartneruniversitiesincludingthefirst postdocsapprovedinchinaandjapanin additionalprogrammesareplanne scienceandhealthmattersofteninvolveethicalcon siderationsrochenutleysupportsthenewchoice newresponsibilitiesprogrammewhichintroduce middleandhighschoolstudentstobioethicsthe curriculumsupplementhasreachedapproximately studentssinceitsintroductioninprima rochearengcorporate responsibility partindd roche business report corporate responsibility responsible practice ourreputationisoneofourmostvaluableasset rocheweaskedlocalmanagerstoimplementa itisvitalthatallemployeescomplywithlawsregula comprehensiveanticorruptioncompliancepro tionsandinternalstandardstofulfilourcommit grammeandlaunchedaglobalrochemarkete menttoactwithintegritythisistheminimumour andsalescompliancequestionnairetofurther stakeholdersexpectforthesereasonswejudge promotetheimportanceofgoodbusinessconduct ourselvesnotonlyonourresultsbutalsoonhow wewillcontinuethesemeetingsthroughout weachievethem risk crisis management integrity compliance ourriskmanagementcharterdefinesourriskman therochegroupcodeofconductsetsclearex agementapproachandresponsibilitiesitisavailable pectationsforourpeopleitguidesemployeeson onourwebsitealongwithalistofriskstoourbusi correctbusinessbehaviourhowtoactwithintegrity nessweusestakeholderfeedbacktohelpidentify andhowtospeakupincaseofcompliancecon andassesssocialenvironmentalandethicalrisk cern andopportunitiesandincludethemostsignificantin thegroupriskmanagementprocesswehavein weencourageemployeestospeaktotheirlineman troducedanewsystemtodetermineexposurefrom agerthelocalcomplianceofficerorthechief salesandmarketingrisksthatarenotyetfullymiti complianceofficertheycanalsoreportcompliance gate concernsanonymouslyusingthespeakuptelephone lineandwebservicelaunchedindecember thegroupandallsubsidiarieshaveestablishedcrisis speakupoperatesinlanguagesandcountrie managementteamstoensureweactquicklyinan makingitavailabletoalmostemployees emergencytheseteamsregularlyrehearsedifferent betweendecemberanddecember crisisscenariosalertsandescalationprocedure reportsweremadeviathesystemroughly weareusingourexperienceofourpandemicpre halfweregeneralcommentsaboutrochesbusiness parednessplaninresponsetothehninfluenza whicharenotclassedasnoncompliancesthe pandemicintostrengthenourbusinessconti otherhalfrelatedtoallegedviolationsofthecodeof nuityproceduresglobally conductanalysisoftheissuesreportedshowsthat employeesareusingthespeakuplineresponsibly sustainable supply chain wespentaroundbillionswissfrancsinwith inmaterialbusinessethicsincidentswere rdpartiesonrawmaterialsactivepharmaceuti reportedintotalincludingsevencasesreporte calingredientsandotherdirectspendplusindirect throughthespeakuplineafterinvestigatingeach spendlikecontractrdlicenceslaboratorysup incidentandtakingcorrectiveactionwherenec pliesequipmentconsultancymarketingservice essaryweterminatedemploymentcontractsa andothersensuringthatthecompaniessupply aresultofunethicalbehaviour ingtheseproductsandservicesactresponsiblyis anessentialpartofsustainableprocurement wecarriedoutvariousactivitiestostrengthen complianceinweupdatedouronlinetraine rocheisamemberofthepharmaceuticalsupply programmesonourcodeofconductandonanti chaininitiativepsciandendorsesthepsciprinci trustissuesbyclearlylistingtheoptionsavailablefor pleswhichsetstandardsforsuppliersintheareas reportingconcernsinwebeganrollingout ofethicslabourhealthandsafetytheenvironment amoreuserfriendlyonlinetrainingprogrammecalle andrelatedmanagementsystemsoursuppliercode rochebehaviourinbusinessrobibandseta ofconductintroducedinincorporatesthese targetforofemployeestocompleteitin principlesaswellasotherimportanttopicssuch asinnovationfinancialsecurityandsupplierdiversity weheldseveralmeetingsforlocalcomplianceoffi attheendofthemajorityofkeysupplier cerstosharebestpracticeinwenowusethe hadprovidedtheirwrittencommitmenttothesupplier genentechstaglinecomplianceisgoodbusiness codewhichisnowincludedinnewsuppliercon tocommunicateaconsistentmessagethroughout tract rochearengcorporate responsibility partindd corporate responsibility roche business report roche supplier assessment prioritisation direct spend indirect spend priority auditing contract manufacturer cro laboratories improvement api manufacturer party waste management hazardouschemical manufacturer animal temp labour logistics service chemicalsbiotech raw material construction marketing service primary packaging fleet service travel facility management informatic general admin service secondary packaging consulting service engineering service equipment inmayweintroducedonlinetrainingtoteach contractresearchcompaniestemporarylabour procurementstaffhowtoencouragesustainability agenciesmarketingagencieslogisticsprovider amongoursuppliersthetrainingisavailableonour andotherserviceprovidersthemajorityofsup intranetinchineseenglishgermanandspanish pliersmetourstandardswhilefindingsrequire morethanemployeeshavetakenthecourseto actionrelatedmainlytolabourconditionshealth datesomeclassroomtrainingsessionswerealso andsafetywewillworkwithsupplierstocorrect heldourpharmaceuticaldivisionintroducedanew problemsfoundandprovidetrainingtoprevent procurementcodeofconducttoguideprocure futureissue mentmanagersinresponsiblesource aspartofourworkwiththepsciwehavebegunto wewillcontinuetoimplementboththesupplierand alignoursuppliersustainabilityauditprotocolwith procurementcodesofconductduringwealso thoseofothermembercompaniesthiswillpromote plantoworkwithselectedhighimpactsuppliersto transparencyandenableustoshareauditfinding measureandreducetheirenvironmentalfootprint reducingbureaucracyandduplicationofeffortwe followingapilotprojectwithalogisticssupplier havesuccessfullypilotedthealignedauditproto colwithtwosupplierssofar wemonitorcompliancewithoursustainabilityre quirementsatcriticalsuppliersusinginternaland responsible research externalauditswetakeariskbasedapproach ourbusinessmodelreliesonscientificexcellenceand toprioritisethecompaniestoauditwhichfactor adetailedunderstandingofthemechanismsof inrisklevelsbyindustryaswellasprevioussus diseasesowecantranslatescientificbreakthroughs tainabilityperformance intoinnovativemedicinesanddiagnosticsthatmake adifferencehoweverethicalquestionsinevitably inweconductedauditsinthedirectspend ariseasweexplorethepotentialofcuttingedgetech areaegapichemicalsandbiologicalssupplier nologieswecarefullyconsiderandmanageany contractmanufacturersforthefirsttimewebegan concernstomakesurewemaintainourintegritywhile auditsofcriticalserviceprovidersweaudite makingsurethatnoopportunitiesarelost ksir roche supplier code conduct demand high ethical standard supplier demand high standard social responsibility safety health environment management system demand cooperation supplier additional important topic innovation economic sustainability supplier diversity rochearengcorporate responsibility partindd roche business report corporate responsibility ethic wehaveclearpoliciesandpro weprovideregularonlineethicstrainingforem ceduresinplacetopreservehighethicalstandard ployeesandinaprillaunchedanewonline inourresearchanddevelopmentr dactivitie modulebasedoncasestudie ourpositiononclinicalresearchdefinesthesestan dardsandclarifiesourviewsonspecificareasof animal welfare wetakepublicconcernaboutani concern malresearchveryseriouslywepromotetheuseof alternativemethodsandworkhardtoidentifyoption employeeswhoencounteranethicaldilemmain otherthantheuseofanimalshoweveranimaltest theirworkandcannotresolvethiswiththeirimmedi ingremainsindispensabletobiomedicalresearchfor atecolleaguescancontactourglobalethicsliai scientificandlegalreasonsregulatoryauthoritie sonofficeinthisofficereceivedandresolve requireallhealthcarecompaniestotestthesafetyand querieswithouttheneedforescalationthe efficacyofnewdrugsinanimalsbeforetheycanbe vastmajorityrelatedtoinformedconsentandtheuse usedinhuman ofsamplesfrombiobankstheglobalethicsliaison officeconsultsexpertswithinandoutsidethecom inweusedanimalsinourresearch panytobrokerasolutionasneede aslightincreaseonforthefirsttimewealso reportthenumberofanimalsusedbycontractor inwemergedourexternalscienceandethic carryingoutresearchonourbehalfaround advisorygroupseagwiththeclinicalresearch ofallanimalsweremiceandrats ethicsadvisorygroupcreagtoformoneindepen dentbodythatadvisesusonethicalissuesinour wefollowandpromotethersapproachtoanimal rdactivitiesthenewseagcomprisesexternal researchthismeanswereplaceanimaltestswhere expertsinethicslawandsocialscienceaswellas possiblereducethenumberofanimalsusedand patientadvocatesitwillcontinuetoprovideadvice refinetestsandanimalwelfarestandardsallem asrequiredandmeetformallyonceayear ployeesandcontractorswhoperformanimalresearch forusarerequiredtomeetorexceedapplicablelaw andindustrystandard key activity access employee diversity philanthropy supplier healthcare engagement increasepercentage systematicallycollect continueimplementation expandsuccessful achievepositiverating ofwomeninkeyposition andreportoutcomesof ofboththeprocurement accessprogrammesin inemployeeengagement increasefrom affiliatephilanthropic andsuppliercodeof developingcountrie surveyspositive activitiesandcorporate conduct toothercountrie ratingsbyend signatureprogramme rochearengcorporate responsibility partindd corporate responsibility roche business report weuseincentivestrainingandcommunicationsto withanimalsthecommitteecoversrocheresearch promotetherstheseincludetherocher facilitiesineuropeandtheusaandwillincludeour awardforemployeesgloballywhichnexttakesplace shanghaisiteandchugaifrom inthisyearwebeganworkonarsdatabase forsharinggoodpracticesthroughoutthegroup innovation new technology breakthrough whichwillbelaunchedin insciencecreateopportunitiesfornewdrugdis coverydevelopmentanddeliveryforexamplestem rochewasoneofthefoundersofthenewswiss cellsandtheirapplicationsoffertremendouspoten charteronanimalwelfareadoptedinbyinter tialforrelievingchronicpainandevencuringserious pharmatheassociationofresearchbasedphar conditionssuchasarthritisdiabetesandparkinson maceuticalcompaniesinswitzerlandthecharter diseaseinparticularthediscoveryofinducedplurip commitsustoconsistentlyhighstandardsofani otentstemcellsderivedfromadultcellsprovidesan malwelfarethroughaprogrammeofauditingem alternativetoembryonicstemcellsopeningupaddi ployeetrainingstakeholderdialoguepromotion tionalopportunitiesinthispromisingfield ofthersandmanagementofexternalcontractors wewillreportourprogressinimplementingthe weareinvolvedinstemcellresearchpartnerships charter includingtheinstituteforstemcelltherapyandex plorationofmonogenicdiseasesisteminfrance ouranimalwelfareethicscommitteebecamefully andthemassachusettsgeneralhospitalandharvard operationalandmetfourtimesinthecommit universityintheunitedstatesinweestab teehasdevelopedrecommendationsfortheuse lishedstemcellsforresearchscrinbaseland ofcontractorsforanimalresearchandwillexamine nutleytodevelopourexpertiseinthisareathis allnewstudiesusingnonhumanprimatesnhps groupfocusesondrugdiscoverypreclinicalsafety particularlythosecarriedoutbycontractorsthe testinganddiseasemodelle committeehascreatedaquestionnairetohelpre searcherssubmitnhpstudiesforexaminationitalso wearecommittedtoresponsibleandtransparent advisesemployeesonbestpracticeswhenworking stemcellresearchwehavethereforeestablishe customer relation responsible report green energy efficiency ship management marketing evaluateandimplement promotebestpracticesof reduceenergycon provideaddedvalue applythenewsale improveditsystem useofvirtualittoreduce sumptionandimprove throughcustomersatis marketingcompliance forreportingonkeycon energyconsumptionand energyefficiency factionassessment questionnairegroupwide tributionstohealthcare solutionstoreducetravel reductionfrom tomeetorexceed institutionspatientorgani andenableexpande customerexpectation sationsandindividual communication hcp rochearengcorporate responsibility partindd roche business report corporate responsibility animal research roche contract responsible marketing research organisation strictregulationsandindustryguidelinesgovern thesaleandmarketingofmedicinesanddiagnostic tomakesuretheyareprescribedadministere mice rat andusedcorrectlyandthatpatientsunderstandthe rodent benefitsandrisksoftakingthem rabbit dog howeverregulationsvaryfromcountrytocountry primate evenwithineuropeinrocheandothercorpo fish frogs ratemembersoftheeuropeanfederationofphar maceuticalindustryassociationsefpiadevelope aleadershipstatementwhichprovidesguidance infivesensitiveareastheserelatetopatientinfor bindingprinciplesforstemcellresearchinconsul mationtrainingformedicalsalesrepresentative tationwithinternalandexternalstakeholderswhich theprovisionofmedicalsamplestohealthcarepro wewillpublishin fessionalsorganisingmeetingsforhealthcare professionalsandrelationshipswithpatientorgani inpartnershipwithbiopharmaceuticalcompany sationsrochehasfullycommittedtofollowe halozymeweareexploringanewmethodofdrug thisguidanceinadditionourchiefcomplianceoffi deliverythatcouldmakeitpossibletogivebiological cerjoinedefpiasnewtrustreputationandcom medicinessuchasherceptinandmabthera pliancepolicycommittee rituxanbysubcutaneousinjectionratherthanintra venouslyhalozymesenhanzetechnologyallows rochemanagersareresponsibleforensuringall subcutaneousinjectionoflargevolumesofmedicine marketingactivityundertheircontrolcomplie injustthreetofiveminutesmakingitmorecon withourcodeofconductandindustrymarketing venientandcosteffectivethanintravenousdelivery codesinwelaunchedtherochemarkete working stakeholder good product regulator policy maker physician healthcare provider input regulatory filing clinical trial design participation clinical trial design result publication product shape treatment guideline feedback product performance profile input training education material shape treatment guideline patient patient group payer reimburser market research patient need health outcome study focus group product profile ease use determination medical value codevelop support awareness reimbursement programme educational material training patient group rochearengcorporate responsibility partindd corporate responsibility roche business report andsalescompliancequestionnairermscqto tionsandpoliciesforpublichealthaswellasfor helpmanagersassesshowwelltheiroperation moregeneralareassuchastheassessmentofthe performonsensitivecompliancetopicsallgeneral valueofhealthcareandourworkwithpublic managershavetosignadeclarationthatconfirm healthorganisationsthinktanksandacademics theircompliancewealsoranrefreshertrainingon responsiblemarketingforglobalproductstrategy oneexampleisourcontributiontotheeuropean teamsinthepharmaceuticalbusinesswewill commissionprocessoncorporateresponsibilityin carryoutrefreshercoursesonantitrustissuesand thefieldofpharmaceuticalsthisprocesswas anticorruption launchedintoimprovetransparencyandbusi nessethicsaccesstomedicinesindevelope customer relationship management countriesandpricingandreimbursementsystem ourcustomersrangefrompatientshealthcarepro ineuropewearealsoparticipatinginaproject fessionalshospitalsandreferencelaboratoriesto todevelopmarketaccessforbiosimilardrug publicandprivatehealthcarepayersitisimportant tomanagetheserelationshipsinaprofessional inwedevelopedguidelinesforsharinginfor andtransparentwayweconsidertheirneedsand mationonthepotentialofmisuseofdrugsinsport viewswhendevelopingourproductsandservice inassociationwiththeworldantidopingagency wadarocheandwadasignedamemorandum wefocusonbuildingstrategiclongtermpartner ofunderstandingdescribingtheprocesstofollow shipswithhealthcareadministratorsaswellasspe whensuspicionariseswadapresentedrochewith cialistsinindividualdiseaseareasthishelpsus anawardinrecognitionofourroleinthisarea gainabroaderoverviewofpatientneedsacrossall areasofhealthcareandenablesustoofferafull wealsocontributetopolicydevelopmentthrough rangeofappropriatepharmaceuticalanddiagnostic ourmembershipofindustrybodiessuchasthe productsthisapproachalignsmorecloselywith europeandiagnosticsmanufacturersassociation ourvisionforpersonalisedhealthcareandwillim edmatheeuropeanbiopharmaceuticalenter provecustomerserviceidentifyadditionaloppor prisesebetheinternationalfederationofpharma tunitiesandcreateefficienciesandcostsaving ceuticalmanufacturersandassociationsifpma andtheeuropeanfederationofpharmaceuticalin forexamplegenentechemploysthoughtleader dustryassociationsefpiainefpiaapprove liaisonswhoworkwithexternalmedicalexpertsto fourpriorityareasforthenexttwoyearsthesere ensureweunderstandtheiropinionsandestablish latetoimprovingtheeffectivenessofhealthtechnol lastingmutuallybeneficialpartnership ogyassessmentsstrengtheningintellectualproper tyframeworksenhancingethicstrustandreputation wecarryoutcomprehensivemarketresearchand andattractingmorerdtotheeuropeanunion analysistobetterunderstandtheneedsofspecific throughefpiawecontributedtoupdatestoeuro customergroupsandmarketsinindepen peanunioneulegislationaimedatstrength dentresearchamongcancerspecialistsinthe eningsystemsformonitoringthesafetyofmedicine unitedstatesandfiveeuropeancountriesshowe inparticulartoprotectagainstcounterfeitmedi thatrochescustomerretentioninthesemarket cinesandensurepatientsreceivereliableinformation iscomparedwithanaveragerateof onprescriptionmedicinesthisworkwillcontinue amongourpeersinadditiontoproductefficacy themaindriversofcustomerretentionwasfoundto bethesalesrepresentativesconductknowledge wehavecontributedtotherevisionoftheeudirec andexpertiseandtheinformationandsupportpro tiveontheprotectionofanimalsusedforscientific videdforpatientsandclinicians purposessincetheprocessbeganinthedirec tiveaimstobalancetheneedsofresearchandpa public policy tientswithanimalwelfaresignificantnewprovision weshareourviewsandexpertisewithgovernment includeamandatoryethicalreviewprocessand andregulatorstohelpdevelopeffectivelawsregula thedevelopmentandimplementationofalternative rochearengcorporate responsibility partindd roche business report corporate responsibility methodsthattangiblyimproveanimalwelfarethe cessesthataredifficulttoreproducecopiesofabio directivewillapplyinalleumemberstatesfrom logicalproductarethereforesimilarbutnotidenti november caltotheoriginalthesebiosimilarproductscannot beconsideredgenericmedicinesorapprove wecontributedtoresponsesfromedmaandebe basedonthelimiteddatasetmostregulatorybodie toaeuropeancommissionconsultationonin vitrodi acceptforgeneric agnosticsivdsinwesupportthecommis sionsproposedriskbasedclassificationsystemfor wesupportthedevelopmentofaclearregulatory ivdsaslongasmanufacturersaregivenenough frameworkfortheapprovalofbiosimilarproduct timetoadjusttotheincreaseindevelopmentcost whichcomparesthemwiththeoriginaldrugthe itwillincurmoreclarityisneededonpropose europeanmedicinesagencyhasestablishedsucha requirementsforprovidingclinicalevidenceforhigh systemandpublishedadditionaldraftguidelineson riskivdsalsothroughedmawecontributedto similarbiologicalmedicinalproductscontainingmon theeuropeancommissionsreviewofthemedicalde oclonalantibodiesforreviewtheuscongressintro vicessectorwhichidentifiedmajorchallengesrelat ducedalegislativeprocessforapprovingbiosimilar ingtocompetitivenessinnovationandpatientaccess aspartofthehealthcarereformsinmarchfor countrieswherethereisnospecificframeworkfor combat counterfeit counterfeitmedicalprod approvingbiosimilarswebelievethatregulatory uctsareillegalandaseriousglobalpublichealth authoritiesshouldfollowtheworldhealthorgani problemtheyendangerpatientsundermineconfi zationwhoguidelinesonevaluationofsimilar denceinthehealthcareindustrybreachintellectual biotherapeuticproductswhereacomparisonwithan propertyrightsandwastehealthcarebudgetswe originalbiologicalproductisrequiredtoestablish workwithrelevantstakeholderstoimproveproduct similarityinweengagedwithregulatoryauthor securitystrengthenandenforceexistinglawstrain itiesandbiosimilarmanufacturersaroundtheworld localofficialsandeducatethepublicthroughefpia topromotethewhoguidelinesastheminimumstan wehavecontributedtotheproposedeuropeancom dardwewillcontinuetodosotoensuresimilar missiondirectiveoncounterfeiting versionsofourbiotherapeuticproductsbroughtto marketaresafeandeffectiveanupdatedposition eliminatingcounterfeitsrequiresacomprehensive onbiosimilarsisavailableonourwebsite universalapproachacrossthepharmaceuticalindus trythisshouldincludestandardisedproductseriali political contribution rochedoesnotfundin sationanduniversalsafetyfeaturessawthe dividualpoliticiansemployeesintheusacanmake conclusionofanefpiapilotprojectofonepotential personalcontributionsthroughrochesgoodgov approachasystemforverifyingthatmedicinesdi ernmentcommitteeggcandgenentechsgenen pensedinpharmaciesaregenuineoneachpacka pacbotharevoluntarypoliticalactioncommittee uniquebarcodesmallerthanafingernailholdsa pacinemployeesdonatedusdol randomserialnumberandtheproductcodebatch larstopoliticalcampaignsthroughthesepacs numberandexpirydatebeforedispensingamedi cinepharmacistsscanthebarcodetocheckitis web authenticpharmacistsinstoresscannedandver position paper wwwrochecom policiesguidelinesandposition ifiedalmostpacksfrommanufacturer responsible marketing risk management compliance includingrochetheresultsshowthatthetechnol wwwrochecombusinessintegrityandresponsible marketing ogyisafeasiblecosteffectiveandsecuremean wwwrochecomriskmanagementandcompliance ofenhancingpatientsafetyandsupplychainsecurity pharmaceutical industry principle responsible supply chain management httppharmaceuticalsupplychainorg patent counterfeit biosimilar biosimilar product unliketraditionalmedicine wwwrochecommedicalvaluepatentsandpricing whichcontainsmallmoleculesproducedbychemical wwwrochecompatent new product technology synthesisbiologicalmedicalproductshavecomplex wwwrochecomcsrresearchanddevelopment molecularstructurestheyareproducedfromlive wwwrochecominnovationandtechnologie systemsusingsophisticatedmanufacturingpro rochearengcorporate responsibility partindd corporate responsibility roche business report safety security health environmental protection rocheisdedicatedtogoodhealthweareascom supplementthesecoursesinweexpande mittedtopreservingthesafetyandwellbeingof thenumberoflanguagesouronlineshetrainingis ouremployeesandtheenvironmentaswearetoim availableinbringingthetotaltoandensure provinghealthandqualityoflifeforpatient allrocheemployeescanunderstandthematerial thisenabledemployeestoaccessthepro manage grammeandofthesehaveparticipatedin goodsafetysecurityhealthandenvironmentalshe wewillexpandthisprogrammetogenentech managementisessentialtoourbusinessweem employee ployateamofdedicatedpeopleatourheadquar tersinbaselwhichiscomplementedbyateamof security intheunitedstateswhileoverfulltimeem thevisionofsecurityatrocheistoprotectourem ployeessupportoursheprogrammeacrossour ployeesandvisitorsphysicalassetsintellectual sitesmaintaininggoodperformanceiseveryem propertyandproductsfromharmorlossourglobal ployeesresponsibility networkofsitesecurityofficersworkedwithroche chiefsecurityofficerinonsupplychainsecuri eachsiteidentifiesitsspecificsherisksandoppor tytravelsecurityincidentmanagementandtraining tunitiesandcommunicatestheseaccordingtolocal preferencesthisensuresthatcolleaguesunder wehavelaunchedapilotprojectinlatinamericato standandadheretoourshepolicyandguideline systematicallyassesstransportsecurityrisksinour supplychainsuchastrucksbeinginterceptedand ourpolicyistointernallyauditcriticalsitessuchas implementadditionalsecuritymeasuresasnece chemicalandpharmaceuticalmanufacturingfacilitie sarywehavealsoimprovedthehelpavailablefor everythreeyearsandallotherrelevantsitesperiod employeesshouldemergencysituationsarisedure icallyaccordingtorisktheseauditsratesheper businesstravelthisincludessecurityanalysisbefore formanceaccordingtointernalstandardsandstipu travellingtodangerouscountriesandasecurityand latefutureimprovementswehaveincorporate medicaladviceserviceforuseduringtravel genentechsitesintothecorporatesheauditpro grammeandthesearenowassessedagainstthe regionalsecurityrisksneedtailoredsolutionsin samestandardsasotherrocheoperation thegroupsecurityteamchairedaseriesofre gionalsecurityworkshopstoreinforcethisapproach audits forexampleaworkshopinindianapolisunite statesenabledparticipantstoexchangeinsightsand experiencesintheareasofintellectualpropertypro worldwide audits tectionworkforceviolenceandsupplychainsecurity firsttime audits health safety inwevisitedsitesfourforthefirsttimeof thesitespreviouslyauditedalmostallhadim provedtheirperformancerecommendedimprove roche accident rate mentsinincludeincreasedtrainingontopic occupational accident suchasemergencymanagementbusinesscontinu occupational illness ityandsafedrivingasweexpectsimilarlyhigh workrelate fatality shestandardsfromoursuppliersourprocurement workrelate accident departmentconductssheauditsatthirdparty million working locationsandissuesfollowuprecommendation hour trainingisatthecoreofourshestrategylocal employeehealthandsafetyisoneofourforemost managersprovidetailoredtrainingthroughlecture prioritieswehaverigorouspoliciestosafeguard andcoursescustomisedtositespecificsherisk theirwellbeingandexpectthesamestandardsfrom regularregionalsheconferencesandworkshop ourcontractor rochearengcorporate responsibility partindd roche business report corporate responsibility investmentsinshetrainingappeartobepaye total environmenttal impact ecobalance offwehavereducedworkrelatedaccidentspermil lionworkinghoursbysinceemployee use resource energy reportedoccupationalaccidentsina raw material increaseinfrequencycomparedwithlastyearhow water evertheaverageseveritytheresultingnumberof emission air lostdaysdecreasedoveralltherocheacci voc dentrateameasurethatcombinesfrequencywith severityimprovedbyapproximatelyoccupa tionalillnessimprovedinbothincidenceandseverity withcasesreporte halogenate hydrocarbon ouroccupationalaccidentandillnessprofileremain particle consistentwithslipsfallsandrepetitivestrain water representingthemajorityofworkrelatedcomplaint toc intherewerenomajoraccidentsthisyear heavy metal forthethirdconsecutiveyear phosphorus nitrogen thoughwearepleasedwiththispositivetrendwe landfille waste inert waste recognisetheneedtoremainvigilantwehave construction waste installeddefibrillatorsincentrallocationsatalmost reactor waste allsitesandcontinuetosupportouremployee mio impact point wellbeingbothduringandoutsideofworkhour ecobalance employee manyrochesitesorganisecampaignstoreduce accidentsoutsidetheworkplacesuchassellingpro tectivesportsequipmentandrunningmotorcycle ecoefficiency rate eer safetycourse environmental footprint sale million chf ourtotalenvironmentalfootprintiscomprisedof environmental manyindividualimpactsincludingenergyusewater expenditure andwastewemeasureourtotalimpactusingthe million chf ecobalancemetricdevelopedbytheswissagency environmental damage fortheenvironmentbafuthisweightstheim environmental pactsofairandwateremissionslandfillwastepri damage unit maryenergyandrawmaterialusagetocalculatea eer totalfootprintwealsocalculateimpactperemployee sowecanmeasureourprogressasthebusiness weassesstheefficiencyofourenvironmentalin growswesetourselvesatargettoimproveoureco vestmentsandrunningcostsbycomparingsalesfig balancebyfromlevelsby ureswithourtotalenvironmentalexpendituresand impactascalculatedaccordingtothebafumethod wearepleasedtohavereachedthisgoalearlyand ologyourresultingecoefficiencyrateeerha nowplantoimproveourecobalanceafurther decreasedtoachangefrom fromlevelsbythisyearinkeepe thereisadetaileddefinitionatwwwrochecom withanupdatedbafuecobalancemethodology factsheetecoefficiencypdf wehaveincludedadditionalparameterssuchas wateruseresultinginanecobalanceof rochearengcorporate responsibility partindd corporate responsibility roche business report energy climate change greenhouse gas emission equivalent asrochesgreenhousegasemissionsresultmainly fromenergyuseourclimateandenergystrategie areinextricablylinke total emission million tonne ourpriorityistoreduceemissionswhileremaininga total emission viableprofitablecompanyweplantodothisby million chf sale increasingenergyefficiencyandswitchingtosustain tonne ableenergythroughagroupdirectivewehave developedasystematicapproachforconservingen ergythisincludesmeasuressuchasdesigne energy use terajoule newplantsandbuildingstobemoreenergyefficient andoptimisingandretrofittingexistingassetsthe directivecoversallaspectsofourbusinessfrompur total energy use chasingandoperationstoresearchmarkete total energy use administrationandtransport million chf sale total energy use inwesetagoaltoimproveenergyefficiency employee measuredasconsumptionperemployeeby bywithanimprovementofinfiveyear employeeawarenessandmotivationwillalsobecriti wemissedthisgoalthisshortcomingislargelydue caltoachievingourgoalswearefortunatetohave torecentacquisitionsandcorrespondingincrease innovativeanddedicatedemployeesourannualre inbusinesstravelwhichhaveraisedouroverall sponsiblecareawardrecognisesthisbyencour energyconsumptiontheenergyefficiencyofbuild agingemployeestocollaborateonideasforenergy ingsplantsandmachineryhasimprovedbymore savingprojectsthisyearwerewardedsitesthat thanduringthisperiod includedremarkableprojectsintheirenergyreduc tionplanswerecognisedelevensitesforonsite wearefirmlycommittedtoimprovingourperfor energyconservationprojectsandfivereceive mancethisyearwedefinedplansforafurther awardsforprojectsinvolvingtheirfleetsandflight efficiencyimprovementbyfromlevel inthelongertermweaimtoreduceusageby whilewearereducingtheamountoffuelweuse peremployeebyfromlevelsachieving toheatcoolandrunourbuildingsandmanufacture thesegoalswillrequiresignificantlearningandin sitesbusinesstravelisprovingmoreofachallenge vestmentweareimprovingourenergymeasurement businessairtravelisincreasingandnowrepresent andmanagementprocessesdefiningaccountabili almostofoverallenergyuseintroducedin tiesanddevelopingframeworksforcommunication ourpolicyofusingonlycarsthatemitamaxi andknowledgeshare mumgrammesofco perkilometreinour europeanpharmafleetbyisbearingfruitand eachbusinessunitandsitewillneedtocontributeif hasimprovedfuelconsumptionefficiencyby wearetoreachourenergyefficiencygoalsthisyear inoneyear weaskedthelargestenergyconsumingsite acrossthebusinesstocreateenergyreductionaction whileefficiencymeasureswillplayalargerolein planstheresponsehasbeenverypositiveresulte reachingourenergytargetwemustalsoconsiderthe intotalpotentialsavingsofterajoulesperyear typesoffuelweuseourlongtermstrategyisto asignificantproportionofthesesavingscomefrom continuetoreplacefossilfuelswithsustainableener retrofittingrefrigerationheatingventilationandair gysourceswhereverpracticalandfeasibleasa conditioningsystemsweareconfidentthatsuccess groupourgoalistoincreasetheproportionofsus fullyimplementingthesubmittedplanswillachieve tainableenergyweusetoby ourgoalandwillcloselymonitorimplementa tionoftheplanstomakesuretheystayontrack rochearengcorporate responsibility partindd roche business report corporate responsibility energy use type acquiredsiteswillworktowardsseparatetimeline togivethemthesametimeframeasoperation fuel involvedintheoriginalprocessforgenentechthus company vehicle thetargettobemetis oil achievingthesetargetswillrequiresignificant investmentthoughwearesearchingforalternative fuel business therearecurrentlynoviablesubstitutesinsomecir air travel cumstanceswewillcontinuetoexaminealternative andworkwithrefrigerationsupplierstomakefurther grid electricity reductionsinthefuture district heating emission air tonne waste renewable energy vocs particulate natural gas nitrogen oxides sulphur dioxide halogenate hydrocarbon tonne ourmanufacturingoperationsemitvolatileorganic compoundsvocsparticulatesnitrogenoxide xandsulphurdioxideso thesecontributeto variousformsofpollutionincludingairpollution smogandacidrainweminimiseemissionstoair holding whereverpossiblethroughavarietyoftechnologies andpracticesfluegasscrubbersreducenoand vocsarereducedthroughvariousincineration emission andfreezingprocessesthoughstillunderinvesti gationinswitzerlandandtheusthelattermay ithasbeenchallengingtoreduceemissionsof alsoreduceenergyusethetableshowsouremis chemicalrefrigerantsthatareeitherozonedepleting sionstoairinparticulatesno andso suchascfcsandhcfcsorhaveahighglobal fluctuatefromyeartoyearbutalwaysatverylow warmingpotentialsuchashfcsthevolumeof level refrigerantholdingsreportedsignificantlyincrease inasgenentechsfiguresincluderented waste tonne orleasedbuildingsandequipmentforthefirsttime wecommittedtophaseoutallcfcsandhcfcsfrom general waste ouroperationsbyandallhalogenatedhydro produce carbonrefrigerantsbythoughwehavemade general waste significantprogressareductionofhalon million chf sale andanreductionoffullyhalogenatedcom chemical waste poundsinsevenyearsexcludinggenentechsite produce ourrecentacquisitionsandlackoftechnicalsolu chemical waste tionsforsomeapplicationshavemadethisgoalun million chf sale realisticinconsultationwithourengineerssite andbusinessrepresentativeswedecidedtorevise rochesincreasedwasteproductionthisyear ourgoalwenowplantoreducehalogenate reflectsanumberofoperationalchangesthe refrigerantsatrochesitesbybynewly increaseingeneralwasteincludeslargeamount rochearengcorporate responsibility partindd corporate responsibility roche business report ofconstructionwastefromdemolishedbuilding ouroperationsdischargedkilogrammesofheavy inmannheimgermanyandbellevilleusachem metalsintowatercoursesprimarilyflushedout icalwasteincreasedslightlyinlinewithhigher frommetalpipeswedischargethesepollutantsonly productionvolume ifthisfullycomplieswithallrelevantregulation includingpretreatmentrequirementswearestrive water toreducetotalwastewatertoxicitybybetween andandarecurrentlydevelopinganalyti calmethodsandperformancemeasurestohelpus water withdraw achievethis million cubic metre water biodiversity million cubic metre pharmaceuticalsandthenaturalworldhavebeen wastewater discharge closelylinkedforcenturiesnatureholdsmuch treatment plant inspirationandpotentialfortreatingillnessandwe million cubic metre mustguardagainstspecieslosswesupportthe organic matter principlesofresourcestewardshipasdefinedinthe discharge water conventiononbiologicaldiversitycbd course treatment tonne thewinnersofrochesecompetitionaward heavy metal havefoundasurprisinglysimpleyeteffectivewayto discharge water countertheprevalenceofinvasiveplantspecie course treatment ourcoloradositerecentlywelcomedaherdofmoun kilogrammes taingoatswithanappetitefortheweedsthreat eningthelocalecosystemcomparedwithharsh wateravailabilityisincreasinglycriticalforroche chemicalsorlabourintensivealternativesthegoat andforsocietyandvariesgeographicallywhile providealowimpactandcosteffectivemeansto rochecurrentlyhasnohighusageoperationsin solvingasignificantenvironmentalchallenge areasofwaterscarcityweadaptconservationand reductionprogrammesaccordingtolocalconditions pharmaceuticals environment pie andneedsforexampleourcaliforniansitesuse tracesofpharmaceuticalproductsmaketheirway droughtresistantlandscapingatothersiteswecol intotheenvironmentprimarilythroughnatural lectandrecyclewaterfromourcoolingtower processesfollowingnormalpatientusemanufactur creatingaclosedloopsystemthatreduceswateruse ingandimproperdisposalbypatientsalsocon tributeasmallproportioncurrentevidencesuggest wecarefullymanagebothwateruseandwastewater thatexposuretotheselowlevelconcentrationsin dischargesourwithdrawalandconsumptionin surfacegroundanddrinkingwaterdoesnotposeany creasedinduelargelytotheinclusionoftwo harmtohumanhealthbutwerecognisetheneed newsitesthisyearouroperationswithdrew forfurtherresearchintotheeffectsandsupportsci millioncubicmetresofwaterreducingtotalwith entificworkinthisfield drawalisanimportantpartofouroverallenviron mentaltargetandourrevisedmethodforcalculate theriskstoaquaticlifearethoughttobegreater environmentalimpactecobalancenowinclude studiestodatedonotsuggestanyshortterm waterusagetoreflectthis effectsfromexposuretolowlevelconcentrationsof pharmaceuticalsbutmoreresearchisbeingcon wecarefullycontrolthequalityofwateremission ductedtoevaluatethepotentialimpactoflongterm inwedischargedmillioncubicmetresto exposure treatmentplantsaftertreatmentwedischarge tonnesoforganicmatteranincreaseprimarily weconsidertheentirelifecycleofourdrugsand causedbytheacquisitionofasubstantialsingapore takestepstominimisereleasesintotheenvironment biotechoperationinlinewithlowlevelfluctuation atallstageswedesignourmanufacturingsitesto rochearengcorporate responsibility partindd roche business report corporate responsibility reducetheriskofactiveingredientsenteringwaste waterandusefinancialincentivestoencourage customerstoreturnunusedproductforproperdis posal compliance incident wemeetalllocallawsorregulationsasamini mumbutsetoursightshigherourgrouppolicie areoftenmorerigorousthanexternalstandard wereceivednosignificantshefinesinforthe eighthconsecutiveyear howeverwepaidthreesmallfinesthisyearforminor infractionstheserelatedtoawaterqualityviola tionaphysicaldefectinastoragetankandexce siveuseofaboilerwhilenoneoftheseincident presentedasignificantrisktoouremployeesorthe localcommunitywetakeallincidentsseriously wehavetakenstepstocorrecteachproblemand preventsimilarincidentsfromoccurringinfuture web performance goal wwwrochecomsheperformance environmental protection wwwrochecomenvironment policy wwwrochecomsafetyhealthandenvironmental protectionpdf group fact sheet position policy guideline wwwrochecompoliciesguidelinesandposition genentech sustainability report wwwgenecomgeneaboutenvironmental rochearengcorporate responsibility partindd independent assurance report roche business report independent assurance report tothecorporategovernanceandsustainabilitycommitteeof therochecorporategovernanceandsustainabilitycommittee rocheholdingltdbaselroche isresponsibleforboththesubjectmatterandthecriteria ourresponsibilityistoprovideaconclusiononthesubjectmat wehaveperformedassuranceprocedurestoprovideassurance terbasedonourassuranceproceduresinaccordancewith onthefollowingaspectsofthecorporateresponsibility theinternationalstandardonassuranceengagementsisae reportingofroche subject matter main assurance procedure dataandinformationdisclosedinthecorporateresponsibility ourassuranceproceduresincludedthefollowingwork reportingofrocheanditsconsolidatedsubsidiariesexclude evaluation application group guideline chugaipharmaceuticalcoltdforthebusinessyearende reviewingtheapplicationoftherocheinternalcorporate decemberonthefollowingaspect responsibilityreportingguideline themanagementandreportingprocesseswithrespectto site visit visitingselectedsitesofrochespharmaceuti thecorporateresponsibilityreportingandtothepreparation calsanddiagnosticsdivisionsingermanyhungary ofsheandpeoplekeyfiguresaswellasthecontrol russiaandtheustheselectionwasbasedonquantitative environmentinrelationtothedataaggregationofthese andqualitativecriteria keyfigure interviewingpersonnelresponsibleforinternalcorporate theshekeyfiguresinthetablesonpagesto responsibilityreportinganddatacollectionatthesite andsomeselectedpeoplekeyfiguresdisclosedonpage wevisitedandatthegroupleveltodeterminetheunder tooftherochebusinessreport standingandapplicationofrocheinternalcorporate responsibilityguideline criterion assessment key figure performingtestson therochegroupinternalcorporateresponsibilityreporte asamplebasisofevidencesupportingselectedsheand guidelinesbasedontheresponsiblecareprogramme peoplekeyfiguresrocheaccidentrateenergycon healthsafetyandenvironmentalprotectionreportingguide sumptioncoemissionsrelatedtoenergyconsumption linespublishedbytheeuropeanchemicalindustrycouncil releaseofhalogenatedhydrocarbonsuseofwater ceficandthesustainabilityreportingguidelinesgpub finesinrelationtosafetyandenvironmentalprotection lishedonoctoberbytheglobalreportinginitiative headcountftedatastaffturnoverandseniormanage griand mentpositionsconcerningcompletenessaccuracy thedefinedproceduresbywhichsheandpeoplekey adequacyandconsistency figuresaregatheredcollatedandaggregatedinternally review documentation analysis relevant policy basic principle reviewingtherelevant responsibility methodology documentationonasamplebasisincludinggroupsustain theaccuracyandcompletenessofcorporateresponsibilityindi abilitypoliciesmanagementandreportingstructure catorsaresubjecttoinherentlimitationsgiventheirnature anddocumentation andmethodsfordeterminingcalculatingandestimatingsuch assessment process datum con solidation dataourassurancereportshouldthereforebereadincon reviewingtheappropriatenessofthemanagementand nectionwithrochesinternalguidelinesdefinitionsandproce reportingprocessesforcorporateresponsibilityreporte duresonthereportingofitscorporateresponsibilityperfor andassessingtheconsolidationprocessofdataatthe mance grouplevel rochearengcorporate responsibility partindd roche business report independent assurance report conclusion global reporting inouropinion initiative sustainability theinternalcorporateresponsibilityreportingguideline arebeingappliedproperly report guideline theinternalreportingsystemtocollectandaggregate sheandpeoplekeyfiguresisfunctioningasdesignedand withthisyearsannualreportwecontinueourapproach providesanappropriatebasisforitsdisclosure ofaligningoursustainabilityreportingtotheguidelinesofthe globalreportinginitiativegri basedonourworkdescribedinthisreportandtheassess mentofcriterianothinghascometoourattentionthatcause asforthelastthreeannualreportsrocheisoftheopinion ustobelievethatthecorporateresponsibilityinformation thatthealevelofthegrigguidelinesappliestoitsannual mentionedinthesubjectmatteranddisclosedwiththecorpo reportthiswascheckedwithandconfirmedbythe rateresponsibilityreportingintherochebusinessreport gri doesnotgiveafairpictureofrochesperformance detailsofhowwereportagainsteachindicatorcanbefound zurichjanuary atwwwrochecomreportingandindice pricewaterhousecoopersag drthomasscheiwiller stephanhirschi severinschwan rochearengcorporate responsibility partindd publish cautionary statement forwardlooke hoffmannla roche ltd statement basel switzerland annual report contain certain forwardlooke state tel ment forwardlooke statement identify fax word believe expect anticipate project intend seek estimate future similar expression discussion thing strategy medium office goal plan intention factor cause actual group communication result differ materially future reflect basel switzerland forwardlooke statement contain annual report tel price product initiative competi fax tor legislative regulatory development eco nomic condition delay inability obtain regulatory investor relation approval bring product market fluctuation currency exchange rate general financial market condi basel switzerland tion uncertainty discovery development tel marketing new product new use exist product fax include limitation negative result clinical trial research project unexpected effect pipeline world wide web market product increase government pricing pre wwwrochecom sure interruption production loss inability obtain adequate protection intellectual property right corporate sustainability committee litigation loss key executive employee adverse publicity news coverage tel email corporatesustainabilityrochecom statement earning share growth profit forecast interpret mean order publication roche earning earning share tel subsequent period necessarily match exceed fax historical publish earning earning share roche email baselwebmasterrochecom trademark mention enjoy legal protection annual general meeting link party page provide convenience march express opinion content party page expressly disclaim liability party information use roche annual report publish german english print nonchlorine bleach fsccertified paper roche annual report issue hoffmannla roche ltd basel group communication cover jone usa participant phase iii emilia trial receive treat ment tdm advanced herpositive breast cancer rochearengimprintindd rochearengimprintindd key figure roche group index sale mchf free cash flow mchf research development mchf total dividend mchf hoffmannla roche ltd basel switzerland operating profit mchf number employee trademark legally protect wwwrochecom income taxis mchf total employee remuneration mchf net income mchf patient clinical trial core earning share chf ecoefficiency rate price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebase key figure index figure annual report core result index global reporting initiative gri propose board director indicator report development phase wwwrochecomreportingandindice calculation ecoefficiency rate wwwrochecomenvironment rochearengkey figuresindd roche annual report roche annual report create value patient rochearugengindd rochearengfront coverindd